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ABSTRACT
Amyotrophic lateral sclerosis (ALS) is a complex fatal degenerative disease 
selectively affecting motor neurones. The cause of the disease is still uncharacterised 
for the sporadic cases (SALS), whereas several disease-linked genes, such as 
SOD1 and VAPB, have been identified in families with ALS (FALS). However, since 
the pathological features are indistinguishable between FALS and SALS, it is 
generally  believed that a common ALS-causing mechanism is responsible for both 
forms of disease. 
To gain a better understanding of ALS pathogenesis, which could also provide cues 
for therapeutic treatment, studies on the characterisation of FALS-linked mutations 
have been carried out. In this study, we screened for novel FALS-linked mutations 
and found three TDP-43 mutations in five unrelated FALS families, that caused 
marked changes at evolutional conserved amino acids and were absent in previously 
screened control populations. In addition, functional characterisation of novel ALS-
linked mutations in DAO (R199W) and VAPB (T46I) were undertaken whereby both 
mutations were shown to disrupt the physiological properties of wild type proteins. 
Whereas the T46I mutation in VAPB led to a sub-cellular redistribution and shift in 
solubility of VAPB protein, and an impairment in the unfolded protein response (UPR) 
and ubiquitin-proteasome system, R199W significantly abolished DAO enzyme 
activity. Cell culture-based functional studies showed that the expression of both 
mutant proteins triggered pathological features including ubiquitin-positive 
aggregates and cell death. Furthermore, an association study was conducted to 
investigate the cause of a dramatic VAPB down-regulation seen in SALS. An intronic 
SNP close to exon 5 of VAPB, rs6100067, was found to be significantly linked to the 
expression levels of VAPB in SALS. As the down-regulation of VAPB profoundly 
affects the activation of IRE1/XBP1, the most characterised UPR pathway, this SNP 
may present as a risk factor for ALS development. 
From these results, we propose an ALS pathogenesis mechanism, whereby VAPB 
plays a central role in sustaining multiple cellular events, such as UPR. Disruption or 
deprivation of VAPB causes impairments in these cellular functions and leads to 
motor neurone death.
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Chapter I INTRODUCTION
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1.1 Amyotrophic lateral sclerosis (ALS)
Amyotrophic lateral sclerosis (ALS), also known as Motor Neurone Disease and Lou 
Gehrigʼs disease, is a fatal degenerative disease which selectively affects motor 
neurones. The diagnostic criteria for ALS include the presence of both upper and 
lower motor neurone degeneration with a progressive phenotype and the absence of 
evidence that indicates other diseases (Brooks, 1994; Brooks et al., 2000). In 
addition to the loss of motor neurones in spinal cord, brain stem and motor cortex, 
ALS is also characterised by prominent sclerosis of the lateral and ventral 
corticospinal tracts, chromatolysis of motor neurones, axonal spheroids, and the 
secondary activation and proliferation of astrocytes and microglia (Kawamata et al., 
1992). The presence of cytoplasmic inclusions immunoreactive for ubiquitin and TAR 
DNA-binding protein 43 (TDP-43) in neurones and glial cells is also a diagnostic 
feature for the disease (Leigh et al., 1988; Hirano, 1996; Arai et al., 2006; Neumann 
et al., 2006). In addition, other aggregates such as Bunina bodies and neurofilament-
rich inclusions are evident within the cell bodies and proximal axons of affected motor 
neurones (Hirano, 1991). Weakness and atrophy of muscles arise as a consequence 
of motor neurone loss in the anterior horns of the spinal cord. This eventually leads to 
death due to respiratory failure within three to five years of symptom onset (Tandan 
and Bradley, 1985; McGeer et al., 1993; Lowe, 1994). Although ALS is thought to 
exclusively affect motor neurones, cognitive impairment and dementia is found to 
coexist with ALS in approximately 3-5% of cases (Al-Chalabi and Leigh, 2000; 
Strong, 2008) and effects in non-neuronal tissues, such as muscles, also occur and 
may exacerbate the disease (Ilieva et al., 2009).
As the most common adult onset motor neurone degenerative disease with incidence 
of 2 per 100,000 persons, ALS affects about 5,000 patients in UK (MND Association 
Resource File, 2006) with an average onset age of 55 years. It is not yet clear how 
the disease attacks motor neurones exclusively, and how it can remain dormant for 
many decades in life and then suddenly appear with a rapid and rampant 
progression. Researchers have devoted a great deal of effort to reveal the disease-
causing mechanisms which can help  define a therapeutic target. So far, the only 
available drug is the glutamate release inhibitor riluzole which has a marginal effect 
prolonging the life expectancy  of patients by a few months on average (Corcia and 
Meininger, 2008).
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ALS can appear as a sporadic form in which no other family member is affected by 
the disease, or familial form, which is caused by a gene mutation that leads to the 
development of the disease in all individuals who carry  the disease causative allele
(s). However, because the clinical features are indistinguishable between familial and 
sporadic forms of disease, it is believed that a common disease-causing mechanism 
is responsible for both forms of disease and the studies of disease-causing mutations 
have aimed to reveal these pathological disturbances. 
1.1.1 Sporadic ALS (SALS)
Amongst all ALS cases, about 90-95% are without obvious family history and are 
thus referred to as sporadic ALS (SALS). Although the aetiology of SALS is unknown, 
the involvement of a genetic contribution to disease pathogenesis is evident from an 
early twin study (Graham et al., 1997). Over the years, a few candidate genes that 
cause other types of neurodegenerative disease or that participate in neuronal 
survival have been screened for mutations or SNPs that are associated with SALS. 
Mutations in dynactin1 (DCTN1), peripherin (PRPH), SOD1 and the newly identified 
ALS-linked genes, TDP-43 and FUS, have been found in a few cases of SALS 
(Gellera et al., 2001; Gros-Louis et al., 2004; Munch et al., 2004; Gamez et al., 2006; 
Sreedharan et al., 2008; Belzil et al., 2009; Del Bo et al., 2009; Lai et al., 2010). 
However, since these mutations account for only a very small percentages of SALS 
cases, the possibility  of low penetrance inheritance can not be ruled out, and it is 
thus concluded that none of these mutations are common causes for SALS (Gros-
Louis et al., 2006; Schymick et al., 2007a). Association studies have also been 
carried out which aim to reveal SNPs or alleles that increase the risk for ALS. The 
genes that have been investigated in these studies include the DNA repair enzyme 
apurinic endonuclease (APEX) (Hayward et al., 1999; Tomkins et al., 2000; 
Greenway et al., 2004), angiogenin (ANG) (Greenway et al., 2006; Corrado et al., 
2007; Del Bo et al., 2008), DCTN1 (Kasperaviciute et al., 2007), paraoxonase (PON) 
(Saeed et al., 2006; Slowik et al., 2006; Morahan et al., 2007b), vascular endothelial 
cell growth factor (VEGF) (Lambrechts et al., 2003; Van Vught et al., 2005; 
Fernandez-Santiago et al., 2006), haemochromatosis (HFE) (Wang et al., 2004; Yen 
et al., 2004; Goodall et al., 2005; Sutedja et al., 2007) and a phosphoinositide 
phosphatase gene FIG4 (Chow et al., 2009). Nevertheless, the associations found in 
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these genes have rarely been validated in other SALS populations, and the 
contribution of these gene to SALS susceptibility is still inconclusive (see reviews of 
Gros-Louis et al., 2006; Schymick et al., 2007a; Dion et al., 2009). 
In addition to mutation screening and association studies that look for a change in 
DNA sequence that increases the risk for developing ALS, researchers have also 
investigated whether chromosomal rearrangements or copy number variants (CNV) 
are linked to SALS. Indeed, chromosomal translocation or pericentric inversions have 
been observed in 6 out of 108 SALS patients in two independent studies (Kaneko et 
al., 1995; Meyer et al., 2003). The alteration of chromosomal structure can result in 
disruption or deregulation of a gene or genes near the breakpoint area, which in turn 
leads to the disease phenotypes. However, no causative genes had been identified in 
these studies. 
The first study linking gene copy number variants to ALS was published in 2002 
which found an association of abnormal copy numbers of survival motor neuron 1 
(SMN1) gene with increased incidence of SALS (Corcia et al., 2002; Corcia et al., 
2006). The abnormal copy number (1 or 3, instead of 2) of the gene results in a 
reduced SMN protein level in patients (Veldink et al., 2005b) that may affect the 
survival of motor neurones. However, neither SMN1 nor any other common CNV 
locus was found significantly associated with ALS in two later whole genome CNV 
screening studies (Blauw et al., 2008; Cronin et al., 2008a). 
Given that a high degree of genetic heterogeneity of SALS might have diluted the 
significance of the strength of association studies which resulted in the lack of 
reproducible results, researchers have recently  turned to genome-wide association 
(GWA) studies to find common risk SNPs/alleles that underlie SALS. Without 
selecting any candidate genes, whole genome-wide SNPs are genotyped in GWA 
studies which usually consist of a few hundreds to thousands of cases and controls. 
At the same time that the results are published, the raw genotyping data is put on-
line which is then available to be incorporated with later studies. Since the first GWA 
study was published in 2007, which consisted of 276 SALS cases and 271 controls 
and genotyped 555,352 SNPs but found none linked to disease (Schymick et al., 
2007b), six GWA studies have been conducted with USA, Dutch and Irish 
populations (Dunckley et al., 2007; van Es et al., 2007; Cronin et al., 2008b; van Es 
et al., 2008; van Es et al., 2009). None of the genes of previous smaller scale 
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association studies were found linked to disease in these large scale screening 
studies, instead, SNPs within three novel genes, FGGY carbohydrate kinase domain 
containing (FGGY), inositol 1,4,5-triphosphate receptor, type 2 (ITPR2) and 
dipeptidyl-peptidase 6 (DPP6), have been linked to disease (Dunckley et al., 2007; 
van Es et al., 2007; Cronin et al., 2008b), of these, only DPP6 has been validated in 
another independent screening (van Es et al., 2008). Recently, a SNP rs12608932 
within the boundaries of unc-13 homolog A (C. elegans) (UNC13A) was linked to 
SALS in a GWA study consisting of 2323 SALS and 9013 controls (van Es et al., 
2009). However, this result still awaits to be validated in other populations and 
screening studies. 
Apart from the genetic contribution, the involvement of environmental factors has 
also been considered. The contribution of environmental factors to ALS pathogenesis 
first emerged with the observation of an unexpectedly  high disease incidence rate in 
certain particular areas, such as the Chamorro population of the island of Guam 
(Brody et al., 1975; Waring et al., 2004). The aetiological agent underlying this high 
ALS incidence is believed to be either a neurotoxin, such as β-methylamino-L-
alanine (BMAA), which is found in the cycad flour that is consumed by the local 
population (Spencer et al., 1986; Kisby et al., 1992; Khabazian et al., 2002), or is due 
to defects in mineral metabolism and secondary  hyperparathyroidism which is 
provoked by  nutritional deficiencies of calcium and magnesium (Garruto et al., 1985). 
In addition to neurotoxins, polymorphisms in the microtubule-associated protein tau 
(MAPT) gene have also been reported with high prevalence within ALS populations 
in Guam (Poorkaj et al., 2001; Sundar et al., 2007; Sieh et al., 2009), which indicates 
that MAPT may function as a potential modifier factor and together with the exposure 
to neurotoxins, cause the development of disease. Another population with increased 
risk for ALS that is linked to the exposure to neurotoxins is that of the veterans who 
participated in the first Gulf war (Horner et al., 2003). Other environmental factors 
that may contribute to susceptibility of ALS include exposure to electromagnetic fields 
(Hakansson et al., 2003; Li and Sung, 2003), exposure to agricultural chemicals (Doi 
et al., 2006; Qureshi et al., 2006; Furby et al., 2010), head injuries (Chen et al., 
2007a; Schmidt et al., 2010) and smoking (Kamel et al., 1999; Weisskopf et al., 
2004). Excessive physical activity may also lead to higher risk for developing ALS as 
an increased incidence of disease was observed in professional football players in 
Italy (Chio et al., 2005; Chio et al., 2009) and USA (Abel, 2007). Nevertheless, this 
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observation is not supported by other studies (Valenti et al., 2005; Veldink et al., 
2005a). Gender effects have also been explored since the male-to-female ratio of 
SALS is about 1.3 to 1.6:1 (Nelson, 1995; Sejvar et al., 2005) which suggests female 
hormones such as oestrogen would have a protective effect over other ALS risk 
factors (Choi et al., 2008). 
The involvement of epigenetic factor has attracted much attention since it provides a 
plausible link between the environment and alterations in gene expression that may 
lead to disease phenotypes as shown for Alzheimerʼs disease (Migliore and 
Coppede, 2009). The alterations introduced by epigenetic mechanisms can be 
inherited or can be the result of environmental stimuli occurring at an early stage of 
life. The most well characterised mechanism of epigenetic regulation is the 
hypermethylation of CpG islands within the promoter region of a gene, which results 
in repression of gene expression (Jirtle and Skinner, 2007). It is proposed that 
epigenetic silencing of genes that are required for physiological functions or survival 
of motor neurones may underlie ALS development. However, no abnormal levels of 
promoter methylation have been found within SOD1, VEGF, metallothionein 1A 
(MT1A) and MT2A which are involved in detoxification mechanism for heavy  metals, 
and EAAT2 which is responsible for the clearance of glutamate at the synapse 
(Morahan et al., 2007a; Oates and Pamphlett, 2007; Yang et al., 2010).
The difficulty in identifying causative alleles or genes for SALS reflects the complexity 
of the nature of the disease. As a heterogeneous disease, ALS displays a wide 
spectrum of phenotypes, of which different degrees of motor neurone loss with or 
without cognitive impairment and dementia, have been reported. The fact that no 
single allele or gene has been consistently found associated with the disease shows 
the high degree of genetic heterogeneity  whereby different disease-causing alleles 
may exist in different patient populations. Since the GWA studies looking for the 
common risk alleles for ALS did not detect mutations in genes such as TDP-43, it can 
be concluded that studies of this kind will not be useful in identifying variants that are 
only present in a small percentage of SALS cases. “There was no major gene that 
had a huge effect with ALS” says Bryan Traynor of the National Institute of Mental 
Health in Bethesda, Maryland, the first group conducting a GWA study (Garber, 
2008). Indeed, there may have a number of alleles in different genes whereas each 
of them contributes mildly in increasing ALS susceptibility. In addition, the gene-to-
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gene and gene-to environmental factor interactions should certainly be taken into 
account while evaluating factors underlying ALS susceptibility. 
1.1.2 Familial ALS (FALS)
The familial from of ALS accounts for 5-10% of total ALS cases (Mulder et al., 1986; 
Logroscino et al., 2005). The clinical features of FALS are indistinguishable from 
SALS, however, it is noted that the mean age of onset for FALS is 10 years earlier 
than SALS and the gender discrepancy is not as pronounced as in SALS cases 
(Camu et al., 1999). Until now, nine FALS-associated genes have been identified in 
the family-based linkage studies (Table1.1), most of which show autosomal dominant 
(AD) inheritance whereas a few mutations cause disease through recessive (AR) 
inheritance. 
Table 1.1 Genes within which mutations have been found causing FALS. 
Gene Chromosomal locus Inheritance First identified in ref.
SOD1 21q22.1 AD and AR (Rosen et al., 1993)
ALS2 2q33 AR (Hadano et al., 2001; Yang et 
al., 2001)
SETX 9q34 AD (Chen et al., 2004)
DCTN1 2p13 AD (Puls et al., 2003)
VAPB 20q13.33 AD (Nishimura et al., 2004)
ANG 14q11 AD (Greenway et al., 2006)
TDP-43 1p36.22 AD (Sreedharan et al., 2008)
FUS 16q12 AD and AR (Kwiatkowski et al., 2009; 
Vance et al., 2009)
DAO 12q24 AD (Mitchell et al., 2010)
SOD1 was the first gene linked to ALS, within which more than 100 mutations have 
been identified that account for 20% of FALS cases (Deng et al., 1993; Pramatarova 
et al., 1995). Mutations found in SOD1 are evenly  distributed along the gene, most of 
which are autosomal dominant although a few mutations show low penetrance and 
are recessively inherited (Andersen et al., 1996; Andersen, 2006). The protein 
product of this gene is Cu/Zn superoxide dismutase which converts harmful 
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superoxide radicals to oxygen and hydrogen peroxide thereby  preventing the further 
generation of reactive oxygen species (ROS). However, the ALS-linked mutations are 
not thought to cause disease through loss of dismutase activity since some ALS-
linked SOD1 mutations yield a protein which still retains enzyme activity (Andersen et 
al., 1997; Radunovic et al., 1997; Yamanaka and Cleveland, 2005) and SOD1 null 
mice exhibit no phenotype of motor neurone degeneration (Reaume et al., 1996). It is 
believed that mutant SOD1 acquires a gain-of-function toxicity, which disrupts cellular 
homeostasis and leads to cell death. As the most well studied ALS-causing gene, 
mutant SOD1 transgenic mice have been widely used as the main ALS animal model 
which develops a motor neurone disease phenotype with different mutations, just as 
observed in human ALS (Bendotti and Carri, 2004).  
Mutations in ALS2 and SETX lead to atypical juvenile-onset ALS (Hentati et al., 1994; 
Hadano et al., 2001; Chen et al., 2004). ALS2 encodes for alsin which contains three 
guanine-nucleotide exchange factor (GEF) domains and participates in endosomal 
trafficking and microtubule assembly (Otomo et al., 2003; Kunita et al., 2004). ALS-
linked mutations in ALS2 produce an unstable truncated protein (Yamanaka et al., 
2003). Patients carrying homozygous mutant alleles develop  ALS whereas 
heterozyous individuals are unaffected. ALS2 null mice display mild MND (Cai et al., 
2005), however, knockdown of the zALS2 homologue in zebrafish produces a much 
more severe perturbation in motor neurones (Gros-Louis et al., 2008). In addition, 
mutations in ALS2 are also found to be responsible for other neuronal disorders such 
as juvenile primary lateral sclerosis (Hadano et al., 2001; Yang et al., 2001; Mintchev 
et al., 2009) and infantile-onset hereditary  spastic paraplegia (Eymard-Pierre et al., 
2002; Devon et al., 2003; Lesca et al., 2003; Verschuuren-Bemelmans et al., 2008; 
Herzfeld et al., 2009). Defects in SETX cause an autosomal dominant, juvenile-
onset, slow progressing form of ALS (Chen et al., 2004). This gene encodes a DNA/
RNA helicase which shares strong homology  to human RENT1 and IGHMBP2, both 
of which are involved in RNA processing (Chen et al., 2004; Chen et al., 2006). 
Interestingly, mutations in IGHMBP2 are linked to spinal muscular atrophy, a motor 
neurone disease characterised by the degeneration of lower motor neurones 
(Grohmann et al., 2001).
The first missense mutation G59S in DCTN1 was identified in a family with adult-
onset, slow progressing autosomal dominant MND (Puls et al., 2003). Additional 
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DCTN1 mutations have subsequently  been found in SALS, FALS and a family with 
FTD (Munch et al., 2004; Munch et al., 2005). DCTN1 encodes the largest subunit of 
the dynactin complex that comprises the major axonal retrograde motor. Transgenic 
mice expressing human mutant DCTN1 in neuronal tissues develop MND which is 
characterised by defects in vesicular transport, axonal swelling and degeneration 
(Laird et al., 2008). 
The P56S mutation in VAPB was identified in a large pedigree with autosomal 
dominant MND. Interestingly, this mutation causes a wide spectrum of phenotypes in 
this family including typical ALS, late-onset atypical ALS and late-onset SMA 
(Nishimura et al., 2004; Marques et al., 2006). Cellular aggregates containing 
ubiquitin and TDP-43 were found in motor neurones of P56S transgenic mice 
although no neuronal degeneration or motor impairment has been observed (Tudor 
et al., 2010).
Mutations in angiogenin (ANG) have been identified in patients of various populations 
including Irish, Scottish, Italian, North American, French and German (Greenway et 
al., 2006; Wu et al., 2007; Gellera et al., 2008; Paubel et al., 2008; Fernandez-
Santiago et al., 2009), of which both familial and sporadic cases have been reported. 
As a ubiquitously expressed protein, ANG not only participates in new blood vessel 
formation as it is a downstream effector of VEGF (Kishimoto et al., 2005), but also 
has a neuroprotective effect in motor neurones of ALS animal models (Kieran et al., 
2008). However, ALS-associated ANG mutations reduce the neuroprotective activity 
of the protein (Kieran et al., 2008; Sebastia et al., 2009), which suggests that the loss 
of function of ANG caused by these mutations leaves the motor neurones in a more 
fragile state contributing to ALS pathology. 
Recently, ALS-linked mutations have been identified in two RNA binding proteins, 
TDP-43 and FUS. Mutations in these two genes are mostly  found in the C-terminal 
domain and cause typical ALS (Dejesus-Hernandez et al.; Tamaoka et al.; Gitcho et 
al., 2008; Kabashi et al., 2008; Kuhnlein et al., 2008; Rutherford et al., 2008; 
Sreedharan et al., 2008; Van Deerlin et al., 2008; Yokoseki et al., 2008; Belzil et al., 
2009; Daoud et al., 2009; Del Bo et al., 2009; Drepper et al., 2009; Kwiatkowski et 
al., 2009; Lemmens et al., 2009; Ticozzi et al., 2009; Vance et al., 2009; Lai et al., 
2010; Van Langenhove et al., 2010) with rare cases developing ALS with cognition 
deficits or dementia (Benajiba et al., 2009; Corrado et al., 2009). Taken together, 
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these reports suggest that mutations in TDP-43 account for ~3% of FALS cases and 
~1.5% of SALS, whereas mutations in FUS account for ~4% of FALS. Both proteins 
directly bind to RNA and single- or double-stranded DNA, mostly localised in the 
nucleus and shuttle to cytoplasm (Zinszner et al., 1997). It is proposed that both 
proteins are involved in RNA processing and translocation in neurones since both are 
found as components of RNA granules that translocate to dendritic spines following 
stimuli (Belly  et al., 2005; Fujii et al., 2005; Fujii and Takumi, 2005; Wang et al., 
2008a). However, it is not yet clear whether mutations in these two genes cause the 
disease phenotype through a loss-of-function or gain-of-function mechanism.
A point mutation resulting in an amino acid substitution R199W  in D-amino acid 
oxidase (DAO) was recently  identified in a FALS pedigree (Mitchell et al., 2010). One 
of the physiological substrates of DAO is D-serine which functions as a potent 
activator through binding to the glycine site of the NMDA glutamate receptor 
(Wroblewski et al., 1989; Schell et al., 1995). After activating NMDA receptor together 
with glutamate, D-serine is taken up and degraded by astrocytes where DAO is 
expressed (Urai et al., 2002; Rutter et al., 2007). In this study, we reported that 
R199W  mutation leads to the loss of enzyme activity (Mitchell et al., 2010), which 
may enhance glutamate excitotoxicity. Furthermore, increased ubiquitin-positive 
aggregates are found in cells expressing mutant DAO suggesting a gain of function 
mechanism (Mitchell et al., 2010).
1.1.3 ALS-FTD
Although ALS primarily  affects motor neurones, it can occasionally occur together 
with frontotemporal dementia (FTD). FTD is the second most common form of pre-
senile dementia after Alzheimerʼs disease and is characterised by the degeneration 
of the frontal and anterior temporal lobes of the brain leading to behavioural 
disturbance and personality change (Neary et al., 2005). Since the first case of ALS 
with FTD was reported in 1973 (Finlayson and Martin, 1973), to date, it has been 
suggested that roughly half of patients with ALS have evidence of frontal and 
temporal lobe impairment (Lomen-Hoerth et al., 2003; Strong et al., 2003; Ringholz 
et al., 2005) and 5-15% of ALS cases are clinically  diagnosed with FTD (Hudson, 
1981; Al-Chalabi and Leigh, 2000). Pathologically, the finding that ubiquitinated 
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TDP-43 is present in the neuronal inclusions of both ALS and a subset of FTD 
(Wilson et al., 2001; Arai et al., 2006; Neumann et al., 2006) indicates that ALS and 
FTD phenotypes are part of the same disease spectrum (Talbot and Ansorge, 2006). 
In supporting this hypothesis, family linkage studies have identified three loci in 
pedigrees with both ALS and FTD. The first locus on chromosome 9q21-22 was 
identified in five families with individuals developing either ALS-FTD, or ALS or FTD 
alone (Hosler et al., 2000). However, this locus has not been validated in any  other 
ALS-FTD kindreds. Instead, a second locus, 9p21.3-13.3, has been found in ALS-
FTD pedigrees from the Netherlands, Scandinavia, Canada, France and Australia 
(Morita et al., 2006; Vance et al., 2006; Valdmanis et al., 2007; Luty et al., 2008; Le 
Ber et al., 2009). Although a great effort has been devoted into the identification of 
the disease-causing mutation within this region, the causative gene has not yet been 
found. The last locus is on chromosome 17q21, within which mutations in MAPT 
haven been reported in patients with ALS-FTD and Parkinsonian features (Hutton et 
al., 1998; Zarranz et al., 2005). In addition to the loci found in family linkage studies, 
a point mutation R1101K in DCTN1 was found in a family  where individuals carrying 
this mutant gene develop  either ALS or FTD (Munch et al., 2005). Moreover, a 
balanced chromosomal translocation t(18;21)(q23;q22) was reported in one patient 
with ALS-FTD (Prudlo et al., 2004). However, this chromosomal translocation was 
also found in the (at that time) unaffected 37-year-old son of the index patient, and it 
is yet to be confirmed whether the disease phenotype is caused by this chromosomal 
translocation. 
1.2 Cellular disturbance contributing to ALS pathogenesis
As ALS is a clinically and genetically heterogeneous disease, the pathogenic 
processes underlying it are also likely to be multifactorial. Based on the studies of 
ALS-causing gene mutations and the biochemical data gathered from patients, we 
now know that the cellular homeostasis of the affected neurones has been largely 
disrupted. Evidence of deficits in various cell physiological mechanisms concerning 
cytoskeletal organisation, axonal transport, RNA processing and mitochondrial 
dysfunction has been reported. In addition to the deregulation of cellular 
homeostasis, cells also face the challenges from oxidative stress, glutamate 
excitotoxicity and ER stress. Moreover, the contributions from non-neuronal cells 
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such as astrocytes and glial cells have been shown to play an important role in ALS 
pathogenesis. However, these cellular processes do not occur independently, 
instead, they are linked closely to each other so that the activation of one event can 
trigger or enhance the next. For instance, the dysregulation of cytoskeleton is very 
likely  to affect the axonal transport, whereas the proteins can not be sorted or 
exported efficiently and correctly, ER stress is triggered. All in all, motor neurones 
become overwhelmed with these cellular disturbances and subsequently undergo 
apoptotic cell death. As a result, the final ALS phenotype arises cumulatively  from the 
interaction of these abnormal cellular processes. In this section, the detailed 
mechanism mediating cellular disturbances is introduced based on the knowledge we 
have learned from in vitro, in vivo animal models and ALS patients. 
1.2.1 Oxidative stress
The effect of oxidative stress in non-dividing cells, such as neurones, may be 
cumulative and cellular injury by free radical species is a major potential cause of the 
age-related deterioration in neuronal function (see review of Shaw, 2005). The 
involvement of oxidative stress in ALS pathology is supported by the observation of 
elevated levels of markers of free radical damage or abnormal free radical 
metabolism in the cerebrospinal fluid (CSF) and post-mortem central nervous system 
(CNS) of ALS patients (Shaw et al., 1995a; Ferrante et al., 1997; Smith et al., 1998; 
Tohgi et al., 1999). Furthermore, fibroblasts from ALS patients are more sensitive to 
oxidative insults compared with the cells from control (Aguirre et al., 1998).
However, the more direct and detailed evidence comes from studies of ALS-causing 
SOD1 mutant protein. As a superoxide dismutase, the physiological function of SOD1 
is to covert superoxide radicals to oxygen and hydrogen peroxide. It has been 
suspected that the disease-causing mutations may alter the protein structure and 
increase the accessibility of active copper site to aberrant substrates such as 
hydrogen peroxide or peroxynitrite (Beckman et al., 1993). As a substrate of mutant 
SOD1 protein, hydrogen peroxide is converted into reactive hydroxyl radicals 
(Wiedau-Pazos et al., 1996) and peroxynitrite is catalyzed to a reactive nitrating 
species leading to increased rates of nitrotyrosine formation, both of which promote a 
cascade of oxidative damage. As evidence supporting this idea, increased levels of 
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3-nitrotyrosine, a marker for peroxynitrite-mediated oxidative damage, has been 
observed in both mutant SOD1 transgenic mice and ALS patients (both FALS and 
SALS) (Beal et al., 1997; Bruijn et al., 1997). In addition, levels of oxidised products 
have also been found markedly increased in G93A-SOD1 mice in parallel with 
disease progression (Andrus et al., 1998; Hall et al., 1998). However, preventing 
nitric oxide synthesis (Facchinetti et al., 1999; Upton-Rice et al., 1999; Son et al., 
2001) or copper loading of SOD1 protein (Subramaniam et al., 2002; Wang et al., 
2003) has no effect on disease development. Therefore, at least in SOD1 animal 
models, oxidative stress may  only be one of the pathological disturbances that 
occurs during disease development but is not the sole event that initiates and leads 
to disease pathogenesis. 
Interestingly, a recent report showed that exposure of cultured neuronal cells to 
oxidative stress can damage wild type SOD1, modify  its properties to being “mutant 
protein-like” (Ezzi et al., 2007). Like mutant protein, the oxidised wild type SOD1 is 
poly-ubiquitinated, interacts with HSP70, triggers the release of the inflammatory 
molecule TNFα from microglial cells and induces motor neurone death in a dose-
dependent manner (Ezzi et al., 2007). This study provides a link between SALS and 
SOD1-linked models and elucidates the role of SOD1 protein in SALS pathogenesis. 
1.2.2 Glutamate excitotoxicity
Glutamate is the predominant excitatory neurotransmitter in CNS where it binds to 
various types of glutamate receptor, such as NMDA or AMPA receptors, which upon 
activation, allow the influx of sodium and/or calcium into the cytosol. This activation is 
rapidly terminated via clearance of glutamate by the glutamate transporter (EAAT2) 
on astrocytes (Arriza et al., 1994; Fairman et al., 1995; Arriza et al., 1997). Failure to 
clear glutamate from the synapse leads to glutamate excitotoxicity  whereby 
excessive stimulation of glutamate receptors causes increased calcium influx and 
excessive free radical production that eventually results in cell death (Choi, 1994; 
Cleveland and Rothstein, 2001). Studies of cultured spinal cord neurones showed 
that motor neurones are particularly  vulnerable to increased levels of glutamate 
through AMPA receptor-mediated glutamate excitotoxicity  (Rothstein et al., 1993; 
Carriedo et al., 1996; Lu et al., 1996; Saroff et al., 2000) partly due to the fact that 
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levels of calcium binding proteins are markedly lower than other types of neurones 
(Alexianu et al., 1994).
There are several lines of evidence indicating the involvement of glutamate 
excitotoxicity in ALS. First of all, high levels of glutamate and decreased expression 
of EAAT2 are found in the CSF in ALS patients (Rothstein et al., 1990; Rothstein et 
al., 1992; Shaw et al., 1995b; Spreux-Varoquaux et al., 2002) and SOD1 animal 
models (Fray et al., 1998; Trotti et al., 1999; Howland et al., 2002). Of the five 
glutamate transporters (EAAT1-5), EAAT2 is expressed throughout CNS astrocytes 
and is responsible for the majority  of glutamate uptake (Tanaka et al., 1997; Danbolt 
et al., 1998). It is found that reducing the expression of EAAT2 in G93A-SOD1 mice 
impairs motor neurone survival (Pardo et al., 2006) and increasing EAAT2 activity 
enhances the viability of motor neurones (Guo et al., 2003; Rothstein et al., 2005; 
Ganel et al., 2006). One of the mechanisms underlying the down-regulation of 
EAAT2 in ALS is abnormal RNA processing, which is supported by the observation of 
exon skipping and intron retention in a subset of SALS cases (Lin et al., 1998). 
However, this result was not replicated by several other groups who demonstrated 
the presence of these EAAT2 splice variants in normal controls as well as ALS cases 
(Meyer et al., 1999; Honig et al., 2000; Flowers et al., 2001). Another putative 
causative agent is oxidative stress which is shown to inactivate EAAT2 potentially 
through caspase-3-mediated cleavage of EAAT2 in mutant, but not wild type SOD1 
expressing cells (Trotti et al., 1999; Boston-Howes et al., 2006; Gibb et al., 2007). 
In addition to the impairment of glutamate clearance, the properties of the glutamate 
receptor, AMPA receptor, are also altered in ALS. The AMPA receptor consists of four 
types of subunits, GluR1-4, amongst these, GluR2 plays a crucial role in controlling 
calcium permeability of AMPA receptor. Generally, the receptors containing GluR2 
are calcium impermeable whereas receptors without GluR2 are calcium permeable 
(Seeburg et al., 2001). The ability to prevent calcium influx by GluR2 is dependent on 
its Q/R editing site. This is a single nucleotide conversion from adenosine to inosine 
by posttranscriptional RNA editing which, under normal circumstances, results in a 
substitution of glutamine (Q) to arginine (R) that renders the AMPA receptor calcium 
impermeable when activated (Seeburg, 2002). The enzymes that carry out this RNA 
editing are adenosine deaminases acting on RNA (ADAR), of which, ADAR2 is 
specifically responsible for the Q/R site editing of GluR2 (Higuchi et al., 1993). 
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Interestingly, the expression level of ADAR2, as well as the extents of GluR2 Q/R 
editing, are markedly reduced in the spinal cords of SALS cases (Kwak and 
Kawahara, 2005; Kawahara et al., 2006). Supporting this, knockout of the GluR2 
gene or expressing GluR2(N), equivalent to Q at Q/R site, accelerates disease 
progression in G93A-SOD1 transgenic mice (Kuner et al., 2005; Van Damme et al., 
2005) whereas overexpressing GluR2, thereby decreases the number of calcium 
permeable AMPA receptors, delays disease progression (Tateno et al., 2004). 
Another receptor that is capable of mediating glutamate excitotoxicity is the NMDA 
receptor. The activated NMDA receptor is calcium permeable and prolonged 
activation will cause glutamate excitotoxicity as occurs at the AMPA receptor (Prehn 
et al., 1995). However, the activation of NMDA receptor requires the presence of a 
co-activator, glycine or D-serine (Shleper et al., 2005; Panatier et al., 2006), together 
with its substrate, glutamate. D-serine is converted from L-serine by serine racemase 
(SR) in glial cells (Wolosker et al., 1999) and released to the synapse upon NMDA 
receptor activation. After this activation, D-serine is cleared from the synapse by 
astrocytes where it is degraded by D-amino acid oxidase (DAO) (Urai et al., 2002; 
Rutter et al., 2007). The involvement of NMDA receptor-mediated toxicity was first 
shown by the protective effect of memantine, an NMDA receptor antagonist in ALS 
mouse model (Wang and Zhang, 2005). In addition, elevated levels of D-serine are 
also found in G93A-SOD1 transgenic mice in parallel with disease progression 
(Sasabe et al., 2007). 
Taken together, there is plenty  of evidence showing glutamate excitotoxicity occurring 
in ALS, including increased levels of glutamate (Rothstein et al., 1990; Rothstein et 
al., 1992; Shaw et al., 1995b), impairment of glutamate clearance (Rothstein et al., 
1995; Fray et al., 1998) and elevated glutamate receptor activation (Kwak and 
Kawahara, 2005; Kawahara et al., 2006). Animal studies also reveal that the 
impairment of glutamate clearance or increased massive calcium influx accelerates 
disease progression (Kuner et al., 2005; Van Damme et al., 2005; Pardo et al., 2006) 
whereas enhancing glutamate clearance or preventing massive calcium influx has a 
protective effect (Guo et al., 2003; Tateno et al., 2004; Rothstein et al., 2005; Ganel 
et al., 2006). All these studies emphasise the importance of glutamate-mediated 
neuronal excitation mechanism, disturbance of any of the anticipants exposes 
neurones to disruption of cellular calcium homeostasis which leads to cell death. Of 
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note, the only approved treatment of ALS remains to be the glutamate release 
inhibitor, riluzole, which has a marginal effect that prolongs survival in ALS patients 
for an average of three months (Gurney et al., 1996; Lacomblez et al., 1996; Cheah 
et al., 2010). 
1.2.3 cytoskeletal dysfunction
A pathological hallmark that is common to all forms of ALS and animal models is 
cytoskeletal disorganisation in motor neurones, in both the cell bodies and proximal 
axons (Hirano et al., 1984a; Hirano et al., 1984b), where the accumulation of both 
phosphorylated and non-phosphorylated neurofilaments have been found (Ince et al., 
1998). Neurofilaments are neurone-specific intermediate filaments that together with 
microtubules, microtubule-associated proteins and actin make up  neuronal 
cytoskeleton with functions including stimulating axonal growth and determining 
axonal diameter (Walker et al., 2001). On the basis of molecular mass, three types of 
neurofilament subunits have been identified: high molecular weight (NF-H), 
intermediate molecular weight (NF-M) and low molecular weight neurofilaments (NF-
L). Neurofilament subunits are assembled in the motor neurone cell body and 
transported down the axon by slow axonal transport, with progressive 
phosphorylation during movement down the axon (see review of Perrot et al., 2008). 
The finding that transgenic mice expressing mutant neurofilament subunits display 
selective motor neurone dysfunction accompanied by neurofilament accumulation 
and axonal disorganisation (Cote et al., 1993; Xu et al., 1993; Lee et al., 1994), leads 
to the notion that damage in neurofilaments may contribute to ALS pathogenesis. 
Indeed, mutant SOD1 transgenic mice show neurofilament abnormalities including 
alterations in neurofilament organisation with the development of neurofilament 
spheroids, reduced protein levels of neurofilaments and reduced transport rate in 
ventral root axons (Tu et al., 1996; Zhang et al., 1997). In addition, increased NF-H 
expression in mutant SOD1 transgenic mice, which traps most neurofilaments in the 
cell body, effectively improves disease course and prolongs the survival of the mice 
for about six months (Couillard-Despres et al., 1998). A similar effect has also been 
found with mice overexpressing NF-L (Kong and Xu, 2000). The reason for this effect 
is yet understood, however, it is suggested that overexpressed neurofilaments within 
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the cell body may function as a buffer for some other deleterious processes, such as 
providing phosphorylation sites for dysregulated intracellular kinases (Cleveland and 
Rothstein, 2001; Nguyen et al., 2001; Shaw, 2005). On the other hand, deleting NF-L 
expression in mutant SOD1 transgenic mice also has a protective effect which 
extends the life span of the mice by 5-6 weeks despite causing an early motor 
neurone loss at the postnatal stage (Williamson et al., 1998). This protective effect is 
believed to be a result of compensating the reduced slow axonal transport caused by 
mutant SOD1. 
Nevertheless, aberrant neurofilament levels are evident in ALS patients where the 
steady-state mRNA of NF-L is selectively reduced in degenerating spinal motor 
neurones (Bergeron et al., 1994; Wong et al., 2000; Menzies et al., 2002b). The 
stability of NF-L mRNA is regulated by some mRNA stability determinants which are 
either reduced in expression or not functional in ALS tissues (Ge et al., 2002; Ge et 
al., 2003). Amongst the proteins that affect levels of NF-L mRNA, mutant SOD1 has 
been identified as one of these proteins that bind to NF-L mRNA and destabilise it 
(Ge et al., 2005). In addition to the dysregulation of mRNA levels, increased genetic 
variants in the KSP repeat domain have also been found in about 1% of ALS cases 
(Figlewicz et al., 1994; Tomkins et al., 1998; Al-Chalabi et al., 1999). The KSP repeat 
domain in the sidearms in NF-H and NF-M are phosphorylated by a number of 
proline-directed kinases (Jaffe et al., 2001). These neurofilament variants may not 
cause disease by themselves, however, they may represent a risk factor for ALS. 
In addition to neurofilaments, the involvement of another intermediate filament, 
peripherin has also been investigated. The toxic isoform, peripherin 61, has been 
detected in the spinal cords of patients with SALS (Robertson et al., 2003) whereas 
overexpression of the major peripherin isoform, peripherin 58, in mice leads to the 
disruption of neurofilament assembly and the development of late onset motor 
neurone degeneration (Beaulieu et al., 1999). However, manipulating the expression 
levels of peripherin in mutant SOD1 transgenic mice has no effect on disease 
development or progression (Lariviere et al., 2003).
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1.2.4 Defects in axonal transport
As a consequence of cytoskeleton disorganisation, defects in axonal transport occur 
in ALS. Neurones are polarised with axons and dendrites. Whilst most proteins are 
synthesised in the cell body and transported along the axon toward the synapse if 
needed, proteins that are synthesised on-site in the axon or that are taken up from 
the synapse through endocytosis can also be sent to the cell body via axonal 
transport machinery. The axonal transport machinery is composed of rails 
(microtubules), motors (kinesin and dynein) and cargos (proteins, vesicles or 
organelles). According to the transporting direction, two types of axonal transport 
have been defined: anterograde transport is mediated by the kinesin family which 
carries proteins or organelles from the cell body  toward the axonal terminal; 
retrograde transport is mostly  mediated by dynein which takes chemical messages 
and endocytosis products from the axon back to the cell body. Furthermore, the 
transporting machinery can also be categorised as fast or slow axonal transport 
based on the speed of cargo movement. In general, vesicles and organelles such as 
mitochondria are moved by fast axonal transport whereas cytoskeleton components 
move in slow axonal transport (Roy et al., 2000; Wang et al., 2000a). Nevertheless, 
this machinery  must be regulated in a delicate manner, in which the components 
function in an interdependent way so that the disruption of movement in one direction 
will affect movement in the other direction (Brady et al., 1990; Waterman-Storer et al., 
1997; Martin et al., 1999) 
In the human nervous system, motor neurones have axons that can extend up  to one 
metre in length, and are thereby highly dependent on efficient axonal transport 
system. Impairments of axonal transport machinery have been shown to lead to the 
development of motor neurone degenerative phenotypes of different severities in 
animal models (LaMonte et al., 2002; Hafezparast et al., 2003; Chevalier-Larsen and 
Holzbaur, 2006; Chen et al., 2007b), which implies the involvement of axonal 
transport dysfunction in neurodegeneration. Indeed, reduced activity of axonal 
transport and expression of molecular motors have been reported in ALS patients 
(Sasaki and Iwata, 1996; Pantelidou et al., 2007). These defects in axonal transport 
have been further explored in ALS animal model expressing mutant SOD1 in which 
both slow and fast anterograde transports are slowed (Zhang et al., 1997; Borchelt et 
al., 1998; Williamson and Cleveland, 1999) and disruption in retrograde transport is 
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also observed (Breuer et al., 1987; Breuer and Atkinson, 1988; Collard et al., 1995; 
Murakami et al., 2001; Sasaki et al., 2005). These transport defects are found at the 
early stage of disease, mostly  before the occurrence of motor defective symptoms, 
and are exacerbated as disease progresses (Zhang et al., 1997; Borchelt et al., 
1998; Ligon et al., 2005). It has been shown that mutant but not wild type SOD1 
interacts with dynein and this interaction disrupts the function of dynein, which may 
lead to a decreased efficiency  of the motor protein (Ligon et al., 2005; Zhang et al., 
2007; Perlson et al., 2009). In addition, mitochondrial anterograde transport is 
impaired in mutant SOD1 transgenic mice, which leads to the depletion of 
mitochondria from axons (Miller and Sheetz, 2004; De Vos et al., 2007). This 
pathology of mitochondria accumulation in cell bodies has also been seen in human 
(Sasaki et al., 2007; Sasaki and Iwata, 2007). Another marker of dynein dysfunction, 
Golgi fragmentation, has also been found in cells expressing mutant SOD1 (Gonatas 
et al., 2006; Perlson et al., 2009). 
Although both mutant SOD1 expression and overexpression of either wild type or 
mutant dynein lead to motor neurone deficit phenotypes, the molecular mechanism 
between these two is not quite the same. As has been found with mice expressing 
mutant or excessive wild type dynein, the retrograde transport of survival molecules 
and neurotrophic factors are inhibited in mutant SOD1 transgenic mice (Strom et al., 
2008; Perlson et al., 2009). However, an increased association of dynein with “death” 
factors, such as activated caspase-8 and the stress-activated protein kinase JNK, is 
exclusively found in mutant SOD1 transgenic mice but not mice expressing mutant or 
excessive wild type dynein (Perlson et al., 2009), which may explain the more severe 
phenotype of mutant SOD1 transgenic mice. Whereas transgenic mice expressing 
mutant or excessive wild type dynein only develop mild neurodegeneration (LaMonte 
et al., 2002; Hafezparast et al., 2003), it is suggested that the elevation in the 
transport of stressed induced factors may contribute to mutant SOD1-specific rapid 
cell death.
The importance of axonal transport dysregulation in ALS pathogenesis has been 
supported by the finding of ALS-associated mutations in two genes, DCTN1 and 
VAPB, both of which participate in cellular trafficking (Puls et al., 2003; Nishimura et 
al., 2004). Of these two genes, DCTN1 encodes the largest subunit of the dynactin 
complex that interacts with dynein (Gill et al., 1991; Schroer and Sheetz, 1991) and 
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directly participates in axonal transport. Pathological abnormalities such as the loss 
of motor neurones, the sub-cellular accumulation of ubiquitinated inclusions and 
neurofilaments, and astrocytic gliosis have been observed in transgenic mice 
expressing human mutant DCTN1 (G59S) in neuronal tissues (Laird et al., 2008). 
This ALS-linked mutation in DCTN1 destabilises the protein and disrupts the function 
of dynactin (Lai et al., 2007), which lead to impaired sub-cellular vesicle transport in 
cell bodies of motor neurones together with axonal swelling and axo-terminal 
degeneration that contribute to the inevitable cell death (Laird et al., 2008). 
Perturbations in cellular trafficking have also been reported in ALS2 knockout mice 
(Hadano and Ikeda, 2005; Devon et al., 2006) and mutant VAPB expressing cells 
(Prosser et al., 2008). 
1.2.5 Mitochondrial dysfunction
Mitochondria are the energy  factory  of a cell responsible for the generation of 
intracellular ATP and free radicals. Mitochondria are also a storage site for calcium 
that buffers cellular calcium as well as being the site where intrinsic apoptosis is 
initiated. Therefore, damage to mitochondria can lead to disruption of cellular calcium 
homeostasis and initiation of apoptosis through cytochrome c release. It has long 
been observed that abnormal mitochondrial morphology occurs in ALS patients (Afifi 
et al., 1966; Atsumi, 1981) as well as defects in the respiratory  chain complex 
(Wiedemann et al., 1998; Borthwick et al., 1999) and elevated levels of mitochondrial 
calcium (Siklos et al., 1996). In addition, aberrant mitochondrial DNA alterations, 
such as mutations and decreased levels of mitochondrial DNA, have been found in 
motor cortex, spinal cord and muscle tissues of patients with SALS (Dhaliwal and 
Grewal, 2000; Wiedemann et al., 2002). These observations have been further 
explored in SOD1 models where mitochondrial abnormalities such as swelling, 
vacuolisation and decreased activity of respiratory chain complex are apparent at 
early presymptomatic stage, and drastically  increase in both number and volume as 
disease progresses (Kong and Xu, 1998; Bendotti et al., 2001; Jung et al., 2002; 
Sasaki et al., 2004). Similarly, expression of mutant SOD1 in neuronal cells leads to 
morphological change of mitochondria (Jung et al., 2002; Raimondi et al., 2006) as 
well as impairment of calcium homeostasis (Damiano et al., 2006) and ATP 
production (Menzies et al., 2002a; Fukada et al., 2004).
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Although SOD1 is mostly a cytosolic protein, a fraction of mutant SOD1 migrates to 
intermembrane space of mitochondria and forms intra-mitochondrial protein 
aggregates in affected tissues (Takeuchi et al., 2002a; Liu et al., 2004; Pasinelli et al., 
2004). It is believed that mutant SOD1 causes direct damage on mitochondria by 
targeting to it (Magrane et al., 2009). For instance, the mitochondrial intermembrane 
space-localised mutant SOD1 can expand the space which results in a detachment 
between the inner and outer membrane that contributes to mitochondrial vacuolation 
(Higgins et al., 2003). The other proposed mechanisms by which mutant SOD1 
induces mitochondrial dysfunction include the obstruction of protein translocation into 
mitochondria by mutant SOD1-induced aggregates (Liu et al., 2004) and abnormal 
interaction with mitochondrial proteins such as Bcl-2 (Pasinelli et al., 2004).
Since mitochondrial dysfunction can both result from and cause oxidative toxicity, it is 
not yet clear whether it represents a primary or secondary pathological feature. In 
either case, pathological mitochondria can mediate apoptosis by  releasing calcium 
and cytochrome c into the cytoplasm, which initiates intrinsic apoptosis pathway (see 
reviews of Lockshin and Zakeri, 2001; Nelson and White, 2004). Reducing 
mitochondrial membrane permeability by creatine or minocycline effectively delays 
disease onset of G93A-SOD1 transgenic mice and increases the survival of motor 
neurones (Klivenyi et al., 1999; Zhu et al., 2002).
1.2.6 ER stress and protein degradation
Endoplasmic reticulum (ER) is the organelle responsible for the synthesis, folding 
and post-translational modification of most secretory  and membrane-bound proteins, 
as well as the site for cellular calcium storage (Gaut and Hendershot, 1993). To 
maintain the quality of proteins, cells adjust the protein-folding capacity of the ER 
according to their requirements through the actions of signal transduction pathways 
with sensors residing on the ER membrane. The accumulation of unfolded or 
misfolded proteins, or the disturbance of calcium homeostasis, leads to the activation 
of unfolded protein response (UPR), which activates the so-called ER stress sensors 
on the ER membrane. The principle aims for UPR are to reduce protein loading in ER 
and increase the capacity of ER machinery. However, if the homeostasis can not be 
re-established, UPR eventually triggers cell death to protect the organism from rogue 
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cells that display misfolded proteins (see reviews of Szegezdi et al., 2006; Ron and 
Walter, 2007). The three integral membrane ER stress sensors are inositol-requiring 
protein-1 (IRE1), activating transcription factor-6 (ATF6) and protein kinase RNA 
(PKR)-like ER kinase (PERK), each of which represents an independent arm of 
signalling pathway activated by ER stress. Under non-stressed normal 
circumstances, the ER chaperone GRP78/Bip  binds to the ER luminal domain of 
these three sensors and inactivates them. On accumulation of unfolded proteins, 
GRP78 dissociates from these three sensors, and this leads to their activation and 
triggers the UPR.
IRE1 is the most well characterised arm of the UPR, which upon activation, dimerises 
on the plane of the membrane allowing for auto-phosphorylation (Credle et al., 2005; 
Zhou et al., 2006). The phosphorylated IRE1 causes endonucleolytic cleavage of X-
box binding protein-1 (XBP1) mRNA (Yoshida et al., 2001; Calfon et al., 2002) which 
in turn produces a stable transcriptional activator that up-regulates genes encoding 
for ER chaperones (Lee et al., 2003) and components of ER-associated degradation 
(ERAD) (Travers et al., 2000; Lee et al., 2003; Yoshida et al., 2003; Oda et al., 2006). 
In addition, phosphorylated IRE1 also activates the stress-induced Jun N-terminal 
kinase (JNK) (Urano et al., 2000) and interacts with components of the cell death 
machinery, such as caspase-12 (Yoneda et al., 2001; Hetz et al., 2006). As occurs for 
IRE1, after dissociated from GRP78, PERK also undergoes dimerisation and trans-
autophosphorylation which successively  phosphorylates the α subunit of eukaryotic 
translation initiation factor-2 (eIF2α) (Bertolotti et al., 2000). The phosphorylation of 
eIF2α results in a global transcriptional attenuation to hold back the novel protein 
synthesis and thus prevent the further overloading of the ER (Harding et al., 1999; 
Harding et al., 2000). Meanwhile, phosphorylated eIF2α also contributes to up-
regulation of some UPR-targeted genes such as CHOP (Marciniak et al., 2004). The 
third arm of UPR is mediated by ATF6, which once released from GRP78, 
translocates to Golgi where it is cleaved by site 1 and site 2 protease (S1P and S2P) 
respectively (Ye et al., 2000; Shen et al., 2002). The cytosolic effector domain is then 
imported into the nucleus where it up-regulates ER chaperones, XBP1 and CHOP 
(Haze et al., 1999; Wang et al., 2000b; Szegezdi et al., 2006). 
Although the primary target of UPR is to facilitate the proper folding of proteins that 
accumulate in ER lumen, ERAD is also activated to remove excessive proteins and 
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proteins that have failed to fold properly. Being subject to ERAD, the aberrant 
proteins are targeted for retrotranslocation to the cytosol where they are degraded 
through ubiquitin-proteasome system (see reviews of Meusser et al., 2005; Vembar 
and Brodsky, 2008). The basal activity  of ERAD is limited and several components of 
ERAD, such as Derlin-2 and EDEM, which are required for substrate 
retrotranslocation, are up-regulated by IRE1 during UPR (Lee et al., 2003; Yoshida et 
al., 2003; Oda et al., 2006). The deficiency in ERAD machinery leads to a constitutive 
UPR (Travers et al., 2000), which may be a result of chronic accumulation of aberrant 
proteins in ER that would eventually damage the cells.  
As the presence of cytosolic inclusion bodies containing mis-folded/ubiquitinated 
proteins has been recognised as a pathological feature of various neurodegenerative 
diseases, it is not surprised that the up-regulation of ER stress has been found in 
association with Parkinsonʼs disease (Ryu et al., 2002; Hoozemans et al., 2007), 
Alzheimerʼs disease (Nakagawa et al., 2000), polyglutamine disease (Duennwald 
and Lindquist, 2008) and ALS (Ilieva et al., 2007; Atkin et al., 2008). The first piece of 
evidence suggesting an involvement of ER stress in ALS is the up-regulation of 
GRP78, which was demonstrated in mutant SOD1 transgenic mice in 2003 
(Tobisawa et al., 2003). Since then, considerable evidence has accumulated for the 
activation of the full spectrum of ER stress-related proteins in mutant SOD1 
expressing cells (Nishitoh et al., 2008; Oh et al., 2008) and in mutant SOD1 
transgenic animals where the activation of all three ER stress sensors IRE1, PERK 
and ATF6 (Kikuchi et al., 2006), induction of ER chaperones such as PDI and Erp57 
(Atkin et al., 2006) and induction of CHOP and caspase-12 which contribute to ER 
stress-induced cell death (Wootz et al., 2004; Kikuchi et al., 2006; Ito et al., 2009) 
have been shown. Most importantly, the up-regulation of IRE1, PERK and ATF6 have 
also been found in SALS spinal cord (Ilieva et al., 2007; Atkin et al., 2008). In addition 
to the activation of ER stress, dysfunctional proteasome activity  has also been 
reported in mutant SOD1 transgenic mice (Cheroni et al., 2009), which furthermore 
contributes to cellular stress and thus may lead to irreversible cell damage. 
The cause of ER stress in ALS is still unknown. One possibility  is that the ER 
machinery is saturated in ALS affecting motor neurones because of the excessive 
production of misfolded proteins. This hypothesis is supported by the finding that 
mutant SOD1 causes a gain-of-function effect by interacting with ER chaperones 
such as GRP78 and Hsp70 (Urushitani et al., 2004; Kikuchi et al., 2006). As a result 
of this, protein chaperone capacity is markedly  reduced in mutant SOD1 transgenic 
mice (Shinder et al., 2001; Tummala et al., 2005). On the other hand, overexpression 
of chaperones reduces mutant SOD1 aggregation and enhances cell survival in cell 
culture (Takeuchi et al., 2002b) and in mutant SOD1 transgenic mice (Sharp et al., 
2008). Another candidate mechanism by which ER stress may be induced in ALS is 
through mutant proteins or other cytotoxic agents in ALS which impair ER machinery 
so that ER stress can not be resolved efficiently and develops into a chronic stress. It 
has been found that mutant SOD1 interacts with an ERAD component, Derlin-1, and 
thus interferes with the assembly of ERAD. Disruption of this interaction effectively 
prevents mutant SOD1-induced ER stress and cell death (Nishitoh et al., 2008). 
Although ER stress takes place early in ALS pathogenesis (Shinder et al., 2001; 
Tummala et al., 2005; Saxena et al., 2009), it is believed that the activation of ER 
stress is cytoprotective rather than harmful. However, no matter through which of the 
two proposed mechanisms, the mutant proteins eventually paralyse the ER stress-
coping response as well as the ubiquitin-proteasome system. Administration of 
salubrinal, which enforces the activation of PERK pathway by inhibiting 
dephosphorylation of eIF2α, efficiently reduces the level of mutant SOD1 
aggregation, increases cell viability and also delays disease onset in transgenic 
animals (Oh et al., 2008; Saxena et al., 2009).
1.2.7 RNA processing
Recently, the involvement of RNA processing in ALS pathogenesis has gained much 
attention with the identification of ALS-associated mutations in two RNA binding 
proteins, TDP-43 and FUS (Sreedharan et al., 2008; Kwiatkowski et al., 2009; Vance 
et al., 2009). RNA processing includes RNA transcription, pre-mRNA splicing, editing, 
transportation, translation and degradation, and the control of mRNA fate plays an 
important role both during the development of the nervous system and for the 
maintenance of neuronal activities (Besse and Ephrussi, 2008; van Blitterswijk and 
Landers, 2010). To respond to various acute electrical and chemical stimuli, mRNAs 
and RNA-binding protein complexes are transported to the dendrite, where in situ 
protein synthesis takes place (Miller et al., 2002; Tiruchinapalli et al., 2003; Antar et 
al., 2004; Huang et al., 2005). Under certain stress circumstances, the protective 
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stress granules containing specific mRNAs (such as Hsp70) and RNA binding 
proteins are formed, which bypass global translation arrest and facilitate the ability  of 
cells to endure cellular insults (Kedersha and Anderson, 2002; Anderson and 
Kedersha, 2008). To be able to maintain cellular homeostasis at the same time as 
allowing neurones to effectively  respond to stimuli at dendrite terminals, a precise 
spatial-temporal control of mRNA translation is essential and specific RNA binding 
protein complexes are also required. However, abnormal RNA metabolism and 
mislocalisation of some RNA binding proteins have been observed in ALS animal 
models (Lu et al., 2007; Chang et al., 2008; Kong et al., 2008) indicating 
disturbances of RNA processing participating in ALS pathogenesis. 
Among the known RNA binding proteins that participate in the in situ RNA processing 
regulation, two are linked to ALS with mutations being found to cause the disease: 
TDP-43 and FUS. Although both proteins are mostly localised at the nucleus, they 
also function as RNA chaperones as they continuously shuttle between nucleus and 
cytoplasm (Zinszner et al., 1997) and are incorporated into RNA granules (Belly et 
al., 2005; Elvira et al., 2006) and stress granules in response to cellular insults 
(Andersson et al., 2008; Colombrita et al., 2009). Both TDP-43 and FUS contain 
RNA binding motif (Zinszner et al., 1997; Buratti and Baralle, 2001; Lerga et al., 
2001; Kashima et al., 2007) through which they participate in the regulation of mRNA 
translation and splicing (Krecic and Swanson, 1999; Delva et al., 2004) as well as the 
processing of non-coding RNAs (Gregory et al., 2004; Wang et al., 2008b). The 
known substrates of TDP-43 include SMN2 (Bose et al., 2008) and NF-L (Strong et 
al., 2007; Volkening et al., 2009; Volkening et al., 2010), the expression of which play 
a crucial role in neuronal survival as discussed above. ALS-associated mutations in 
these two genes are concentrated in the conserved C-terminal domain, which is 
believed to be responsible to protein-protein interaction (Buratti et al., 2005). As the 
presence of TDP-43 in sub-cellular aggregates is found in the ALS-affected cells 
(Leigh et al., 1988; Hirano, 1996; Arai et al., 2006; Neumann et al., 2006) and the 
ALS-associated mutations in both TDP-43 and FUS cause re-distribution of both 
proteins (Sreedharan et al., 2008; Kwiatkowski et al., 2009; Vance et al., 2009), it is 
speculated that the impairments of RNA processing mediated by either of these 
proteins contribute to the development of ALS.
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In addition to TDP-43 and FUS that directly  bind to RNA, other ALS-associated 
genes that are known to be involved in RNA processing include ANG and SETX, 
which either act as a regulator directly  influencing the production of small RNAs, such 
as rRNA and tRNA (Xu et al., 2002, 2003; Fu et al., 2009; Yamasaki et al., 2009), or 
interact with other RNA modification proteins and thus indirectly participate in this 
process (Suraweera et al., 2007; Suraweera et al., 2009). As further evidence to 
support the idea that the disturbance in RNA processing could lead to neuronal 
dysfunction associated with ALS, mutant SOD1 has also been found to cause 
destabilisation and dysregulation of mRNA transcripts such as NF-L and VEGF 
(Menzies et al., 2002b; Ge et al., 2005; Lu et al., 2007; Li et al., 2009). Other 
abnormalities in RNA processing observed in ALS include deranged RNA splicing of 
EAAT2 (Lin et al., 1998) and impaired Q/R site editing of GluR2 mRNA (Kwak and 
Kawahara, 2005), both of which lead to a reduced capacity of glutamate excitotoxicity 
as previously introduced. 
 
1.2.8 Non-cell autonomous toxicity 
Since ALS is a disease specifically attacking motor neurones, it was initially 
speculated that the disease was caused via motor neurone cell autonomous toxicity, 
meaning that damage within a selective population of affected neurones alone 
suffices to produce disease phenotype. However, this idea was overturned with three 
unexpected reports published between 2000 and 2002 which showed that selectively 
expressing mutant SOD1 in either neuronal cells or glial cells alone was not sufficient 
to produce an ALS phenotype in mice models (Gong et al., 2000; Pramatarova et al., 
2001; Lino et al., 2002). It was later confirmed that although motor neurones are the 
primary target of cell death in ALS, the expression of disease proteins in other cell 
types, which contribute to the alteration of neuronal environment, could affect the 
survival of neurones and the development of disease. 
As the most abundant cells in CNS, glial cells play an important role in supporting 
neurones with trophic factors and maintaining glutamate homeostasis by an active 
uptake of excess glutamate through glutamate transporters. Disturbances in 
astrocyte properties such as elevated level of astrocyte proliferation and reduced 
expression of glutamate transporter have been observed as early features during 
44
disease development (Rothstein et al., 1995; Ince et al., 1996; Bruijn et al., 1997; 
Howland et al., 2002). As astrocytes provide such an important support for neuronal 
survival, it is not surprising to find increased viability of mutant SOD1 expressing 
motor neurones while surrounded by or co-cultured with wild type astrocytes 
(Clement et al., 2003; Di Giorgio et al., 2007; Nagai et al., 2007). On the other hand, 
when co-cultured with, or surrounded by the mutant SOD1 expressing astrocytes, 
even wild type motor neurones undergo cell death (Clement et al., 2003; Di Giorgio 
et al., 2007; Nagai et al., 2007). In addition, chimeric mice with a deletion of mutant 
SOD1 expression in astrocytes of mutant SOD1 transgenic mice show slowed 
disease progression (Yamanaka et al., 2008) whereas the excision of mutant protein 
expression in motor neurones causes delayed disease onset but does not alter the 
rate of disease progression after onset (Boillee et al., 2006). Supporting this, focal 
transplantation of lineage-restricted astrocyte precursors shows a protective effect by 
slowing disease progression (Lepore et al., 2008). Taken together, these results 
indicate that, at least in the case of mutant SOD1-induced ALS, damage within motor 
neurones drives disease onset, whereas damage within their glial cell neighbours 
accelerates disease progression. It is yet clear how mutant astrocytes convey toxicity 
to motor neurones, however, evidence has been shown that they are unable to up-
regulate the glutamate transporter subunit GluR2 in neighbouring motor neurones as 
the wild type astrocytes do (Van Damme et al., 2007) and induce Bax-dependent cell 
death of motor neurones (Nagai et al., 2007; Cassina et al., 2008).  Interestingly, this 
non cell-autonomous toxicity  seems to be restricted to astrocyte-motor neurone 
interaction as mutant SOD1 expressing astrocytes show no toxicity to dorsal root 
ganglion neurones, spinal primary GABAergic interneurones and embryonic stem 
cell-derived interneurones (Nagai et al., 2007). 
The contribution of microglia to motor neurone degeneration is not as straightforward 
as that of astrocytes. Although the activation of microglia is one of the early  events of 
disease progression (Ince et al., 1996) and reduced expression of mutant SOD1 in 
microglia or myeloid lineage cells substantial slows disease progression in animal 
model (Boillee et al., 2006; Wang et al., 2009), mutant microglial cells do not induce 
overt motor neurone death as mutant astrocytes do in the direct co-culture 
environment (Nagai et al., 2007). It may be that microglial cells exert their influence 
through the regulation of immune response. 
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Inflammatory responses have been observed with proliferation of activated microglia 
in areas of significant motor neurone loss, which include motor cortex, motor nuclei of 
the brainstem, the corticospinal tract and the spinal ventral horn both in mutant SOD1 
transgenic mice and ALS patients (Kawamata et al., 1992; Ince et al., 1996; Alexianu 
et al., 2001; Turner et al., 2004). Activated microglia transform to phagocytic cells 
which are capable of releasing a series of cytotoxic molecules such as ROS, 
proteases, inflammatory cytokines and nitric oxide (Gonzalez-Scarano and Baltuch, 
1999). As the acute neuroinflammatory response is typically short-lived and 
terminated shortly after the insults have been removed, the long-standing and self-
perpetuating chronic neuroinflammation is believed to be responsible for the ALS-
linked neuronal death. Indeed, studies of ALS mouse models show prominent and 
sustained microglial activation and proliferation throughout disease progression 
(Alexianu et al., 2001; Hensley et al., 2002; Hensley  et al., 2003) with elevated levels 
of cytokines such as TNFα even before the appearance of motor deficits (Elliott, 
2001). In addition to TNFα, the up-regulation of a wide range of inflammatory 
cytokines has been observed, which includes IL-6, IL-1β, COX2 and PGE2 in spinal 
cord or CSF of patients with ALS and in spinal cord of disease mouse models 
(Sekizawa et al., 1998; Almer et al., 2001; Elliott, 2001; Almer et al., 2002; Hensley et 
al., 2002) together with the increase of the extracellular domains of the two TNFα 
receptors in the serum of ALS patients (Akiyama et al., 1994; Poloni et al., 2000). 
The sustained release of these inflammatory cytokines subsequently perpetuates the 
inflammatory cycle, activating additional microglia and resulting in further release of 
inflammatory factors which ultimately leads to neuronal apoptosis. As evidence of 
aggressive neuroinflammation contributing to ALS, it has been shown that levels of 
TNFα correlate positively with severity  of motor neurone loss in mouse model (Elliott, 
2001; Yoshihara et al., 2002) as has been found of ALS patients where the levels of 
inflammatory markers correlate with the severity of disability of the patients (Keizman 
et al., 2009).
Treatment with anti-inflammatory agents such as minocycline increases the life 
expectancy of mutant SOD1 transgenic mice (Kriz et al., 2002; Van Den Bosch et al., 
2002; Zhu et al., 2002; West et al., 2004) and also neutralises the toxicity of ALS 
CSF in cultured spinal cord motor neurones (Tikka et al., 2002). On the other hand, 
chronic stimulation with proinflammatory molecules exacerbates disease progression 
in mutant SOD1 transgenic mice (Nguyen et al., 2004). Consistent with those results, 
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bone marrow transplantation to replace mutant SOD1 expressing microglia slows 
disease progression but does not affect disease onset (Beers et al., 2006) which is 
controlled by mutant motor neurones.
Other mediators which convey inflammation-induced cytotoxicity in ALS include nitric 
oxide, MCP-1 and NF-κB, all of which are found up-regulated in both ALS patients 
and mouse models (Migheli et al., 1997; Cha et al., 2000; Ciriolo et al., 2000; 
McManus et al., 2000; Casciati et al., 2002; Raoul et al., 2002; Kuhle et al., 2009). 
The activation of NF-κB, which is observed exclusively  in astrocytes but not motor 
neurones from ALS patients (Migheli et al., 1997), subsequently induces the 
expression of NO synthase and COX2 resulting in astrocytic glutamate release and 
free radical formation. Indeed, evidence has been found of elevated NO synthase 
and COX2 in both ALS patients (Almer et al., 2002) and mouse models (Cha et al., 
2000; Almer et al., 2001) and treatment with a COX2 inhibitor is protective in the ALS 
mouse model (Drachman et al., 2002). 
Interestingly, most ALS-associated proteins are ubiquitously  expressed, amongst 
which SOD1 and VAPB have already been shown to be secreted (Mondola et al., 
1996; Mondola et al., 1998; Cimini et al., 2002; Tsuda et al., 2008). Although both 
proteins participate in the machinery of exocytosis and this property is impaired by 
ALS-linked mutations (Prosser et al., 2008; Urushitani et al., 2008), it seems that the 
secretion of VAPB is potentially impaired by P56S mutation (Tsuda et al., 2008) 
whereas the presence of extracellular mutant SOD1 is ambiguous (Turner et al., 
2005; Urushitani et al., 2006; Gomes et al., 2007). However, conditioned medium 
derived from mutant SOD1 expressing neuroblastoma cells trigers the activation of 
microglia, as demonstrated by elevated levels of TNFα (Urushitani et al., 2006).
As ALS causes weakness and atrophy of muscles as a consequence of motor 
neurone loss, the effect of mutant protein expression in muscles has also been 
investigated. Transgenic mice with selectively expressing mutant SOD1 in skeletal 
muscle displays damages to muscle reminiscent of features seen in ALS, such as 
progressive muscle atrophy associated with a significant reduction in muscle 
strength, alterations in the contractile apparatus, mitochondrial dysfunction and the 
induction of oxidative stress (Dobrowolny et al., 2008). However, the expression of 
mutant SOD1 in muscles does not cause motor neurone degeneration (Dobrowolny 
et al., 2008) and diminished muscular mutant SOD1 synthesis has no effect on 
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mutant SOD1-mediated disease (Miller et al., 2006; Towne et al., 2008). Therefore, 
the deficits in muscle are more likely to be due to a secondary effect accompanying 
disease progression and mutant muscles are not the primary cells causing non-cell 
autonomous toxicity. 
Taken together, it is now clear that in addition to motor neurones, other cell types also 
actively participate in the generation of the pathological phenotypes by shaping the 
micro-environment of motor neurones, and contributing to the effect of non-cell 
autonomous toxicity. 
 
1.2.9 Apoptosis
As the disease progresses, molecular signals exchanged between each pathway 
trigger the activation of a vicious cycle that fortifies cellular perturbation. For instance, 
abnormal RNA processing which affects the expression of neurofilaments and 
glutamate transporters affects cytoskeletal organisation and calcium homeostasis; 
activation of glutamate receptors produces ROS and calcium influx (Bondy and Lee, 
1993; Mattson and Sherman, 2003) whereas free radicals can increase glutamate 
release (Pellegrini-Giampietro et al., 1990; Gilman et al., 1994); aberrant proteins 
that cannot be degraded efficiently induce ER stress and the dysfunction of both ER 
and mitochondria leads to disruption in cytosolic calcium homeostasis. Eventually, as 
the convergence of multiple cellular disturbances accumulated, degeneration of the 
affected motor neurone occurs. 
In general, cell death can be classified into three categories: necrosis, autophagy, 
and apoptosis. Necrosis refers to a cell that swells and ruptures during its demise, 
often in response to profound damage of a physical insult, thereby releasing its 
intracellular components into the surrounding tissue (Nelson and White, 2004). 
Autophagy is an ordered cellular process involving a large number of gene products 
whereby cell lysis is prevented and this process is generally believed to be a 
response to nutritional deprivation (Nelson and White, 2004). Although the up-
regulation of autophagy markers has recently been identified in both ALS mice and 
patients (Morimoto et al., 2007; Hetz et al., 2009) and forced activation of 
macroautophagy-lysosome-mediated protein degradation efficiently  dissolves cellular 
mutant SOD1 aggregation (Hetz et al., 2009), there is no evidence yet showing the 
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autophagy-mediated cell death has taken place in ALS. On the other hand, 
biochemical markers from both animal models and post-mortem patient tissues 
indicate that disease-affected motor neurones eventually undergo programmed cell 
death, apoptosis.
Apoptosis is also an ordered cell death process characterised by a series of 
molecular and morphological changes that result in the ʻpackagingʼ and rapid 
removal of the dying cell. Features of this type of cell death include chromatin 
condensation, DNA fragmentation, loss of mitochondrial membrane potential, plasma 
membrane lipid asymmetry, and detachment from the cellular matrix as well as the 
activation of a series of caspases (Nelson and White, 2004; Chipuk and Green, 
2005). Based on how the death signal is transduced, two apoptotic pathways have 
been identified (Figure 1.1). The intrinsic pathway, also known as mitochondria-
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Figure 1.1 General scheme of apoptosis. Apoptotic cell death is categorized generally into intrinsic 
and extrinsic pathways. Whereas intrinsic pathway is initiated by cellular stresses, extrinsic pathway is 
triggered by the binding of death ligand to the plasma membrane death receptor. However, these 
death signals activate intracellular cascades involving activation of pro-apoptotic molecules, increased 
mitochondrial permeability and cytochrome c release. In the end, the executioner caspase-3 is 
activated provoking further caspase activation that culminate in substrate proteolysis and cell death.
dependent pathway, is triggered by elevated levels of cytosolic ROS, calcium or other 
cellular stresses. With the translocation of pro-apoptotic BCL2 proteins such as BAX 
and BAD, increased mitochondrial permeability  occurs which further leads to 
cytochrome c release from the mitochondrial intermembrane space. Once released 
to the cytosol, cytochrome c induces the oligomerisation of apoptotic-protease-
activating factor-1 (APAF1), together they recruit and activate caspase-9. Activated 
caspase-9 cleaves and activates executioner caspases, such as caspase-3, -6 and 
-7. The extrinsic pathway is induced by the ligation of death-receptors with death 
ligands, which in turn causes the recruitment of adaptor molecules leading to the 
activation of caspase-8. In addition to the induction of downstream executioner 
caspases cleavage, activated caspase-8 also triggers the proteolysis of BID which 
can promote mitochondrial cytochrome c release and assembly of the apoptosome 
(see the reviews of Chipuk and Green, 2005; Mattson and Magnus, 2006; Taylor et 
al., 2008).
There is plenty of evidence showing the activation of a wide range of apoptosis 
markers both in ALS mouse models and in ALS patients. Activation of caspase-1 and 
caspase-3 has been found in human (Guegan et al., 2001), mice (Li et al., 2000; 
Pasinelli et al., 2000; Vukosavic et al., 2000) and mutant SOD1 expressing cells 
(Durham et al., 1997; Pasinelli et al., 1998) together with cytochrome c release and 
caspase-9 activation (Guegan et al., 2001; Zhu et al., 2002). In supporting the 
involvement of mitochondrial mediated apoptosis, a redistribution of a series of BCL2 
family proteins, such as the pro-apoptotic Bax and Bak, and down-regulation of anti-
apoptotic Bcl-2 has been identified in ALS (Mu et al., 1996; Martin, 2000). BCL2 
family proteins control cell fate by interacting with the membranes of mitochondria 
and ER. The pro-apoptotic protein members of this family such as Bax, Bak and Bad 
increase mitochondrial membrane permeability and the release of apoptotic factors, 
whereas the anti-apoptotic protein members such as Bcl-2 and Bcl-XL stabilise the 
membrane (Yuan and Yankner, 2000; Cheung et al., 2005). It is known that SOD1 
can bind to Bcl-2, which may have an protective effect initially, however, mutant 
SOD1 would not let go of Bcl-2 and thus traps it into aggregates (Rabizadeh et al., 
1995; Pasinelli et al., 2004) thereby resulting in a functional deprivation of Bcl-2 in 
mutant SOD1 expressing cells. Crossing Bcl-2 overexpression transgenic mice or 
Bax knockout mice with mutant SOD1 mice markedly preserves motor function and 
extends survival with delayed symptom onset (Kostic et al., 1997; Gould et al., 2006). 
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In addition, the administration of caspase inhibitor (Li et al., 2000) or minocycline 
(Kriz et al., 2002; Van Den Bosch et al., 2002; Zhu et al., 2002; Zhang et al., 2003) 
which inhibits mitochondrial cytochrome c release shows neuroprotection in mutant 
SOD1 transgenic mice. Unfortunately, the protective effects of minocycline in ALS 
mouse model are not validated in patients (Gordon et al., 2007).
In summary, ALS causes motor neurone degeneration via disruption of various 
cellular functions as well as exposing motor neurones to all kinds of stresses. 
Furthermore, the micro-environment of motor neurones is also modified due to the 
disease-affecting astrocytes and microglia, and this makes motor neurones more 
vulnerable. In the end, motor neurones are overwhelmed by stress and dysfunctional 
physiological activity, resulting in apoptotic cell death. Muscle weakness and atrophy 
arise as a consequence of losing motor neurones, which eventually  leads to fatal 
respiratory failure of patients. 
1.3 Project rationale
Although the recent advances in genetic screening technology have led to the 
identification of novel ALS-causing mutant genes in FALS, the causes of the majority 
cases are still unknown. In addition, even though multiple cellular disturbances have 
been characterised in cell culture and animal models, it is not yet clear how mutant 
proteins lead to these disease-related functional disruptions. In this project, we aim to 
answer four main questions in ALS pathogenesis:
• What are the other disease-associated genes for the remaining 70% of FALS 
cases?
• What is the prevalence of known disease-associated genes in our ALS cohort?
• How do these mutant genes cause ALS pathology?
• How are the effect of these disease-associated genes linked to SALS?
Our group has recruited about 200 families with FALS as well as about 100 patients 
with SALS mainly from UK. Mutations in SOD1 were identified in about 20% of these 
FALS families (Orrell et al., 1995a; Orrell et al., 1995b; Hosler et al., 1996). In 
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addition to SOD1 screening, this cohort has also been used to screen for other 
genes, such as the apoptosis inhibitory  protein NAIP, SMN and thioredoxin reductase 
1 (TXNRD1) (Orrell et al., 1997; Mitchell et al., 2009). Moreover, since we have 
obtained post-mortem spinal cord tissues from ALS cases and control individuals, 
gene expression profiles have also been evaluated and correlated with disease onset 
and duration (Malaspina et al., 2000, 2001; Anagnostou et al., 2010). Two disease-
associated loci have been identified in linkage studies, the first is on chromosome 
16q12.1-q12.2 in a family with ALS (Abalkhail et al., 2003) and the second locus on 
chromosome 9p21.3-p13.3 was identified in a family with ALS-FTD (Morita et al., 
2006). However, no disease-causative gene has been identified in either regions. 
Recently, two linkage studies have been carried out with two families of this cohort, 
which led to the discovery of two novel disease-associated genes, TDP-43 and DAO 
(Sreedharan et al., 2008; Mitchell et al., 2010). Nevertheless, further functional study 
is required to characterise the property of these mutant proteins.
To gain a better understanding in ALS pathogenesis based on previous work of this 
group, the aims of this project include:
• Screening for mutations in the FALS cohort. Amongst the known ALS-associated 
genes, we screened for mutations in our FALS cohort, in particular TDP-43, to gain 
insight of the prevalence of this gene in our FALS population.
• Investigating the genetic involvement of VAPB in SALS. As our group had 
previously found a significant down-regulation of VAPB in SALS spinal cords 
(Anagnostou et al., 2010), an association study was carried out to investigate 
whether SNPs in the VAPB gene were linked to gene expression levels. 
• Functional characterisation of ALS-associated VAPB mutations. Our group had 
identified a novel VAPB mutation in one of our FALS cases. In this project, we used 
cell culture-based functional analysis to investigate the cellular disturbances caused 
by mutant VAPB, especially relating to the involvement of ER in ALS pathology.
• Extended gene screening of the chromosome 12 ALS locus and functional 
characterisation of the novel ALS-associated DAO mutations. A novel ALS-linked 
locus was identified in a chromosome12-linked pedigree, within which a point 
mutation in DAO was found in all affected individuals but not in the unaffected 
relatives or spouses of this family. In this project, more genes within the linked 
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chromosome region were screened which yielded no other mutation, thereby 
confirming that the mutation in DAO is ALS-causative in this pedigree. Further cell-
based functional studies were carried out to characterise the property of this 
mutation.
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Chapter II MATERIALS and 
METHODS
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2.1 Overview
In this study, a wide range of advanced techniques concerning gene cloning, cell 
culturing and protein property analysis were used. In this chapter, details of the 
procedures of these protocols are described and buffer compositions are provided. 
2.2 DNA Amplification, Purification and Quantification 
The preparation of purified DNA is a common procedure to produce DNA for various 
applications, such as sequencing and cloning. 
2.2.1 DNA extraction from blood
DNA was extracted from the aqueous phase of TRIZOL homogenates (Anagnostou 
et al., 2010) using 0.5 ml of BEB buffer (4M guanidine thiocyanate, 50 mM NaCl, 1M 
Tris). After centrifuging for 30 min at 12000×g, the upper phase was transferred to a 
fresh tube and DNA was then precipitated by adding isopropanol (0.4 ml, BDH). The 
sample was centrifuged for 15 min at 12000×g at 4°C to pellet DNA. After a 70% 
ethanol wash and air dry, DNA was resuspended in water for use.
2.2.2 Polymerase Chain Reaction (PCR)
To amplify the desired region of DNA fragments, 20 ng of genomic DNA or ~10 ng of 
plasmid DNA were used as template, which was then mixed with a PCR mixture 
containing 1× PCR buffer (provided with enzyme), 1.5 mM MgSO4, 0.2 mM dNTP 
mixture (Invitrogen) 0.5 μM of forward and reverse primer respectively and 1U of Taq 
polymerase. Throughout this study, two Taq polymerases were used. Platinum Taq 
(Invitrogen) was the primary polymerase that was used for most of the PCRs, 
however, for some difficult reactions, GoTaq (Promega) was used in its place. 
Whatever polymerase was used, the reaction mixtures were then placed in the PCR 
machine for thermo cycle consisting of denaturation (94 ℃ for 30 seconds), 
annealing (50-60 ℃ depending on the DNA/primer sequence, for 30 seconds) and 
elongation (72 ℃ for 1 minute) stages. This cycle was typically repeated for 35-38 
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times with an initial denaturing step (94 ℃ for 5 minutes) and an extended elongation 
step (72 ℃ for 7 minutes) after completion of the cycles. PCR performance 
enhancing reagents such as DMSO (Sigma) or PCR Enhancer (Invitrogen) were 
sometimes used to facilitate the performance of PCR, the concentration of which are 
specified in such cases. 
Amplification products were examined by gel electrophoresis.
2.2.3 Agarose gel electrophoresis
To separate DNA fragments according to their sizes, or to examine the performance 
of PCR, agarose gel electrophoresis was adapted. In this study, 0.8 to 2% of agarose 
gels were used to segregate different ranges of DNA fragments. For instance, low 
percent agarose gel, such as 0.8%, shows good resolution of large DNA fragments 
ranging from 5-10 kb. However, if a small size difference, such as 100 bp, is needed 
to be discriminated between small DNA fragments, a higher percentage (i.e. 2%) 
agarose gel is more suitable. For general usage, such as checking PCR 
performance, a 1% agarose gel was used. To make the gel, an adequate amount of 
agarose (BDH) was dissolved in 0.5× TBE running buffer (43.75 mM of Tris base, 
44.48 mM of boric acid and 1mM of EDTA pH8.0) with 0.5 μg/ml of ethidium bromide 
(Sigma) which binds to nucleotides and emits an orange fluorescence under UV light. 
DNA markers were loaded at the same time as DNA samples. Two different markers 
were used in this study depending on discrimination that was required: ΦX174 DNA/
BsuRI (HaeIII) (Fermentas) and HyperLadder™ II (Bioline) (Figure 2.1). The gel 
electrophoresis was performed at 100V for about 1 hour to separate DNA fragments 
which were then visualised under UV light.
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Figure 2.1 DNA markers used in this study. A, ΦX174 DNA/BsuRI (HaeIII) B, HyperLadder™ II. 
Sizes of fragments are as indicated on the right hand side. These pictures are provided by Fermentas 
and Bioline respectively. 
A B
2.2.4 DNA purification
Depending on the follow-up applications, two different procedures of DNA purification 
were undertaken in this study. 
To purify single banded DNA from a PCR mixture, DNA clean-up using SureClean 
(Bioline) or QIAquick PCR Purification Kit (Qiagen) was adapted according to the 
manufacturersʼ protocols. To purify a DNA fragment from a restriction enzyme 
digestion or PCR that produced multiple bands, the extraction procedure was 
undertaken which separated the targeted DNA fragment from the rest of DNA by gel 
electrophoresis. The agarose gel containing the targeted DNA fragment was cut out 
and melted in the buffer supplied with the QIAquick Gel Extraction Kit (Qiagen). 
Subsequential clean-up was carried out according to the manufacturerʼs protocol. 
57
2.2.5 DNA quantification
To determine the concentration and purity of DNA, measurement of absorbance of 
UV light at 260 nm and 280 nm was taken using a NanoDrop Analyser (Thermo 
Scientific). At the wavelength of 260 nm, an optical density (OD) of 1 corresponds to 
a concentration of 50 μg/ml for double-stranded DNA, based on which the 
concentration of DNA was calculated. The ratio of the absorbance at 260 and 280nm 
(A260/280) is used to assess the purity of nucleic acids. For pure DNA, A260/280 is ~1.8 
and for pure RNA A260/280 is ~2. The value of A260/280 lower than 1.6 indicates 
contamination of protein (Sambrook and Russell, 2001). In this study, purified DNA 
samples with an A260/280 between 1.6-1.8 were used in all applications.
2.2.6 DNA Sequencing
DNA to be sequenced was purified first and resuspended in 10 μl of distilled water 
containing 3.2 pmole of sequencing primer. 500 ng of plasmid DNA or 10 ng/100 bp 
PCR produced DNA was required for sequencing. The samples were prepared 
freshly before sending for sequencing. Automated DNA sequencing was carried out 
by MRC CSC Genomics Core Laboratory, Imperial College London. 
2.3 Plasmid construction and preparation
To monitor the expression and the effects of exogenous genes in mammalian cells, 
expression constructs containing either wild type or mutant genes were generated 
and used in this study. 
2.3.1 Vectors
A wide range of vectors were used for different purposes in this study. To clone a 
DNA fragment directly from PCR, pCR2.1 (Invitrogen) and pcDNA3.1/NT-GFP-TOPO
(Invitrogen) were used. As Taq polymerase has a nontemplate-dependent activity 
that adds a single deoxyadenosine (A) to the 3  ́ ends of PCR products, these 
linearised vectors have single 3  ́deoxythymidine (T) residues allowing PCR products 
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to ligate efficiently with the vector (Figure 2.2A, B). This TA ligation was carried out 
according to the manufacturerʼs protocol. pCR2 was used as a primary cloning vector 
with the insert being subsequently subcloned to other expression construct, whereas 
pcDNA3.1/NT-GFP-TOPO was used as an expression vector which, with the insert 
ligated downstream of the GFP sequence, produces a N-terminal GFP-tagged fusion 
protein driven by  CMV promoter (Figure 2.2B). Another expression vector, pDsRed2-
C1, was also used in this study to produce N-terminal RFP-tagged fusion protein 
(Figure 2.2C).
Other vectors used in this study included Venus-XBP1, which is a kind gift from 
Professor Miura, University of Tokyo, and was used as an IRE1/XBP1 activation 
reporter  (details given in section 6.4.3) (Iwawaki et al., 2004), and GFP-CL1 (ATCC), 
the reporter of efficiency of ubiquitin-proteasome degradation system (Bence et al., 
2001). 
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Figure 2.2 Maps of cloning vectors used in this study. A, pCR2.1 and B, pcDNA3.1/NT-GFP-
TOPO (Invitrogen). PCR products are introduced via TA cloning. C, pDsRed2-C1 (Clontech). DNA 
inserts are introduced using the multiple cloning sites (MCS) provided on the plasmid. Both pcDNA3.1/
NT-GFP-TOPO and pDsRed-C1 are expression vector with CMV promoter driving the expression of 
N-terminal tagged fusion proteins. 
2.3.2 Preparation of DNA inserts and ligation
For ligation via TA cloning, the ligation was carried out immediately after PCR using 
ligase and buffer provided with TA cloning vectors (Invitrogen). The procedure of TA 
cloning was carried out according to the manufacturerʼs protocol. 
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For ligation using restriction enzyme sites, both vector and insert were cut by the 
enzymes that produced the cloning sites. The conditions for restriction enzyme 
cutting were as provided by the manufacturers. In general, 1 U of enzyme was used 
in each restriction enzyme digestion and for the cutting at 37℃, the reactions were 
taken overnight, whereas the reactions that were at 42 or 55℃ were left at the 
indicated temperatures for about 2 hours. Treatment of antarctic phosphatase (NEB) 
was carried out for the preparation of linearised vector fragment directly  after 
restriction enzyme digestion, which removes the 5´ phosphate groups from DNA and 
thus prevents vector self-ligation. Inserts and vectors were purified and mixed in a 
3:1 ratio for ligation. Ligation was performed using T4 DNA ligase (NEB) at 16℃ 
overnight as the manufacturerʼs suggestion. 
2.3.3 Transformation and plasmid preparation
To generate large amounts of plasmid DNA for cloning or transfection purposes, 
bacterial transformation was carried out. In this study, we used One Shot® TOP10 
Chemically  Competent E. coli and One Shot® TOP10ʼ Chemically Competent E. coli, 
both from Invitrogen, as competent cells for transformation. 1 μg of plasmid DNA or 
half volume of ligation mixture was mixed with a tube of competent cells where the 
transformation was carried out according to the manufacturerʼs protocol. LB broth 
(Merck) and plates which are prepared with the addition of 15-20 g of agar per 1L LB
(Merck) were used to grow bacteria. Antibiotics, such as ampicillin (50 μg/ml, Sigma), 
kanamycin (50 μg/ml, Sigma) or chloramphenicol (170 μg/ml, Sigma), were added in 
LB broth and plates to select transformed bacteria. Blue/white screening was carried 
out to screen the presence of DNA insert in pCR2 vector, by which 40 μl each of 100 
mM IPTG (Calbiochem) and 40 mg/ml X-Gal (Calbiochem) were spread onto the 
plates before plating transformed cells. The white colonies which indicated the 
presence of DNA insert were picked the next day. Plasmids were extracted with the 
QIAprep Spin Miniprep  Kit (Qiagen) to confirm the presence and orientation of DNA 
insert. Large amount of plasmid DNA for the usage of transfection was prepared with 
the EndoFree Plasmid Maxi Kit (Qiagen). 
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Bacterial stocks were made with transformed clones of cells, by which 15% of sterile 
glycerol was mixed into overnight bacterial liquid culture which was then stored at 
-80℃ (Sambrook and Russell, 2001).
2.4 Cell culture and transfection
2.4.1 Cell culture
To investigate the effect of gene expression in mammalian cells, several cell lines 
were used in this study, which included the African green monkey kidney fibroblast-
like cell line, COS-7; the mouse neuroblastoma, N2a; and the mouse spinal cord 
motor neurone cell line, NSC-34 (provided by Professor Neil Cashman). Cells were 
maintained in DMEM medium (Invitrogen) containing 10% FBS (Invitrogen). 0.5× of 
trypsinise (Invitrogen) diluted in PBS (Oxoid) containing 0.5 mM of EDTA (BDH) was 
used to trypsinised cells. Cells were cultured in incubator with temperature of 37℃ 
and 5% of CO2.
2.4.2 Transfection
Cells were seeded onto a new plate the day before transfection. Transfection was 
carried out using Lipofectamine 2000 (Invitrogen) for COS-7 and N2a cells, and 
Lipofectamine™ LTX with PLUS™ Reagent (Invitrogen) for NSC-34 cells. Amounts of 
plasmid DNA used were according to the manufacturerʼs suggestion. 
2.5 Immunocytochemistry and immunofluorescence
To detect the expression of the candidate proteins in cel ls, both 
immunocytochemistry and immunofluorescence approaches were undertaken. For 
immunocytochemistry analysis, cell lysates were collected and the presence and 
amount of candidate proteins were evaluated. For immunofluorescence studies, cells 
were fixed and the distribution of candidate proteins which was either fluorescence-
tagged or stained by fluorescence-tagged antibody, was studied with fluorescence 
microscopy. 
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2.5.1 Western blotting 
To collect cell lysates, cells were washed with ice-cold PBS twice before being 
scraped off the dish in RIPA lysis buffer. After being constantly agitated for 30 
minutes at 4℃, cell debris was collected by centrifuging for 20 minutes at 12000×g at 
4℃. The supernatants containing cell lysates were transferred to a new tube and the 
protein concentration was determined using the Bio-Rad protein assay kit (Bio-Rad). 
A Mini-PROTEAN Tetra Cell (Bio-Rad) was used for protein vertical electrophoresis. 
10% SDS-polyacrylamide gel exectrophoresis (PAGE) gels were made and the 
Precision Plus Protein All Blue Standards (Bio-Rad) was used as protein size marker. 
Electrophoresis was performed at 200 V for about 1 hour. Transfer of proteins from 
gel to nitrocellulose membrane (Amersham Hybond™ ECL™, GE Healthcare) was 
carried out immediately  after electrophoresis using a semi-dry transfer system, Semi-
Phor (Hoefer Scientific Instruments). The assembly of gel-membrane-blotting paper 
package was undertaken according to the manufacturerʼs instruction. The transfer 
was performed at a constant current of (0.8 × the area of the gel) mA for 1 hour. The 
gel was discarded after the transfer whereas the membrane was stored by soaking in 
PBS at 4℃ or used directly.
PBST was the basic buffer used for making up the blocking buffer, diluting antibodies 
and washing the blotting membrane, and was used for most of our western blotting. 
The only exception was for the blotting for phospho-eIF2α, which used TBST instead 
of PBST in the protocol described below. 
To prevent the non-specific background binding of the primary and/or secondary 
antibodies, membrane was incubated in blocking buffer (5% non-fat milk in PBST) for 
1 hour at room temperature under agitation. After briefly rinsing in PBST, the 
membrane was used for primary antibody incubation which was carried out at 4℃ 
overnight except for actin staining which was undertaken for 1 hour at room 
temperature. Secondary antibody incubation was carried out at room temperature for 
1 hour. The membrane was washed three times with PBST, 5 minutes per wash, after 
the primary and secondary antibody incubations respectively. Detection of HRP-
conjugated antibodies was carried out using Immun-Star HRP chemiluminescent kits 
(Bio-Rad) and Amersham Hyperfilm ECL (GE Healthcare).
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Densitometry  measurement was carried out using ImageJ using the recommended 
procedure. 
2.5.2 Immunofluorescence
To perform immunofluorescence analysis, cells were plated on cover slips coated 
with 0.01% of poly-lysine (Sigma) (Sambrook and Russell, 2001). On the day of 
harvest, cells were fixed in 4% of paraformaldehyde (30 minutes at room temperature 
or 4℃ overnight) and permeabilised with 0.5% of Triton X-100 (Sigma) in PBS (15 
minutes at room temperature).
Where the staining for a particular protein was required, a blocking step  was 
introduced, in which cells were incubated in 10% of FBS/PBS for 1 hour. The 
incubation with primary and secondary antibody, which were diluted in blocking 
buffer, was carried out at 4℃ overnight and 1 hour at room temperature, 
subsequently. 
Nuclei were stained with DAPI (Sigma, 0.5 μg/ml in PBS) for 10 minutes at room 
temperature. PBS washes were applied between reagent changes. After the final 
staining and wash, cover slips were mounted onto slides using Fluorsave reagent 
(Calbiochem), and left to dry at 4°C overnight
2.5.3 Buffers used in Western blotting and immunofluorescence
RIPA Buffer (Radio Immuno Precipitation Assay Buffer)
! 150 mM NaCl (BDH)
" 1% NP-40 (Sigma)
" 0.5% sodium deoxycholate (Sigma)
" 0.1% SDS (sodium dodecyl suplhate, BDH)
" 50 mM Tris, pH8.0 (BDH)"
" 1× complete protease inhibitor cocktail (Roche)
" 1× complete phosphatase inhibitor cocktail (Roche)
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1× SDS gel-loading buffer
! 50 mM Tris-HCl, pH6.8
" 100 mM dithiothreitol (Sigma)
" 2% SDS
" 0.1% bromophenol blue (Sigma)
" 10% glycerol (Sigma)
10% Resolving Gels of SDS-PAGE (10ml)
! H2O                                                          4 ml
" 30% acrylamide (National diagnostics) 3.3 ml
" 1.5 M Tris (pH8.8)                                 2.5 ml
" 10% SDS                                               0.1 ml
" 10% ammonium persulfate (Sigma)      0.1 ml
" TEMED (Sigma)                                 0.004 ml
5% Stacking gels for SDS-PAGE (5ml)
" H2O                                                  3.4 ml
" 30% acrylamide                             0.83 ml
" 1.5 M Tris (pH6.8)                          0.63 ml
" 10% SDS                                       0.05 ml
" 10% ammonium persulfate            0.05 ml
" TEMED                                         0.005 ml
SDS-PAGE Running buffer
" 25 mM Tris base"
" 250 mM glycine (Sigma)
" 0.1% SDS    
Western Transfer buffer
" 24 mM Tris base
" 192 mM glycine
" 20% methanol (Sigma)
10× TBS, pH7.6 (1L)
" Tris-HCl                                         24.33 g
" NaCl                                              80.06 g
" H2O                                                  to 1 L
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1× PBST/TBST
" 1×PBS/TBS with 0.1% of Tween 20 (Sigma)
4% Paraformaldehyde (100 ml)
" 4 g of paraformaldehyde (BDH) was dissolved in 50 ml of distilled H2O which 
was than added by 1 ml of 1M NaOH (BDH) solution. The solution was stirred and 
heated to 60-65℃ to allow the fully dissolving of paraformaldehyde. 50 ml of 2× PBS 
was added and mixed with the solution. After cooling down, the solution was 
aliquoted and stored at -20℃.
"                               
   
2.5.4 Antibodies used in Western blotting and immunofluorescence
The primary antibodies used in this study  included: rabbit polyclonal anti-GFP 
(1:3000, Abcam); rabbit polyclonal anti-ubiquitin (1:200, Dako); rabbit polyclonal anti-
phospho-eIF2α (1:1000, Cell signaling). Peroxidase conjugated secondary antibody, 
HRP-goat anti-rabbit IgG (1:1000, Vector) was used for western blotting and Alexa 
Fluor 594 goat anti-rabbit IgG (1:2000, Invitrogen) was used in immunofluorescence 
staining. HRP-conjugated anti-β-actin (1:25000, Sigma) antibody was used as a 
loading control in western blotting.
2.6 Flow cytometry
Flow cytometry is a technique which allows the high speed simultaneous analysis of 
multiple parameters of individual cells that pass through the laser beam, thereby 
detecting molecules expressed by cells. In this study, a BD FACSCalibur model was 
used to perform flow cytometric measurement. This system uses an argon-ion laser 
which generates a wavelength 488 nm laser beam. As shown in Figure 2.3, at the 
intersection of the laser beam with cells, laser light is scattered by the cell in all 
directions, which, after passing the collection lens and spectrally split by a collection 
of mirrors and filters, is measured by detectors, named FSC, SSC, FL1, FL2 and 
FL3. As fluorescence-tagged particles intercept the laser light in the flow cell, 
scattered and fluorescent light provide information about particle size, shape, 
granularity, and fluorescence intensity (Coligan, 2010).
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Figure 2.3 BD FACSCalibur optics system. An argon-ion laser is used to produce a 488 nm 
excitation beam which intersects cells generating signals that are collected by various detector 
according to their optic characteristics. The five detectors of BD FACSCalibur system are FSC, SSC, 
FL1, FL2 and FL3. FSC and SSC are measurements of cell size and granularity whereas FL1, FL2 
and FL3 measure fluorescence-emission light. This diagram is taken from BD FACSCalibur user 
manual.
18 BD FACSCalibur Instructions for Use
Optics Components and Theory of Operation
The standard BD FACSCalibur system includes a 15-mW, 488-nm, argon-ion 
laser and detectors for three fluorescent parameters. The FL4 option provides a 
second 635-nm, red-diode laser and an additional detector. Laser light is focused 
onto the flow cell by a focusing lens. As fluorescently tagged particles intercept 
the laser light in the flow cell, scattered and fluorescent light provide information 
about particle size, shape, granularity, and fluorescence intensity.
Forward scatter (FSC) signal is collected by the FSC diode. Side scatter (SSC) and 
fluorescent signals are collected by a fluorescence collection lens and spectrally 
split by a collection of dichroic mirrors (DMs) and filters. See page 220 for 
wavelength characteristics of the dichroic mirrors and filters.
Figure 1-6  BD FACSCalibur optics system (standard)
488/10 530/30
90/10 beam splitter
DM 560SP
DM 640LP
585/42
650LP
FSC diode488/10
focusing lens
collection lens
fluorescence
488-nm 
blue laser
flow cell
Forward scatter (FSC) and side scatter (SSC) detectors are not sensitive to 
fluorescence and are used to discriminate cells from particulate debris. FSC is 
usually an index of cell size whereas SSC is an index of cellular complexity. FL1 to 
FL3 measure fluorescence-emission bands as determined by optical filters installed 
in front of the detectors: FL1 detects light emitted at 530 nm, FL2 detects light at 585 
nm, and FL3 detects light at >650 nm.
2.6.1 Fluorochromes
Each fluorescent protein and fluorochrome has its excitation and emission spectra, 
which enables its use in our flow cytometric system. They need to be excited by 488 
nm laser beam and the emission light is then detected by one of the fluorescence 
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detectors. The fluorescent proteins/fluorochromes used in this study are listed in 
Table 2.1.
Table 2.1 Fluorescent proteins and fluorochromes used in this study. 
fluorescent protein/
fluorochrome
Emission peak (nm) Detector Filter
EGFP 510 (green) FL1 530/30
Venus 530 (yellow) FL1
PE 575 (orange-red) FL2 585/42
RsRed2 582 (orange-red) FL2
7-AAD 647 (red) FL3 670LP
2.6.2 Gating and compensation
Prior to data acquisition, the fluorescence channels are adjusted so that positive and 
negative cells can be discriminated. To achieve this, a negative control (unstained or 
untransfected cells) is used which forms a negative peak near the origin for either of 
the fluorescence channels. On the other hand, a marked shift of the peak formed by 
cells used as a positive control is to be observed in the stained/transfected cells. For 
instance, to determine the annexin V positive population, the PE-conjugated annexin 
V which is detected in the FL2 channel is used to stain the cells treated with the 
apoptotic inducer, STS (Sigma). As shown in Figure 2.4, the STS-treated cells form a 
distinct peak which is clearly  discriminated from the unstained negative control, and 
is thus defined as the annexin V positive population. 
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Figure 2.4 Positive and negative controls used to define staining positive population. To define 
PE-positive annexin V staining, the unstained cells are prepared for negative control which form a 
peak close to origin of FL2 channel. On the other hand, the STS-treated cells stained for PE-annexin 
V is used as a positive control which show a distinct peak shift in FL2 channel.
unstained control
positive control
A great advantage of flow cytometry  is to be able to use multiple fluorescent markers 
in one analysis. To be coupled with each other, these fluorescence proteins/
fluorochromes must have different emission spectra that are measured by separate 
detectors. However, because fluorescence emissions occur over a broad range of 
wavelengths, the spectrally selective optical filters may not be sufficient to 
discriminate between them efficiently. In our study, we have used Venus co-
transfected with DsRed-tagged protein as well as PE-conjugated annexin V and 7-
AAD double staining. As shown in Figure 2.5, although they can be individually 
measured by different detectors, overlaps in emission signal do occur, which is more 
profound in the case of Venus (Figure 2.5A). Venus is principally detected by FL1, 
however, a considerable amount of the Venus signal is “leaked” to FL2 channel 
where it can be included in the RFP signal and leads to false-positive measurement. 
Therefore, an adjustable electronic-signal subtraction “compensation” is required to 
eliminate residual spectral overlap between fluorochromes. 
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Figure 2.5 Excitation and emission spectra of fluorescence proteins and fluorochromes used in 
this study. Excitation and emission spectra of Venus (named here as EYFP) coupled with DsRed2 
(A) and PE coupled with 7-AAD (B) are shown. Excitation spectra of the fluorescence proteins and 
fluorochromes are shown in dash lines and the emission signal range detected by fluorescence 
detectors are as highlighted (FL1, 530/30; FL2, 585/42; FL3, 670/LP). 
A
B
To determine the amount of signal overlap between channels, single positive controls 
are prepared for each fluorochromes. Electronic compensation involves subtraction 
of signal measured as fluorescence emission B as a function of the amount of the 
same signal measured as fluorescence emission A. In the case of Venus and RFP 
double transfection, in order to eliminate the Venus emission in FL2 channel, the 
electronic compensation is applied to force the orange fluorescence measure of this 
sample of Venus single transfected cells to be identical to that of the unstained cells 
(Figure 2.6). A similar procedure is followed for RFP singly transfected cells. 
This compensation procedure was applied to all our experiments using more than 
one fluorescent marker.
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Figure 2.6 Emission of fluorescence signals before and after compensation. This is an example  
of compensation adjustment applied for Venus and RFP double transfection analysis. As seen in the 
upper panel which shows the emission of fluorescence signals before compensation, although the 
emission of Venus is primary detected in FL1, the signal leaks into FL2 channel especially at high 
fluorescent intensity. The application of electronic compensation reduces the FL2 measurement of 
Venus signal to the same level as the negative control. Same procedure is applied to RFP signal 
leakage into FL1 channel. 
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2.7 Statistics 
Studentʼs t-test was used to examine the significance of difference between two 
groups of samples/conditions, whereas one-way ANOVA was used to test whether 
there is any difference in a population comprised of more than two groups. The 
Bonferroniʼs multiple comparison test was usually applied when a significant p-value 
was obtained from one-way ANOVA. The significant ANOVA result suggests rejecting 
the global null hypothesis that the means are the same across the groups being 
compared, Bonferroniʼs multiple comparison procedures are then used to determine 
which means differ. Unless specified, all the statistic analyses and graphs produced 
from them were carried out using the software, GraphPad Prism.
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Chapter III MUTATION 
SCREENING IN TDP-43
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3.1 Introduction
TDP-43 is the major protein in the cytoplasmic ubiquitinated inclusions which are 
present in various neurodegenerative diseases such as FTD and ALS (Arai et al., 
2006; Neumann et al., 2006). In addition, it has recently been identified as a 
causative gene of ALS (Sreedharan et al., 2008). In this study, we carried out gene 
screening to investigate the prevalence of TDP-43 mutations in our FALS cohort. 
3.1.1 Structure of TDP-43 gene and protein
TDP-43 is encoded by the gene TARDBP, TAR DNA binding protein, which is located 
on chromosome 1p36, composed of six exons including the non-coding exon 1. The 
cDNA of TARDBP is 1245 bp  in length which is translated into a 414 amino-acid 
protein, TDP-43 (Figure 3.1). TDP-43 protein contains two RNA recognition motifs, 
RRM1 and RRM2, and a glycine-rich C-terminus which is believed to be responsible 
for protein-protein interactions (Buratti et al., 2005; D'Ambrogio et al., 2009). In 
addition, the nuclear localisation and export signal (NLS and NES) domains are 
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Figure 3.1 Structure of TDP-43. TDP-43 is encoded by the gene, TARDBP which contains six exons 
including UTRs (open boxes) and five coding exons (filled boxes). While translated into protein, 
TDP-43 contains two RNA recognition motif, RRM1 (amino acid 106-171) and RRM2 (192-241). In 
addition, nuclear localisation (NLS) and export (NES) signal peptides are identified at amino acid 
82-98 and 239-250, respectively. The region encoded by TARDBP exon 6 is as indicated, which 
includes a small portion of RRM2 as well as NES, but mostly is the glycine-rich C-terminus. 
identified in TDP-43 (Winton et al., 2008), which correlates with the finding that 
although TDP-43 is mostly  localised in the nucleus, it functions as an RNA chaperone 
and can shuttle between nucleus and cytoplasm (Dion et al., 2009).    
The functions of TDP-43 are not fully understood. Evidence has been shown that 
TDP-43 participates in splicing regulation of genes such as CFTR (cystic fibrosis 
transmembrane conductance regulator) and SMN (Buratti et al., 2004; Bose et al., 
2008). Furthermore, TDP-43 also functions as a stabiliser for NF-L mRNA (Strong et 
al., 2007) and modulates microRNA biogenesis (Gregory et al., 2004; Buratti et al., 
2010). As TDP-43 is incorporated into RNA granules (Belly  et al., 2005; Elvira et al., 
2006) in response to stimuli, it is believed that TDP-43 plays an important role in 
neuronal plasticity by  regulating in situ protein synthesis in dendrites (Wang et al., 
2008b). However, functional studies concerning the cytological characteristics of 
TDP-43 are still incomplete and much is yet unknown regarding its role in 
neurodegeneration. 
3.1.2 TDP-43 protein pathology in neurodegenerative disease
Neurodegenerative diseases are often characterised by the presence of insoluble 
sub-cellular inclusions within which the components may vary  in different disorders. 
However, the presence of TDP-43 in cellular inclusions is not only found in most 
cases of SALS and a subset of FALS (Neumann et al., 2006; Mackenzie et al., 2007; 
Tan et al., 2007), but also in FTD with or without MND (Arai et al., 2006; Neumann et 
al., 2006; Cairns et al., 2007) as well as some cases with Alzheimer's disease (Arai et 
al., 2009; Davidson et al., 2009). The pathological form of TDP-43 is associated with 
cytoplasmic accumulation in ubiquitinated inclusions accompanied by clearance of 
the protein from the nucleus (Neumann et al., 2006; Van Deerlin et al., 2008). In 
addition, pathological TDP-43 has been found to be cleaved by caspase, producing 
the abnormally hyper-phosphorylated and ubiquitinated C-terminal truncated 
fragment that is recruited to the inclusions (Zhang et al., 2007; Rutherford et al., 
2008). Although evidence from cell culture expression experiments has demonstrated 
that the redistribution of TDP-43 to cytoplasm directly correlates with its neuronal 
toxicity  (Winton et al., 2008; Barmada et al., 2010), the cause of TDP-43 
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redistribution in neurodegenerative diseases and the cytological machinery that is 
affected has not yet been identified.   
3.1.3 Mutations of TDP-43 in ALS
Since the first report by Sreddharan et al. in 2008 identifying mutations in TDP-43 in 
a large FALS family and two cases with SALS (Sreedharan et al., 2008), 33 
mutations at 28 amino acid sites have been identified in FALS and/or SALS so far 
(Table 3.1). 899 FALS and 2980 SALS have been screened in these studies along 
with several thousand controls. Mutations have been identified in both sporadic and 
familial cases of various ethnic populations, suggesting that TDP-43 could be a 
common causative protein in disease development. 
Mutation # of FALS # of SALS Ref. Note
D169G 1 (Kabashi et al., 2008b) French
N267S 1 (Corrado et al., 2009) Italian
G287S 2 (Kabashi et al., 2008b; Corrado 
et al., 2009)
Italian, French
G290A 1 (Van Deerlin et al., 2008) Caucasian
G294A 1 (Sreedharan et al., 2008) Australian
G294V 2 1 (Corrado et al., 2009; Del Bo et 
al., 2009; Williams et al., 2009)
Italian (1with 
Dementia, familial 
case), Italian, 
Australian
G295R 2 (Corrado et al., 2009; Ticozzi et 
al., 2009)
Caucasian, Italian
G295S 2 (Corrado et al., 2009; Del Bo et 
al., 2009)
Italian
G298S 2 (Van Deerlin et al., 2008; Nozaki 
et al., 2010)
Japanese, Chinese
M311V 1 (Lemmens et al., 2009) Caucasian
A315T 2 (Kabashi et al., 2008b; Ticozzi et 
al., 2009)
Caucasian, French
Table 3.1 Missense mutations in TDP-43 associated with ALS. 33 ALS-associated missense 
mutations in 17 amino acid sites have been identified in 18 independent studies (including two with 
negative result (Guerreiro et al., 2008; Gijselinck et al., 2009)). 899 FALS and 2743 SALS have 
been screened in these studies. None of these mutations has been found in healthy controls. 
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Mutation # of FALS # of SALS Ref. Note
A321G 1 (Baumer et al., 2009) Caucasian
Q331K 1 (Sreedharan et al., 2008) British
S332N 1 (Corrado et al., 2009) Italian
G335D 1 (Corrado et al., 2009) Italian
M337V 6 (Rutherford et al., 2008; 
Sreedharan et al., 2008; Corrado 
et al., 2009; Tamaoka et al., 
2010; Tsai et al., 2010)
Caucasian, 
Taiwanese, 
Japanese, Italian, US
Q343R 1 (Yokoseki et al., 2008) Japanese
N345K 2 (Rutherford et al., 2008; Ticozzi 
et al., 2009)
Caucasian, 
unspecified
G348C 4 4 (Kabashi et al., 2008b; Kuhnlein 
et al., 2008; Daoud et al., 2009; 
Del Bo et al., 2009; Ticozzi et al., 
2009)
Caucasian, Belgian, 
French, German
N352T 2 (Ticozzi et al., 2009) Caucasian
N352S 2 (Kuhnlein et al., 2008; Kamada et 
al., 2009)
German, Japanese
R361S 1 (Kabashi et al., 2008b) French
P363A 1 (Daoud et al., 2009) French
Y374X 1 (Daoud et al., 2009) French
N378D 2 (Ticozzi et al., 2009; Tsai et al., 
2010)
Taiwanese, 
Caucasian
S379C 1 (Corrado et al., 2009) Italian
S379P 2 (Corrado et al., 2009; Ticozzi et 
al., 2009)
Pacific Islander, 
Italian
A382T 5 5 (Kabashi et al., 2008b; Corrado 
et al., 2009; Del Bo et al., 2009)
Italian, French
A382P 1 (Daoud et al., 2009) French
I383V 4 (Rutherford et al., 2008; Ticozzi 
et al., 2009)
Caucasian, 
unspecified
G384R 1 (Ticozzi et al., 2009) Caucasian
N390D 1 1 (Kabashi et al., 2008b; Ticozzi et 
al., 2009)
Caucasian, Quebec
N390S 1 (Kabashi et al., 2008b) French
S393L 1 (Corrado et al., 2009) Italian
Total 40 30
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Except for one mutation, D169G that is localised in TARDBP exon 4 and causes an 
amino acid change in RRM1 of the protein, all of the ALS-linked mutations been 
identified so far are localised in exon 6. As these mutations are mostly concentrated 
in the glycine-rich C-terminal domain, it is not clear whether they would affect the 
RNA binding directly. Instead, these mutations are more likely  to interfere with the 
protein-protein interaction, which, together with the mutation-caused protein property 
changes, leads to elevation of cytosolic truncated TDP-43 that resembles the protein 
pathology in ALS patients. 
 
3.2 Aims
We have recruited around 200 FALS families, of which mutations in SOD1, VAPB 
and DAO have been identified in about 20% of cases (Orrell et al., 1995; Hosler et 
al., 1996; Mitchell et al., 2010). Recently, one of our FALS families has been 
identified as carrying the ALS-linked TDP-43 mutation, M337V (Sreedharan et al., 
2008). In this study, we screened the rest of the families to investigate the prevalence 
of TDP-43 mutations in our FALS cohort and at the same time investigated whether 
there were any unreported mutation or SNP in our FALS population.
3.3 Materials and Methods
3.3.1 Subjects
In this study, we screened our FALS cohort which is composed of patients and 
families that were referred by general practitioners and physicians on the basis that 
more than one individual in the family  had typical ALS. This cohort has been used in 
previous linkage/association studies (Abalkhail et al., 2003; Bradley et al., 2005; 
Mitchell et al., 2009) and mutation screening (Orrell et al., 1995; Hosler et al., 1996; 
Vance et al., 2009; Mitchell et al., 2010), in which mutations have been identified in 
genes such as SOD1, VAPB, FUS and DAO. In this study, after excluding families 
carrying mutations in known ALS-associated genes, 116 unrelated FALS individuals 
were screened for mutations in TDP-43.  
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3.3.2 TDP-43 gene screening
Primers flanking each exon plus the ~100 bp around the exon/intron junction were 
designed (Table 3.2). Each exon together with its splicing junction regions was 
amplified by PCR, the product of which was subsequently cleaned-up for 
sequencing. The PCR primers were also used as sequencing primers. Every 
mutation/SNP has been double validated by sequencing from both directions. 
exon size of PCR 
product (bp)
Forward primer 
(5ʼ to 3ʼ)
Reverse primer
(5ʼ to 3ʼ)
1 431 CAGCTCCTATACAGCCACAC CGGTCTCACGGCTGACTTCC
2 567 ACCCTTACCTTCACCTCGTC TCGTGGTCTTCCAAACTTGTC
3 455 GCAAACATCACTTCTTGCCAAG TCGAGGCAGGAGGACAGTATG
4 407 GTTTTAAGCCACTGCATCCAG ATGCACTAAGGGCCAAAGAC
5 458 CGTTACTCTTCACTGAAGCC ATCTCCTGACCTCGTGATCC
6 1031 GACTGAAATATCACTGCTGCTG AGCAGTTCACTTTCAACCACTC
Table 3.2 PCR and sequencing primers in TDP-43 screening. 
3.3.3 Bioinformatic resources
In this study, the reference sequences used for human TDP-43 gene and protein are 
NM_007375.3 and NP_031401.1 respectively. The peptide sequences of other 
species are NP_663531 (mouse), NP_001026049 (chicken) and NP_958884 
(zebrafish). The freeware CLC  Sequence Viewer was used to perform peptide 
sequence alignment. To highlight the difference, the RasMol amino acid colour 
scheme is used, which colours amino acids according to traditional amino acid 
properties (Sayle and Milner-White, 1995).
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3.4 Results
3.4.1 PCR condition optimisation 
In order to obtain a clear and accurate sequencing readout, a clean single band of 
PCR product is desired. At the stage of primer designing, we designed the primers 
based on some basic principles, such as avoiding long mononucleotide repeats, 
keeping the G/C  content close to 50% and keeping the length of primer between 18 
to 23 bp. As a result, the predicted annealing temperature of each primer was very 
similar. Prior to embarking on the screening of our FALS cohort, the PCR conditions 
were optimised using control genomic DNA.
As shown in Figure 3.2, we found that most primers worked very well at annealing 
temperature of 58℃ without need for any performance enhancing reagent such as 
DMSO. However, the addition of 2.5% of DMSO was used to improve the 
performance of the PCR of TDP-43 exon 4 and exon 5, in which a faint high 
molecular band was avoided by the adding of DMSO (Figure 3.2). The final PCR 
conditions used for amplifying all six TDP-43 exons were an annealing temperature 
at 58℃, without DMSO for exon 1, 2, 3 and 6, and with 2.5% DMSO for exon 4 and 
5. 
Figure 3.2 PCR condition optimisation for TDP-43 gene screening. 20 ng of control genomic 
DNA was used to optimised the PCR condition of TDP-43 gene screening. PCR was performed with 
annealing temperature at 58 ℃ with or without DMSO. DNA marker (M) was loaded in the first lane of 
each gel with the size indication on the left. Size of PCR products is as listed in Table 3.2. 
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3.4.2 Gene screening for TDP-43
After excluding families carrying mutations in known ALS-linked genes such as 
SOD1, VAPB or DAO, 116 FALS cases including the family  with the previously 
reported M337V mutation (Sreedharan et al., 2008) were screened in this study. 
However, due to the limitation of the quality and quantity of the genomic DNA, we 
only successfully sequenced exon 6 of TDP-43 for 109 individuals whereas all six 
exons were successfully sequenced in 75 individuals. 
Three missense mutations in exon 6 were identified in five families (Figure 3.3B) 
which accounts for 4.6% of our non-SOD1, non-FUS, non-VAPB FALS cases. In 
addition, a known SNP (rs61730366) causing a single nucleotide T to G change at 
cDNA nucleotide 198 was detected in two families, which causes a silent mutation at 
amino acid codon 66 (A66A) (Figure 3.3A). Interestingly, one of the families (F47) 
carrying this silent mutation was identified to have the M337V mutation in exon 6. 
Amongst the mutations identified in exon 6, a novel mutation was found at cDNA 
nucleotide position 1148 which leads to a substitution of serine for isoleucine at 
codon 383 (I383S) (Figure 3.3B). Although I383V mutations have previously been 
reported in four FALS cases (Rutherford et al., 2008; Ticozzi et al., 2009), the 
nucleotide substitution occurred at cDNA nucleotide position 1147 (A to G) resulting 
in a substitution of a conserved residue, valine.
The peptide sequence alignment shows that this glycine-rich C-terminal region 
encoded by TDP-43 exon 6 is highly  conserved between species (Figure 3.3C) and 
the sites where our three missense mutations occur are no exception. Although 
codon 383 is isoleucine in human and chicken, and leucine in mouse and zebrafish, 
these two amino acids share similar properties that may still maintain the 
evolutionary conservation at this position. Taken together, these three TDP-43 
mutations not only occur in evolutionarily conserved residues, but are also found 
exclusively in affected individuals and not in controls analysed in previous reports. 
This observation suggests that these three mutations are pathological causing ALS 
phenotypes. 
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Figure 3.3 Variants identified in TDP-43 gene screening. A, Two families, F47 and F107, were 
identified to carry one allele with a nucleotide substitution T to C at cDNA codon 198 in exon 2. This 
substitution does not lead to an amino acid change in the protein sequence. B, Three variants were 
identified in exon 6 at cDNA codon 1009, 1148 and 1178 which leads to amino acid substitution of 
M337V, I383S and S393L, respectively. Including the already reported family, F47 (Sreedharan et al., 
2008), three families were identified to carry M337V whereas I383S and S393L were found in one 
family respectively. C, Peptide sequence alignment shows that the exon 6-encoded C-terminal region 
of TDP-43 is higher conserved from zebrafish to human, particularly the three sites which are found 
being mutated in our FALS cases (position as indicated). These amino acid substitutions lead to 
marked change in amino acid property which may potentially damage protein function. 
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3.4.3 Clinical features of patients carrying TDP-43 mutations
In this study, we have identified the TDP-43 M337V mutation in three families. In 
addition to F47 which carried both the silent mutation at A66 and missense mutation 
M337V (Sreedharan et al., 2008), M337V was also found in another two unrelated 
individuals, F12 and F72. F12 is a female with classical ALS, born in 1944. Signs at 
onset when examined in 1989 at the age of 45y were slurred speech, quiet, 
emotionally  upset but mobile. Her father, paternal aunt and grandmother were 
affected and died at the age of 63, 69 and 50 y respectively. F72 is also a female with 
classical ALS who was born in 1949. Signs at onset when examined in 1991 at the 
age of 42y were speech problems, right hand weakness and emotional lability. 
Muscle weakness had progressed to upper and lower limb in five years since onset. 
Her mother had limb  weakness and progressive voice loss and died in her 60s. Her 
brother, born in 1963, was diagnosed with ALS at the age of 32y and died one year 
later. 
I383S was identified in F57 who was a male born in 1939, diagnosed with classical 
ALS, and who died in 1997 aged 58y. His mother also had ALS and died in 1983, 
aged 68y  and ALS was suspected but not confirmed in one of her seven siblings. For 
our index patient, onset of the disease occurred at the age 53y and was 
characterised by atrophy and fasciculations of the right hand. 
S393L was identified in F33, a male patient with classical ALS born in 1928. Signs at 
onset, when examined at the age of 59y, were wasting and weakness of right hand 
and brisk reflexes in arms and legs. Sensory  function was normal. His sister was also 
affected and loss of motor neurones was confirmed at autopsy.
In summary, all five of our FALS families carrying TDP-43 mutations were diagnosed 
with classical ALS with the appearance of disease symptoms in middle age. Except 
for F47 in which the appearance of ALS could be traced through several generations 
and the availability of DNA from several family members enabled us to establish the 
segregation of M337V with disease, the other four families were relatively small and 
the information was incomplete. Although we were not able to show segregation of 
mutations with disease in these families, the conservation of amino acids at these 
positions, together with the absence of these mutations in control populations, 
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suggests these mutations can alter TDP-43 protein physiology thereby promoting 
ALS development. 
3.5 Discussion
3.5.1 M337V, I383S , S393L and A66A
In this study, we reported the presence of three missense mutations in TDP-43 in 
4.6% of our non-SOD1 FALS cohort, M337V, I383S and S393L. Combined with 
previous mutation screenings (Table 3.1), M337V has already been found in 8 
individuals all of whom are familial cases. These families carrying the M337V 
mutation come from different ethnic groups including Caucasian and Asian 
populations. Although all families were diagnosed as classical ALS, phenotypes such 
as age and site of onset are variable (Rutherford et al., 2008; Sreedharan et al., 
2008; Corrado et al., 2009; Tamaoka et al., 2010; Tsai et al., 2010). Since this 
mutation has been identified in FALS of different ethnic groups, it is not likely  that this 
mutation occurs due to a recent founder effect. Instead, M337 may be a potential 
mutation hot spot which when mutated, affects the properties of TDP-43 and leads to 
ALS. 
S393L has previously been identified in an Italian SALS case who was diagnosed 
with ALS at the age of 60 and had a duration of disease of 87 months (Corrado et al., 
2009). Similarly, our index patient carrying this mutation also displayed spinal onset 
symptoms at the age of 59. However, since these are the only two cases reported 
carrying this mutation, further correlation to disease phenotype is not available at 
present. 
I383 has previously been found mutated to valine in four families, three of which 
showed disease onset in the late 50s to 60s and one with an early disease onset age 
of 25y. The sites of onset also vary from bulbar, upper limbs, or lower limbs 
(Rutherford et al., 2008; Ticozzi et al., 2009). However, the conversion of isoleucine 
to valine is regarded as a conservative amino acid substitution which may not have a 
destructive impact on TDP-43 protein. Here we reported a novel mutation which 
creates an amino acid substitution of serine for isoleucine at this codon. As a 
relatively conservative amino acid change at this codon could affect the protein and 
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induce ALS, we expect that the substitution of serine can also be pathological, if not 
more damaging. 
Interestingly, the presence of the silent mutation c.198T/C, although does not lead to 
an amino acid substitution in TDP-43 protein, shows relatively high frequency in ALS 
populations. Including our study, it has been reported in nine SALS, four FALS and a 
case with Parkinson disease, all of which are European or Caucasian (Guerreiro et 
al., 2008; Kabashi et al., 2008b; Kuhnlein et al., 2008; Daoud et al., 2009; Del Bo et 
al., 2009; Kabashi et al., 2009). On the other hand, our FALS family  F47 is up to now 
the first case known to carry  this silent mutation together with a non-synonymous 
mutation (M337V) in exon 6. It is unclear whether these two mutations are localised 
on the same chromosome or whether the silent mutation also co-segregates with the 
disease as M337 dose. The presence of this variant in a control population has only 
been reported in one study, where it was found in five out of 806 controls whereas in 
the same study five out of 279 SALS carried this variant (Guerreiro et al., 2008). 
However, apart from the report of Guerreiro al., c.198T/C has not been found in other 
control populations and it is yet clear whether it may represent a risk factor for 
disease. There are cases of other motor neurone degenerative diseases where 
synonymous variants are associated with diseases. For instance, it has been shown 
in SMA that synonymous mutations in SMN gene are pathogenic through affecting 
RNA splicing and protein maturation (Lorson and Androphy, 2000; Singh et al., 2007). 
As the impact of the c.198T/C  variant on TDP-43 RNA/protein properties is still 
uncharacterised, and the incidence of it in control population need to be validated, 
more studies are required to clarify its role in ALS. 
In conclusion, partly  due to the small number of cases carrying TDP-43 mutations 
that have emerged, and partly due to the lack of functional studies, the relationship 
between TDP-43 genotype and ALS phenotype is not yet clear. Only one patient who 
carried G294V mutation developed ALS together with cognition deficits (Corrado et 
al., 2009). Otherwise, patients with TDP-43 mutations develop typical ALS with 
variability in the site and age of onset.
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3.5.2 Potential impacts of exon 6 mutations on TDP-43 protein
TDP-43 protein pathology in ALS and FTP patients is characterised by its presence 
in the cytoplasmic ubiquitinated aggregates and the production of hyper-
phosphorylated C-terminal truncated TDP-43 species in disease affected cells (Arai 
et al., 2006; Neumann et al., 2006). The cause of TDP-43 redistribution is 
uncharacterised, however, it is suggested that the impairment of ubiquitin-
proteasome degradation system in ALS contributes to the cytoplasmic accumulation 
of pathogenic TDP-43. This cytoplasmic redistribution of TDP-43 is directly linked to 
protein toxicity which leads to neuronal death (Barmada et al., 2010). 
In support of the involvement of TDP-43 in ALS, it has been found that ALS-linked 
TDP-43 mutations increase protein stability  and its tendency to form aggregates 
(Johnson et al., 2009; Ling et al., 2010). Interestingly, expressing mutant TDP-43 in 
non-neuronal cells such as COS7, 293, CHO or even the glia cell line C6 shows no 
abnormal protein distribution, aggregation or cell death (Sreedharan et al., 2008; 
Yokoseki et al., 2008). On the other hand, expressing mutant protein in neuronal cells 
indeed leads to an increased tendency of the mutant protein to be redistributed to 
cytoplasm and trigger cell death (Barmada et al., 2010). In addition, expressing ALS-
linked mutant TDP-43 in spinal cord tissues of chicken embryo severely impairs 
embryonic maturation, which is accompanied by increased number of apoptotic 
nuclei in this model (Sreedharan et al., 2008). Taken together, these results suggest 
that mutant TDP-43, when expressed in neuronal cells, shows the neuronal toxicity 
and leads to disease pathology. 
Biochemically, there are speculations concerning how ALS-linked mutations alter the 
properties of TDP-43 protein. Since pathological TDP-43 is the highly ubiquitinated 
and phosphorylated truncated form, it is suggested that some C-terminal mutations 
may cause abnormal phosphorylation by creating or abolishing a putative 
phosphorylation target site (Kabashi et al., 2008b; Kuhnlein et al., 2008; Corrado et 
al., 2009). On the other hand, some mutations may create an ubiquitinated target site 
or increase the propensity for TDP-43 to aggregate through disulfide bond formation 
(Pesiridis et al., 2009) whereas others may render the protein more likely  to be 
cleaved (Wang et al., 2008a). However, these speculations will still need to be 
validated in functional studies.
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3.5.3 Transgenic models --- The expression level matters!
TDP-43 is known as a RNA binding protein which is involved in splicing regulation, 
RNA transport and in situ protein synthesis (Buratti et al., 2004; Strong et al., 2007; 
Bose et al., 2008; Wang et al., 2008b). Although its physiological role is not fully 
characterised, it has been shown that it is an essential protein for development, 
whose expression levels need to be delicately controlled to achieve the essential 
biological activity. This notion is supported by the studies of genetically  modified 
animals which showed that the TDP-43 knockout fly or mouse is not viable (Feiguin 
et al., 2009; Kraemer et al., 2010) whereas heterozygous TDP-43 (+/-) mice show 
signs of motor disturbance and muscle weakness without motor neurone 
degeneration (Kraemer et al., 2010). On the other hand, several studies reported the 
overexpression of TDP-43 in mice, flies, C. elegans and yeast causes marked 
damage to cells that could trigger cell death (Johnson et al., 2008; Tatom et al., 2009; 
Li et al., 2010). Overexpressing wild type TDP-43 in both mouse and fly neuronal 
tissues leads to degeneration of neurones in a dose-dependent manner (Li et al., 
2010; Stallings et al., 2010; Wils et al., 2010). Even neuronal specific TDP-43 
expressing C. elegans shows an “uncoordinated phenotype” (Ash et al., 2010). 
Increased cytoplasmic TDP-43 has been found in these overexpression animal 
models (Wils et al., 2010) and in cell lines (Barmada et al., 2010). The wild type 
cytoplasmic TDP-43 displays features reminiscent of TDP-43 protein pathology in 
ALS, including hyper-phosphorylated, ubiquitinated, fragmentated and present in 
cytoplasmic inclusions (Wils et al., 2010). Transgenic animals expressing ALS-linked 
mutant TDP-43 have also been generated (Stallings et al., 2010; Zhou et al., 2010). 
The primary studies of these transgenic animals suggested that while expressed in 
similar levels, ALS-linked mutant proteins are more prone to form cytoplasmic 
aggregates and lead to more severe motor deficits (Stallings et al., 2010). However, 
since the wild type littermate can also display motor deficits with damage to motor 
neurones occurring in a dose-dependent manner, the mutant protein-induced 
phenotypes must be carefully evaluated.
In conclusion, TDP-43 is an essential protein for cell survival. Reduced or excessive 
expression levels are sufficient to trigger motor deficits. However, since no copy 
number variants has been found in various ALS populations (Guerreiro et al., 2008; 
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Gijselinck et al., 2009), there is no evidence indicating that expression levels of 
TDP-43 are altered in ALS. As the TDP-43 protein pathology is indistinguishable 
between patients with or without mutations in TDP-43 (Van Deerlin et al., 2008; 
Yokoseki et al., 2008; Pamphlett et al., 2009), it is suggested that the protein plays an 
important role in general ALS pathogenesis. Interestingly, the only  exception is the 
presence of TDP-43 pathology  in SOD1-linked ALS. No evidence of TDP-43 
redistribution, fragmentation or hyper-phosphorylation was found in G93A, G37R or 
G85R SOD1 transgenic models (Robertson et al., 2007; Turner et al., 2008). This 
result suggests that there are at least two mechanisms working in parallel in ALS 
pathogenesis: one is the mutant SOD1-triggered pathway which does not lead to 
TDP-43 redistribution, the other is the TDP-43-related mechanism. Both mechanisms 
eventually lead to the one phenotype, ALS. 
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Chapter IV VAPB ASSOCIATION 
STUDY IN SALS
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4.1 Introduction
4.1.1 Work that has led to this study
Recently, our group has conducted an evaluation of the expression of 18 candidate 
genes in postmortem spinal cords of 40 SALS cases and 21 controls using real-time 
quantitative PCR. This cohort of cases has been analysed in a range of studies 
quantifying gene expression of both candidate genes and cDNA arrays (Virgo et al., 
1996; Malaspina et al., 2000, 2001). Amongst the genes examined, VAPB was found 
to be markedly  down-regulated in SALS spinal cord compared to control (Figure 4.1) 
(Anagnostou et al., 2010). Consistent with our finding, another independent study 
had also shown reduced VAPB protein levels in symptomatic SOD1 mouse spinal 
cord (Teuling et al., 2007). As the expression of other FALS genes such as SOD1, 
SETX, DCTN1 and VEGF was also evaluated but no change was found (Anagnostou 
et al., 2010), VAPB is the only  gene that is known to be causative for FALS and also 
mis-regulated in SALS. These results together indicate that the reduced expression 
of VAPB plays an important role in ALS pathogenesis that extends beyond familial 
cases of ALS that possess VAPB mutations. In order to determine whether any SNP 
or haplotype is linked to gene expression which may represent a risk allele to the 
development of the disease, we conducted an association analysis in this study. 
However it is still possible that the reduced levels of VAPB could simply reflect the 
loss of motor neurones in spinal cord.
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Figure 4.1 mRNA levels of VAPB are significantly reduced in SALS spinal cord. A, Levels of 
VAPB mRNA in spinal cord tissues of 40 SALS patients and 21 control individuals were quantified 
by real-time PCR. Results were as shown after correction with GADPH. B, Levels of VAPB 
expression relative to control mean value are shown. Mann Whitney test is used to examine the 
difference between SALS and control, where a two-tailed p-value equal to 0.0003 is obtained. 
SEMs are indicated with error bars. This figure is produced from the data of G. Anagnostou.
 
4.2 Aims
To investigate whether there is a genetic contribution linked to the reduced 
expression of VAPB in SALS, we conducted a SNP association study in our SALS 
and control cohorts. 
4.3 Materials and Methods
4.3.1 Subjects
For SNP association with VAPB expression, genotyping was carried out on cases 
that comprised the tissue expression study previously described in detail by 
Anagnostou et al. (2010), which consisted of 21 controls and 42 cases. 
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For SNP association with disease, genotyping was carried out on SALS and control 
cases from London. These included cases referred by general practitioners and 
further cases consenting for tissue donation, the latter were also used in the study by 
Anagnostou et al. (2010). The total number of cases in this cohort was 85 ALS and 
35 controls (London cohort). Two further control cohorts recruited from east Anglia 
(n=58) and east Yorkshire (n=61) were also genotyped in this study. 
4.3.2 SNP typing
Primers were designed to amplified the ~500bp  genomic region containing the 
targeted SNP (Table 4.1). The PCR products were subsequently subjected to the 
cutting of restriction enzymes that produced distinct cutting patterns depending on 
the occurrence of SNP in the DNA sequence. Different size of DNA fragments were 
then separated by electrophoresis with 0.8 to 1.5 % of agarose gel.
SNP size of PCR 
product 
(bp)
Forward primer 
(5ʼ to 3ʼ)
Reverse primer
(5ʼ to 3ʼ)
rs6026230 571 ACTAGAAGGGAAACTGCATGA
G
GCACTTAGCACTATCTGCAAT
G
rs6026256 509 CTCCATCCAAGAAGGAGCTG CACGATGCTATGACCACCAG
rs2234487 375 GGCGTCCATCCTAAGACATA GATAAAGTACAAACCTCCTTG
A
rs2234489 314 TTGTTCAGTGGTGGGCCTGTC TCCGGTTTTGCCTCCTTCCAC
rs6100067 549 GGCATCATCTTCTTCCTTTG ACATTGATCACACTGGCTTG
rs1802459 470 AGGTCCAAGTCTGAGCCTGA CATACTGTCAGCTGAAGACAA
CC
Table 4.1 PCR primers for VAPB association study. 
4.3.3 Statistic analyses
To evaluate the significance of association between SNPs and phenotypes, various 
statistic analyses were used in this study. Fisher exact test (http://
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www.quantitativeskills.com/sisa/statistics/fisher.htm) was used to evaluate the 
difference of allele frequency and genotype frequency, whereas EH programme was 
used to test the linkage disequilibrium between two SNPs and to compare the 
difference of pairwise haplotype frequency between groups (Terwilliger and Ott, 
1994). The six-SNP haplotype was constructed from the population genotyping data 
by the PHASE programme (v2.1) which also gives us a p-value indicating the degree 
of difference in the haplotype frequency between groups (Stephens et al., 2001; 
Stephens and Donnelly, 2003). BIMBAM24 was used to evaluate the association 
between genotypes and phenotypes (Servin and Stephens, 2007), which, in our 
case, were SNP haplotype and VAPB expression level. Finally, Mantel-Haenszel 
Common Odds Ratios were obtained from SPSS stats package to evaluate the 
association of overall major/minor allele with VAPB expression level.
4.4 Results
4.4.1 The selection and genotyping of SNPs 
In view of our previous observation that the expression of VAPB is significantly 
decreased in SALS spinal cord compared to controls (Anagnostou et al., 2010), we 
investigated whether VAPB SNP variants were associated with the level of VAPB 
expression in spinal cord in this cohort of cases previously described (Anagnostou et 
al., 2010). Since there are no reported SNPs in the coding region or splice sites, we 
chose SNPs that are close to exon boundaries, which might also detect 
uncharacterised functional variants. The six SNPs selected for this study were 
rs6026230T/C, rs6026256T/G, rs2234487C/G, rs2234489G/A, rs6100067C/T and 
rs1802459A/G, and their locations within the gene are shown in Figure 4.2.
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Figure 4.2 The structure of VAPB gene and the position of SNPs that were used in this study. 
The positions of the six SNPs within VAPB gene are shown. The whole VAPB gene, containing six 
exons (represented with filled boxes), spans to 57.5 kb. Five SNPs most close to each exon and one 
in the 3’UTR (represented with open box) were genotyped.  
To determine the genotype of the SNPs, the restriction fragment length polymorphism 
(RFLP) analysis was adapted. This technique simply uses restriction enzymes that 
cut DNA into different sizes of fragments according to the allele variant of the SNP. As 
demonstrated in Figure 4.3, the presence of the rare allele of the SNP would either 
create or erase the cutting site of a chosen restriction enzyme, and the cutting 
pattern can easily be detected by gel electrophoresis which separates DNA 
fragments according to their sizes. Therefore, the genotype for a particular SNP can 
be determined based on the size of DNA fragments produced by the chosen 
restriction enzyme. In this way, we genotyped six VAPB SNPs in both ALS and 
control cohorts using the conditions and restriction enzymes listed in Table 4.2.
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Figure 4.3 An example of genotyping SNP by restriction enzyme digestion. In determining the 
genotype of SNP rs6026230, the DNA region around the SNP is amplified by PCR which yields a PCR 
product of 571 bp. As there is no HhaI digesting site within this region, individual who has at least one 
common allele still has the uncut 571bp band after restriction enzyme digestion. On the other hand, 
since the presence of rare allele at SNP rs6026230 creates a cutting site for HhaI, the DNA fragments 
of individuals with rare alleles are cut into 368 and 203 bp. These patterns of homozygous common, 
rare and heterozygous genotype can be easily distinguished by electrophoresis as shown.
1 571Common allele 
(T)
Rare allele (C) 1 571
203
Hha I
T/T : 571 bp × 2 
T/C: 571 bp + 368 bp  + 203 bp
C/C: 368 bp × 2 + 203 bp × 2
Hha I digestion
M C/
C T/C T/T
603
(bp)
310
872
Table 4.2 Patterns produced by restriction enzyme (RE) cutting used for SNP genotyping. 
SNP RE used for 
typing
fragments produced in 
the case of major allele 
(bp)
fragments produced in 
the case of minor allele 
(bp)
rs6026230 HhaI (NEB) 571 368, 203
rs6026256 BsmAI (NEB) 267, 242 509
rs2234487 MaeIII (Roche) 130, 130, 115 130, 245
rs2234489 Tsp509I (NEB) 216, 60, 31, 4 164, 60, 52, 31, 4
rs6100067 MspI (NEB) 226, 211, 111 437, 111
rs1802459 Hpy188III (NEB) 177, 159, 83, 48 336, 83, 48
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4.4.2 SNP associations with VAPB expression levels 
A total of 63 samples composed of 21 healthy controls and 42 ALS cases were 
genotyped and divided into normal (n=36) and low (n=27) VAPB expression groups. 
Normal levels of expression were defined by the 90% confidence intervals (CI) of the 
control group which contained 19 out of 21 of control cases. 60% of the ALS cases 
were outside this CI. Two groups were formed using this threshold, group 1 
contained samples with normal expression (90% CI of control group) and group  2 
contained samples with low expression and was composed of 27 samples including 
24 SALS, 1 FALS and 2 controls.
A significant difference in allele frequency for SNP rs6100067 was found between 
normal and low VAPB expression (Table 4.3) using both the Fisher exact test 
(p=0.029) and the BIMBAM program (p=0.026). The rare allele was more abundant 
in the group  with normal VAPB expression levels compared to the group  with low 
VAPB expression levels, which suggests that this SNP has a beneficial effect 
preventing decreased VAPB gene expression. Although no significant association 
was found between expression levels and the other SNPs per se, there was a 
consistent trend in which the rare allele frequencies of all six SNPs were lower in the 
low VAPB expressing samples compared to the normal expressing group  (Figure 
4.4). Indeed, a significant linkage was found using the Mantel-Haenszel test, which 
indicates that these six VAPB SNPs show an overall association of major allele with 
VAPB low expression (p<0.0001, the Mantel-Haenszel common odds ratio = 2.04). 
The two-SNP haplotype was then constructed and examined by  the EH program and 
only the rs6026230-rs6100067 haplotype was found to be significantly different 
between the two expression groups (p=0.047) (Table 4.4) where the C-T haplotype 
was decreased by 14% in the low expression group. Consistent with this observation, 
linkage disequilibrium (LD) estimated using r2 and Dʼ shows stronger linkage 
between rs6026230 and rs6100067 in the group  with normal VAPB expression levels 
than that with low VAPB expression levels (Figure 4.5). Furthermore, the last five 
SNPs (rs6026256 to rs1802459) are in stronger linkage with each other in the group 
with low VAPB expression compared to the group  with normal expression (Figure 
4.5). However, when the six-SNP haplotype was constructed and analysed using the 
PHASE programme, it failed to reject the null hypothesis and thus suggested that no 
specific haplotype is over-represented in either of the groups (p=0.806).
Table 4.3 Association of VAPB SNPs with VAPB expression levels. 36 individuals with normal 
VAPB expression and 27 with low VAPB expression were analysed in this study. The p-value was 
obtained from the Fisher exact test, where significant difference was found in the allele frequency of 
rs6100067 when the two expression groups were compared. 
Allele frequency
no of chromosome (%)
Genotype frequency
no of individual (%)
VAPB 
expression 
level
Normal Low
p-
value
Normal Low
p-
value
Comm
on 
allele 
(A)
Rare 
allele 
(B)
Comm
on 
allele 
(A)
Rare 
allele 
(B)
A/A A/B B/B A/A A/B B/B
rs6026230 
T/C
52 
(72.2)
20 
(27.8)
42 
(77.8)
12 
(22.2)
0.539 20 
(55.6)
12 
(33.3)
4 
(11.1)
17 
(63)
8 
(29.6)
2  
(7.4)
0.803
rs6026256 
T/G
50 
(69.4)
22 
(30.6)
45 
(83.3)
9 
(16.7)
0.095 19 
(52.8)
12 
(33.3)
5 
(13.9)
18 
(66.7)
9 
(33.3) 
0 
(0)
0.133
rs2234487 
C/T
42 
(58.3)
30 
(41.7)
40 
(74.1)
14    
(25.9)
0.089 15 
(41.7)
12 
(33.3)
9     
(25)
14 
(51.9)
12 
(44.4)
1    
(3.7)
0.068
rs2234489 
G/A
64 
(88.9)
8 
(11.1)
51 
(94.4)
3  
(5.6)
0.350 28 
(77.8)
8 
(22.2)
0 
(0)
24 
(88.9)
3  (8.1) 0 
(0)
0.326
rs6100067 
C/T
45 
(62.5)
27 
(37.5)
44 
(81.5)
10 
(18.5)
0.029* 17 
(47.2)
11 
(30.6)
8 
(22.2)
18 
(66.7)
8 
(29.6)
1    
(3.7)
0.095
rs1802459 
A/G
63 
(87.5)
9  
(12.5)
51 
(94.4)
3  
(5.6)
0.232 27   
(75)
9     
(25)
0 
(0)
24 
(88.9)
3 
(11.1)
0 
(0)
0.207
Figure 4.4 The rare allele frequency comparison between normal and low VAPB expression 
groups. The rare allele frequencies of the six SNPs are shown where the normal VAPB expression 
group is represented as filled bars and the low VAPB expression group is represented with open bars. 
The group of normal VAPB expression level is comprised of 16 SLAS, 1 FALS and 19 controls 
whereas the group of low VAPB expression level is comprised of 24SALS, 1 FALS and 2 controls. 
Fisher exact test was applied for each SNP and a significant difference of SNP rs6100067 was found 
(p=0.029).
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Table 4.4 The chi-square value for pairwise haplotype analysis between the normal and low 
expression groups. All combination of the two-SNP haplotypes were reconstructed and the chi-
square values were obtained from the EH programme. To reach a significant difference (p<0.05), the 
chi-square value must be higher than 7.815 on the degree of freedom 3. The value in each cell 
indicated the difference observed with the two-SNP combined haplotype frequency. Only rs6026230-
rs6100067 haplotype frequency was found significantly different among the two expression groups.
chi-square rs6026230 rs6026256 rs2234487 rs2234489 rs6100067 rs1802459
rs6026230 - 3.38 6.4 3.34 7.96* 2.4
rs6026256 - 6.08 3.32 6 4.72
rs2234487 - 3.56 5.74 4.94
rs2234489 - 5.54 1.98
rs6100067 - 7.02
rs1802450 -
Figure 4.5 Map displaying level of linkage disequilibrium for pairwise combinations of SNPs in 
normal and low VAPB expression groups. SNP1-6 represent re6026230, rs6026256, rs2234487, 
rs2234489, rs6100067 and rs1802459 respectively. Squares above the center line represent r2 and 
those below represent D’, where a value of 1 signifies complete disequilibrium.
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Having found that SNP rs6100067 is linked to gene expression, we then investigated 
whether any of the SNPs were linked to status as well. The samples were redefined 
by their status (21 healthy controls and 42 ALS cases), and the genotyping results 
are summarised in Table 4.5. However, no difference was observed in allele 
frequency or genotype frequency, nor were any pairwise haplotypes (Table 4.6) or 
the six-SNP haplotype (p=0.39) found to over-represent by status. Thus, we 
concluded that the SNP rs6100067 is linked to the VAPB expression regardless of 
status.
Table 4.5 Association of VAPB SNPs with status. The 63 samples were re-grouped by their status 
(21 individuals of controls and 42 of ALS cases). The p-value was obtained from the Fisher exact test. 
Allele frequency
no of chromosome (%)
Genotype frequency
no of individual (%)
Status Control ALS
p-
value
Control ALS
p-
value
Comm
on 
allele 
(A)
Rare 
allele 
(B)
Comm
on 
allele 
(A)
Rare 
allele 
(B)
A/A A/B B/B A/A A/B B/B
rs6026230 
T/C
33 
(78.6)
9 
(21.4)
61 
(72.6)
23 
(27.4)
0.522 15 
(71.4)
3 
(14.3)
3 
(14.3)
22 
(52.4)
17 
(40.5)
3 
(7.1)
0.076
rs6026256 
T/G
31 
(73.8)
11 
(26.2)
64 
(76.2)
20 
(23.8)
0.828 12 
(57.1)
7 
(33.3)
2 
(9.5)
25 
(59.5)
14 
(33.3)
3 
(7.1)
0.999
rs2234487 
C/T
28 
(66.7)
14 
(33.3)
54 
(64.3)
30 
(35.7)
0.845 12 
(57.1)
4 
(19.1)
5 
(23.8)
17 
(40.5)
20 
(47.6)
5 
(11.9)
0.070
rs2234489 
G/A
36 
(85.7)
6 
(14.3)
79 
(94)
5 
(6)
0.178 15 
(71.4)
6 
(28.6)
0 
(0)
37 
(88.1)
5 
(11.9)
0 
(0)
0.157
rs6100067 
C/T
29 
(69)
13 
(31)
60 
(71.4)
24 
(28.6)
0.837 13 
(61,9)
3 
(14.3)
5 
(23.8)
22 
(52.4)
16 
(38.1)
4 
(9.5)
0.096
rs1802459 
A/G
36 
(85.7)
6 
(14.3)
78 
(92.9)
6 
(7.1)
0.212 15 
(71.4)
6 
(28.6)
0 
(0)
36 
(85.7)
6 
(14.3)
0 
(0)
0-191
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Table 4.6 The chi-square value for pairwise haplotype analysis between cases and controls. All 
combination of the two-SNP haplotypes were reconstructed and the chi-square values were obtained 
from the EH programme. To reach a significant difference (p<0.05), the chi-square value must be 
higher than 7.815 on the degree of freedom 3. The value in each cell indicated the difference 
observed with the two-SNP combined haplotype frequency. 
chi-square rs6026230 rs6026256 rs2234487 rs2234489 rs6100067 rs1802459
rs6026230 - 0.6 1.06 1.46 0.32 1.74
rs6026256 - 1.26 4.54 1.06 0.88
rs2234487 - 2.22 2.28 3.56
rs2234489 - 0.78 1.84
rs6100067 - 2.02
rs1802450 -
To further refine the role of SNP rs6100067, samples were then divided into three 
groups: ALS with normal VAPB expression (17 individuals), ALS with low VAPB 
expression (25 individuals) and controls with normal VAPB expression (19 
individuals). As expected, we found that the rare allele frequency of SNP rs6100067 
was significantly lower in ALS with low VAPB expression when compared to ALS 
cases with normal VAPB expression (Figure 4.6), however, this difference was not 
detected when either ALS groups was compared to controls. Although no other SNP 
frequency was found to be significantly different between groups examined, we again 
observed a trend, that rare allele frequencies of these six SNPs were lower in the low 
VAPB expressing cases. Nevertheless, there were no pairwise (Table 4.7) or six-
SNP haplotype (Low ALS-Normal ALS, p=0.83; Low ALS-Normal controls, p=0.88; 
Normal ALS-Normal control, p=0.61) differences between the three groups. 
Therefore, it is evident that SNP rs6100067 specially  affected VAPB gene expression 
level in ALS cases.
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Figure 4.6 The rare allele frequencies of VAPB SNPs in the three population. We re-divided the 
samples with both VAPB expression and status: ALS with normal VAPB expression (Normal ALS), 
ALS with low VAPB expression (Low ALS) and controls with normal VAPB expression (Normal 
Control). The allele frequency difference was examined by the Fisher exact test by which the only 
difference was identified in SNP rs6100067 when Normal ALS and Low ALS were compared 
(p=0.049).
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Table 4.7 The chi-square value for pairwise haplotype analysis. A, Low VAPB expressing cases 
were compared with the normal VAPB expressing controls. No haplotype frequency difference was 
detected. B, Normal VAPB expressing cases were compared with the normal VAPB expressing 
controls. No difference was detected. C, Low VAPB expressing cases were compared with normal 
VAPB expressing cases. No difference was detected. All combination of the two-SNP haplotypes were 
reconstructed and the chi-square values were obtained from the EH programme. To reach a significant 
difference (p<0.05), the chi-square value must be higher than 7.815 on the degree of freedom 3. The 
value in each cell indicated the difference observed with the two-SNP combined haplotype frequency.
chi-
square rs6026230 rs6026256 rs2234487 rs2234489 rs6100067 rs1802459
rs6026230 - 1.96 3.12 4.58 4.72 2.3
rs6026256 - 4.34 2.36 3.56 3.72
rs2234487 - 6.14 3.08 3.3
rs2234489 - 2.86 2.64
rs6100067 - 6.02
rs1802450 -
chi-
square rs6026230 rs6026256 rs2234487 rs2234489 rs6100067 rs1802459
rs6026230 - 0.76 0.86 3.3 0.68 1.5
rs6026256 - 1.52 1.68 3.04 2.08
rs2234487 - 2.10 1 1.46
rs2234489 - 1.88 2.5
rs6100067 - 3.68
rs1802450 -
chi-
square rs6026230 rs6026256 rs2234487 rs2234489 rs6100067 rs1802459
rs6026230 - 2.42 4.74 0.72 5.82 0.9
rs6026256 - 3.24 2.88 5.22 2.36
rs2234487 - 3.62 4.38 3.22
rs2234489 - 5.28 1.26
rs6100067 - 4.64
rs1802450 -
A
B
C
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4.4.3 SNP associations in further cohorts
In the final part of this section, we extended our sample size in order to strengthen 
the power of this association study. Three control groups were genotyped with all six 
SNPs from east Anglia (CEA, n=58), Yorkshire (CEY, n=61) and London (n=35), the 
latter included 21 individuals with VAPB expression data used above. Unfortunately, 
signifiant differences were found between the CEA and/or CEY and London controls 
for three SNPs (rs026230, rs2234487 and rs6100067) (Figure 4.7), which indicates 
that they are two different populations and could not be combined. SNP genotype 
frequencies from NCBI SNP resource were also taken as a reference, which shows 
more similarity toward London control than CEA and CEY (Figure 4.7). Since our 85 
ALS cases were collected from the London area, we decided to exclude the CEA and 
CEY controls for these SNPs. Both allele frequency and genotype frequency of SNP 
rs2234487 were found to be significantly linked to the status with the rare allele being 
more abundant in cases (Figure 4.7C). Furthermore, pairwise haplotype analysis 
gave high chi-square values for rs2234487-rs2234487, rs2234487-rs6100067 and 
rs2234487-rs1802459 in disease association (Table 4.7). Although only  rs2234487-
rs6100067 reached the significant threshold, the high chi-square values covering the 
region between rs2234487 and rs1802459 confirmed the association between SNP 
rs2234487 and disease. Similarly, the LD maps also show that differences in pairwise 
SNP linkage from rs2234487 to rs1802459 are observed between control and cases 
(Figure 4.8). However, no difference was detected when the six-SNP haplotype was 
reconstructed and examined (p=0.21).
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Figure 4.7 The genotype frequency comparison of VAPB SNPs in different cohorts used in this 
study. A, SNP rs6026230. B, SNP rs6026256. C, SNP rs2234487 D, SNP rs2234489 E, SNP 
rs6100067 F, SNP rs1802459. The two east UK collected control cohorts (CEA and CEY) were 
compared with the control cohort collected from London. Although no difference was found between 
CEA and CEY, they were significantly different from the London control cohort (*, p<0.05; **, p<0.01). 
SNP genotype frequencies of European population published on NCBI SNP resources are shown here 
as reference, except for SNP rs2234487 which has no reported frequency data available. The only 
SNP linked to disease was SNP rs2234487 when compared with the London collected controls 
(p=0.044).
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chi-square rs6026230 rs6026256 rs2234487 rs2234489 rs6100067 rs1802459
rs6026230 - 2.68 4.24 5.8 2.12 2.02
rs6026256 - 6.28 2.52 0.52 1.08
rs2234487 - 7.04 8.1* 7.74
rs2234489 - 2.64 0.62
rs6100067 - 2.12
rs1802450 -
Table 4.8 The chi-square value for pairwise haplotype analysis between cases and controls in 
the extended cohort. 35 controls and 85 cases were used for this analysis. All combination of the 
two-SNP haplotype were reconstructed and the chi-square values were obtained from the EH 
programme. To reach a significant difference (p<0.05), the chi-square value must be higher than 7.815 
on the degree of freedom 3. The value in each cell indicated the difference observed with the two-
SNP combined haplotype frequency. 
Figure 4.8 Map displaying level of linkage disequilibrium for pairwise combinations of SNPs in 
control and ALS samples. SNP1-6 represent re6026230, rs6026256, rs2234487, rs2234489, 
rs6100067 and rs1802459 respectively. Squares above the center line represent r2 and those below 
represent D’, where a value of 1 signifies complete disequilibrium.
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4.5 Discussion
4.5.1 Reduction of VAPB expression
VAPB has just recently been linked to FALS (Nishimura et al., 2004), in which, 
including our report, only  two disease-linked mutations have been identified. Although 
the function of VAPB protein is not yet fully  characterised (for a detailed discussion 
concerning VAPB protein see chapter 6), it is regarded to play a role in vesicle 
trafficking and ER stress responses. Cell culture-based analysis has shown that 
knockdown of the expression of VAPB efficiently prevents the activation of IRE1-
mediated unfolded protein response under ER stress (Kanekura et al., 2006). As 
evidence of down regulation of VAPB mRNA and protein both in patients with ALS 
(Anagnostou et al., 2010) and ALS mouse model (Teuling et al., 2007) has been 
found, it is suggested that the reduced expression of VAPB may be involved in ALS 
pathogenesis. However, the reason for this reduced expression is uncharacterised. 
4.5.2 Contribution of VAPB SNP in ALS
In this study, we reported an association of VAPB SNP rs6100067 with reduced 
expression of VAPB in spinal cord. Although the reduction in VAPB expression is 
exclusively found in association with ALS (Teuling et al., 2007; Anagnostou et al., 
2010), SNP rs6100067 was found linked to VAPB expression levels within cases but 
not to the control population (Figure 4.6). However, another SNP, rs2234487, is 
associated with disease status using a larger cohort consisting of 35 controls and 85 
ALS cases, and a significant association of rs2234487-rs6100067 halpotype was 
also identified with this cohort. Our data suggest that SNP rs2234487 is a risk factor 
for ALS whereas rs6100067 influences gene expression in the disease group.
Despite the fact that neither rs6100067 nor rs2234487 has known function and both 
are outside regulatory regions involved in RNA splicing, they may be linked to a yet-
to-be-identified functional sequence variant which is responsible for the VAPB 
expression difference.
105
4.5.3 The larger picture --- Concerning the Genome-Wide Association Studies
With the advance of technology in the development of high-throughput DNA 
genotyping array, many genome-wide association studies have been conducted 
aiming to reveal the disease associated variants. Depending on the models of SNP 
arrays that are used, the numbers of SNPs typed vary from three hundred thousand 
to six hundred thousand, which covers the whole genome with an average of one 
marker every 5-10 kb. No SNPs close to VAPB gene on chromosome 20q13.33 were 
found in association with disease in these large scale screenings (Dunckley et al., 
2007; Schymick et al., 2007; van Es et al., 2007; Cronin et al., 2008; van Es et al., 
2008; van Es et al., 2009). However, as rs2234487 is not included in the Illumina 
Infinium II HumanHap550 and HumanHap300 SNP arrays, the most commonly used 
arrays, it can not be ruled out that the region containing this SNP is not covered in 
these association studies. On the other hand, rs6100067 is indeed included in the 
Illumina Infinium II HumanHap550 SNP chip, but since our results suggest that it 
linked to VAPB expression levels exclusively within the ALS population, it is not 
surprising that this SNP has not emerged from these genome-wide association 
studies, which evaluated association based on disease status. As ALS is a 
heterogeneous disorder which can be divided into several sub-groups depending on 
appearance of various clinical features, it is possible that the two thirds of SALS 
patients with reduced VAPB expression level are a sub-type which is linked to the 
SNP rs6100067. However, we did not find that VAPB expression levels was linked to 
gender, age of onset or disease duration, the clinical features of this sub-type and the 
pathological impact of reduced VAPB expression requires further characterisation. In 
this study, we found that the common allele of rs6100067 is significantly linked to low 
VAPB expression level, therefore it may influence VAPB expression during disease 
development. 
Although there are some studies showing changes in expression of genes involved in 
cellular trafficking (Pantelidou et al., 2007), calcium homeostasis (Morahan et al., 
2009), mitochondrial dysfunction, inflammation and cell survival (Ishigaki et al., 2002; 
Yoshihara et al., 2002; Dangond et al., 2004; Lederer et al., 2007), our study is the 
only one that has reported a marked change in the expression levels of a FALS gene, 
VAPB (Anagnostou et al., 2010). As this finding indicates a link between ALS 
pathogenesis in both familial and sporadic forms of disease, our report provides 
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evidence suggesting that particular SNPs within the VAPB gene may represent a risk 
factor for the disease and link to gene expression. 
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Chapter V CHARACTERISATION 
OF ALS-LINKED R199W-DAO
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5.1 Introduction
The characterisation of FALS-causative mutant genes plays an important role in 
revealing the mechanisms of disease pathogenesis. However, the ALS-linked gene 
mutations that have been identified so far account for only about 30% of FALS cases, 
whereas the remaining 70% are caused by uncharacterised genetic factors. 
However, there are several ALS loci that have already been reported, which include 
chromosome 16q12.1-12.2 (Abalkhail et al., 2003), chromosome 18q21 (Hand et al., 
2002) and chromosome 9 (Morita et al., 2006; Vance et al., 2006; Valdmanis et al., 
2007). This is still an ongoing process and our group  has identified a further locus on 
chromosome 12 using linkage study with our FALS pedigrees.
5.1.1 Identification of R199W in DAO
In previous studies, we conducted a whole genome screen with microsatellite 
markers in a FALS pedigree lacking known ALS-linked mutations. The history of this 
family can be traced up to three generations and DNA was available from 18 
individuals. Linkage analysis revealed that a region on chromosome 12, flanked by 
microsatellite markers D12S338 and D12S79, was significantly  linked to the disease. 
Candidate genes within this region such as thioredoxin reductase-1, ataxin 2 and 
DAO were sequenced. A point mutation in DAO gene which leads to a substitution of 
tryptophan for arginine at codon 199 (R199W) (Figure 5.1A) was identified in four 
affected and three “at risk” individuals (aged 33, 44 and 48 years, respectively) but 
not in three unaffected or two married-in spouses of this family (Mitchell et al., 2010). 
This mutation is not present in 780 controls, 23 SALS cases or 199 other FALS 
families (Mitchell et al., 2010). Further screening of DAO in 196 FALS did not reveal 
any mutations suggesting that this is `a rare FALS-linked gene. As this residue is 
highly conserved throughout species (Figure 5.1B), it may be an essential amino acid 
of the protein whereas the mutation at this position may lead to a destructive damage 
of DAO protein function. 
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Figure 5.1 Identification of R199W in DAO in a FALS family. A, A C to T change in exon 7 in DAO 
gene which results in a substitution of trypsin for arginine at codon 199 (R199W)  was identified in a 
FALS family. B, Peptide alignment shows that this amino acid, R199, is highly conserved between 
species. Rho,  Rhodotorula, gracilis; FUS, Fusarium Solanii; Strep,  Streptomyces Avermitilis. This 
figure is taken from the paper published by Mitchell et al., 2010.
A
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5.1.2 Current understanding of DAO
DAO was first characterised in 1935 as a flavin adenine dinucleotide (FAD)-
dependent enzyme catalysing the deamination of neutral and basic D-amino acids to 
α-keto acids and ammonia (Krebs, 1935). It is a conserved protein which can be 
found in almost all eukaryotic organisms from yeast to human (Pilone, 2000; 
Pollegioni et al., 2007). The human DAO gene was cloned in 1992 (Fukui and 
Miyake, 1992) as a single copy gene localised on chromosome 12q24. As D-serine, 
substrate of DAO, is abundant in mammalian brain (Hashimoto et al., 1995; Yasuda 
et al., 2001; Williams et al., 2006) and functions as a co-activator of NMDA receptors 
(Schell et al., 1997; Shleper et al., 2005), it is believed that DAO may play  an 
important role in regulating neurotransmission as well as NMDA receptor-mediated 
excitation (see the review of Pollegioni et al., 2007). 
Prior to this study, DAO had not been linked to motor neurone disorders. Instead, 
DAO and its interacting partner, G72, have been independently linked to 
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schizophrenia in SNP association studies (Chumakov et al., 2002; Liu et al., 2004). In 
supporting these association studies, the levels of D-serine in serum and CSF are 
found markedly lower in patients with schizophrenia compared with healthy controls 
(Hashimoto et al., 2003; Bendikov et al., 2007), and this down-regulation of D-serine 
is accompanied by increased levels of DAO in cerebellum and cortex (Burnet et al., 
2008a; Burnet et al., 2008b; Madeira et al., 2008) whereas region specific alterations 
in the expression of serine racemase (SR), which catalysed the production of D-
serine, has also been observed (Steffek et al., 2006). Taken together, these reports 
showed that the dys-regulation of NMDA receptor activation affects neuronal 
development and synaptic connectivity which then contributes to the development of 
schizophrenia. On the other hand, excitotoxocity due to hyper-activation of NMDA 
receptors has been linked to ALS with the finding of elevated levels of D-serine and 
SR in mutant SOD1 transgenic mice (Sasabe et al., 2007). As a modulator of NMDA 
receptor activation, DAO has the potential to participate in ALS pathogenesis though 
the role of it has not yet been characterised. 
 
5.2 Aims
To exclude the involvement of other gene mutations within the chromosome 12 
region in this FALS pedigree, another seven genes that are expressed in spinal cord 
with functions relevant to neuronal physiological properties were sequenced. In 
addition, functional studies were carried out to characterise the property  of R199W-
DAO in ALS pathogenesis.
5.3 Materials and Methods
5.3.1 Primers and PCR conditions for gene screening
The seven genes within our linkage region of chromosome 12 that were sequenced 
in this study are BRAP, C12 orf24, C12, orf34, GLTP, RFX4, SDSL and VSP29. 
Primers were designed to amplify  the coding exons with exon/intron junction with 
conditions as shown in Table 5.1. In the case of two exons separated by a small 
intron, primers outside of these two exons were used to amplify the joint exons with 
the intron in between, such as C12 orf24 exon 4 plus exon 5 and SDSL exon 3 plus 
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exon4. On the other hand, while the coding exon is too large to be amplified with a 
single PCR, it is split into two reactions, such as C12 orf34 exon 2. The PCR 
products were purified before sequencing which used the same set of primers as 
PCR.
Gene/
exon
PCR 
product (bp)
Forward primer
(5ʼ to 3ʼ)
Reverse primer
(5ʼ to 3ʼ)
Tm 
(℃)
DMSO 
(%)
BRAP NM_006768.3 BRAC1 associated protein
1 526 CAATCTCCACGACGTCCTTC TACCTCTCCGTGTCTTCCTG 58 -
2 311 AGAGAACAGAGAGGAGCTTG GTTGAAATTGTAGGCTCATC 58 -
3 433 CAGCTATTCTACAAATAATAGC
TG
CTTCAGGACAAGAGACTATGC 55 -
4 315 CTAACCATACCTCATCTATTC CACACACAGCTATCATACAG 55 -
5 315 GCTGATGAGAATGAATAAAGC
C
TGTCTATGGACTGGCCTATTC 58 -
6 285 GTATTGCTGGTAGATGAAGAG AATGGTTCATTTCTGCTGGTG 58 -
7 317 GCATATAAGAGGAGGAGG CACAGTAAGCCCTGTCTC 55 -
8 327 AGGTGATCCATCTGCCTC AGATGACATTTCAAGCTGGG 58 -
9 218 GTTAAAAGTGTACAGAGACC GAGCAGTAGAAACAGATAG 55 -
10 224 CAGAGGCTGACAACAGTGAC CTGTACTCTGCCTTCCACAC 58 -
11 235 GAGCACACCACATTACCTTTG GAGGGTGTTTCCATAGGAATG 58 -
12 546 AGAAAGGGGACTGTGTCAGC CAACTGTGGCTTGATCCTCAC 58 -
C12 orf24 NM_013300.2 chromosome 12 open reading frame 24
1 812 AAATCCCGTGAGAAACGCGT
CC
TGCTCCCCGCCTCTCACTTG
A
58 -
2 187 TATGTTGTTCAGTGCTTG GTGTAAGTAGTTACAGAC 55 -
3 336 ATTACAGGCGTGAGCCAC CCCTCTAAGCAGCTGATC 55 5
4 & 5 490 GCCAACTTCTCTAATACAATG
C
TTAAACTGAGATGCATTTCCC 58 -
6 329 CTAGGCAGCTGTTCACTTTG GCCTGGCCCAGTATGTTCT 58 -
7 753 GCTGTACAGTAACTTGGCTAG TCTCGAACTCGTGACCTCATG 58 -
C12 orf34 NM_032829.1 chromosome 12 open reading frame 34
1 369 GGTGTCTGCTTTGAGAGT AGAGAGCATAGAGACTTTCC 58 -
2A 942 AAATGAATGGGAAATGAG CCACAGCAGGTAATCCAG 55 -
2B 945 CTCCTGTACCAGCTCAAC CTTGGTATGTGAGGTTGC 58 -
GLTP NM_016433.3 glycolipid transfer protein
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Table 5.1 PCR primers and conditions for gene screening. 
Gene/
exon
PCR 
product (bp)
Forward primer
(5ʼ to 3ʼ)
Reverse primer
(5ʼ to 3ʼ)
Tm 
(℃)
DMSO 
(%)
1 581 ACCTGGGGAAGACTCAC AGTACTTAGGGGTGTCTAGG 58 2.5
2 434 CCTTAGTAACATCCAGAACA ACCCTTTAATTAGACTTTGG 55 -
3 400 TTACAAGTCTTATCCCTGCT ATTAACTAGCATCACACTGG 58 -
4 333 CAAATTCAGAGTCCATCAG GTAAACACAGCCTCACAG 58 -
5 369 ACAGACCCAGGGAAGAC AGTTCACCGACTTGATTC 58 -
RFX4 NM_213594.1 regulatory factor X, 4 (influences HLA class II expression)
1 247 TTCCTGGGCTTCTCCAAACTC CCACACTCACAGCTACCAAG
G
58 -
2 369 GCCACATGAATATTGATGAGC CCAGCCTAGCAATCTAGTGG 58 -
3 187 AACTTGGGAGAGTCGAGAGG ATGAGCATCCTCTGAAGACAG 58 -
4 348 CCATCTCTGGAGGACTAG GTGAAGTTGAAGTTGTCAAA
G
55 -
5 255 AACTCAGTCACTATGCTCC TCCATATTCCCTCTAGGCAC 58 -
6 315 CTTAATAACAGTGCATGTGGG CCCAAATAGTCACTTCAGTTG 58 -
7 217 TCCAAGGGCAGCAGCAATGT
G
GCTCATGAAATAGGAGCTAGT
G
58 -
8 331 TGGAGTCCCAAGCTTCTGTT
G
GCCTCTGGACAGTGCATGATT 58 -
9 264 CTAAGCAACATGTGCAGCAC CTGGTGCTTTATAGTCAACCA
G
58 -
10 273 GCAGTGAGATAAACGTAGGC AACCTGAAAGATCCTGCAGG 58 -
11 262 ACCCATGAGCTAACGAGTTG CCACTTCGGTATTTACTAAGA
C
58 -
12 239 TACAACTGCAGTGATGCGTGT
G
GTTCAGATAGCTTACCATAGG
G
58 -
13 299 AGGCGTGAGCCACTTCAAC GCAAGTTAGACTGTGGTAGAT
TC
55 -
14 328 CTTGTGCAGTTGACCAGACA
G
GATACCACTTAACCTGTTCAC
C
58 -
15 354 GAGAGTGACATCACACAGATT
AG
TGAAGTCTCACTATGTTGCCC 58 -
16 302 GGAAGAACAAGGGATATGAG TTACAGGGTGTGAGCTGCTG
TG
55 -
17 322 CTGATCTGTTCTTGCTATTAC AAAGACTGTCCTCTCCTTGG 58 -
18 671 GTGTATATGCAACCTCAAGC CAGTAGCTTACTAGAAGTGG 58 -
SDSL NM_138432.2 serine dehydratase-like
3 & 4 887 GAGTCACAGATACTTGATGG ATTCTTAGAGCCTGTAGCTT 55 -
5 397 AGGTTCTGATTGGCTCAACC AAGGAGACAGGATGTCTTAG 58 -
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Gene/
exon
PCR 
product (bp)
Forward primer
(5ʼ to 3ʼ)
Reverse primer
(5ʼ to 3ʼ)
Tm 
(℃)
DMSO 
(%)
6 592 ATAGTGTGGCAGTAGGACA GCACATATTCAGTAAAGGAG 58 -
7 650 GAATGAAGCTGAGTGAAGTA TAAGTCAATGAAAGCTTGTT 55 -
8 449 CCTCTGTGACTTATAATGCT AGCAAGATACACTCCTTCTT 58 -
9 800 TAATGATGGATAGAGGAATG TAAGATCTCATAATGGTTGG 55 -
VPS29 NM_057180.1 Vacuolar protein sorting 29 homolog (S. cerevisiae)
1 505 CTCCACCTTTCACCTGACTG CCTTCCCTAGACCTCTTCTG 58 -
2 162 CTGTCTGCAATCAACTTCTTC AATCAAAGCATGGGAATTCGG 58 -
3 375 TTCGGGATCTCTTATGAGAC CCCTGGTCTAAAGATAAAGC 58 -
4 402 CATCAAAACATCCATAGGAG TACGAAATGTCACACATGC 55 -
5 772 CTCTGAATCCAAATAGTCATC GAATCACTGTTAATGTCGGC 55 -
5.3.3 DAO expression constructs
Human DAO cDNA was cloned into the pcDNA3.1/NT-GFP-TOPO vector (Invitrogen) 
which produced N-terminal GFP fusion DAO under the control of CMV promoter. The 
generation of the three DAO (wild type, R199W  and G183R) expression constructs 
was a joint effort of Mitchell. J, Paul. P and myself.  
5.3.3 DAO enzyme activity assay
To measure the activity of DAO, a GFP-DAO fusion protein was expressed in COS-7 
cells for two days before harvesting. After washing for three times with ice-cold PBS 
buffer, the GFP-DAO transfected cells were lysed in ice-cold cell lysis buffer 
containing 50 mM Tris-HCl (pH 8.0), 120 mM NaCl, 0.5% Igepal CA-630 (Sigma), 
1mM phenylmethylsulfonyl fluoride (PMSF, Sigma), 1× of protease inhibitor and 
phosphatase inhibitors (cocktail from Roche). Debris was pelleted by centrifugation 
for 10 minutes at 13,000 ×g at 4℃. The supernatants which contained proteins were 
transferred to a new tube and the protein concentration was measured using the Bio-
Rad Protein Assay (Bio-Rad) which is based on the standard Bradfordʼs method 
(Adage et al., 2008).
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The measurement of DAO enzyme activity was based on a protocol described by 
Gablet et al. which measured DAO activity by detecting the production of hydrogen 
peroxide. As shown in Figure 5.2, this assay  uses the chromogen o-dianisidine to 
detect the production of hydrogen peroxide which is oxidised in the presence of 
peroxidase to yield a red product that can be quantified by spectrophotometer 
(Gabler et al., 2000).
Figure 5.2 Spectrophotometric assay for DAO activity using peroxidase and o-dianisidine. 
Coupled with DAO deamination of D-amino acid, reoxidation of the reduced FAD by oxygen releases 
hydrogen peroxide as a by-product. This measurement uses o-dianisidine as a chromogen which is 
then oxidised with the facilitation of peroxidase. The oxidised o-dianisidine appear in red which can 
then be measured by spectorphotometer. 
D-amino acid!
!"#$
FAD! FADH2!
H2O!
NH3!
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O2! H2O2!
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2H2O!
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200 μg of protein from cell lysates were used for the DAO enzyme activity assay, 
which were then mixed with the reaction mixture containing 200 mM substrate (D-
serine or D-proline, Sigma), 50 mM potassium phosphate buffer (pH 8.0), 0.86 mM ο-
dianisidine, 0.3 kU peroxidase (Sigma) and 0.007 mM FAD (Sigma) in a final volume 
of 1ml. All solutions were air saturated at room temperature. The start of the reaction 
is defined by  the time when the substrates are added to the reaction mixture. 
Spectrophotometrical measurements at 436 nm were taken for 30 minutes from the 
start of the reaction. The reaction was stopped by the addition of 500 μl of 30% 
H2SO4 at 30 minute when an end point reading was taken by photometrical 
measurement at 540 nm. 
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5.4 Results
5.4.1 Additional gene screening 
In our previous study of screening for the disease-linked gene, three genes including 
throedoxin reductase-1, ataxin 2 and DAO were sequenced, and a point mutation 
causing amino acid substitution of tryptophan for arginine at codon 199 (R199W) in 
DAO was identified in affected individuals but not unaffected family members. To 
further exclude the involvement of other genes in this family, we carried out mutation 
screening on another seven candidate genes within this linkage region. The criteria 
of selecting sequencing candidate genes are that they are expressed in spinal cord 
with functions relevant to the known machinery which plays an important role in 
neuronal physiology, such as serine metabolism (serine dehydratase-liked enzyme, 
SDSL), transcriptional regulation (regulatory  factor X 4, RFX4), nuclear targeting 
(BRAC1 associated protein, BRAP), glycolipid transfer (glycolipid transfer protein , 
GLTP) and vacuolar sorting (vacuolar protein sorting 29 homolog, VPS29). In 
addition, two open reading frames that are expressed in spinal cords, C12 orf24 and 
orf34, were also included in this screening. All seven genes were sequenced in an 
index patient from this family, however, no mutations were found except a 
heterozygous SNP, rs10778502, in exon 8 of RFX4. As this SNP appears to be a 
common variant with a frequency of 48% in the European population (NCBI SNP 
data resource), it is highly unlikely to be a disease-related variant.
In this screening, no further disease-associated mutations were found in these spinal 
cord expressed genes, which supported the conclusion that R199W-DAO is the 
disease causative mutant gene in this family.
5.4.2 DAO enzyme activity affected by R199W
DAO is a FAD-dependent enzyme using neutral and basic D-amino acids as 
substrates. Since R199W leads to an amino acid substitution at a conserved site 
which may be critical for the protein property, we examined whether DAO enzyme 
activity in deamination of D-amino acids is damaged by this disease-linked mutation. 
In order to get the best sensitivity for our enzyme activity assay, we tested our 
experimental protocol with two different substrates, D-proline and D-serine. L-serine 
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was also used as a negative control. Consistent with previous findings (Gabler et al., 
2000; Molla et al., 2006), the DAO deamination reaction was most rapid with D-
proline as its substrate whereas it did not react to L-serine at all (Figure 5.3). To 
achieve the best sensitivity  for our assay, we used D-proline as substrate in the 
following experiments. 
To investigate the properties and effects of DAO in mammalian cell lines, expression 
constructs which expressed GFP-DAO fusion proteins were generated. In addition to 
the wild type and R199W  mutant DAO, we also made a second mutant DAO 
construct containing a single mutation which leads to a G183R substitution in DAO 
protein. G183R corresponds to the naturally  occurring mouse G181R mutation which 
has been demonstrated to abolish enzyme activity (Sasaki et al., 1992). As shown in 
Figure 5.4, no DAO enzyme activity was detected with cells transfected with either 
R199W-DAO or G183R-DAO, both of which remained at the same level as non-
transfected and GFP vector transfected cells. Wild-type DAO enzyme activity  was 
determined in  three independent experiments yielding a value of 0.29±0.06 mU/100 
μg of cell lysate protein, whereas R199W  DAO lacked any enzyme activity. 
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Figure 5.3 Comparison of DAO enzyme activity on different substrate. 0, 10, 25, 50 and 75 mU of 
pig DAO purchased from Sigma was used to determined test substrate affinity. 100 mM of substrates 
were used in these reactions. A-B, Photometrical measurement at 436nm using substrates of D-serine 
(A) and D-proline (B) respectively. The reading was recoded every minute for 20 minutes since the 
substrate was added to the reaction mixture. C, Reactions were stopped at 20 minutes by adding 
sulfuric acid and the end point measurements were taken at OD 540. 
A
B
C
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Figure 5.4 DAO enzyme activity assay. 200 µg of proteins harvested from two day transfected 
COS-7 cells were used in this DAO enzyme activity assay. A, Cell lysates were mixed with reaction 
mixture 10 minutes before the substrate was added in (as pointed with the arrow). Photometrical 
measurement at 436 nm was taken every 30 seconds. B, Reactions were stopped 30 minutes after 
the adding of substrate. The end point measurement was taken at OD 540. Three independent 
transfections were done and one representative experiment is shown here. 
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5.4.3 R199W-DAO triggers ubiquitin aggregation
As the presence of cytoplasmic ubiquitin-positive aggregates is a hallmark of 
pathological feature of ALS, we investigated whether they are present in mutant 
DAO-expressing cells. Indeed, the expression of DAO in the motor neurone cell line 
NSC-34 clearly showed the induction of ubiquitinated aggregates by R199W-DAO 
(Figure 5.5B) whereas these ubiquitin-positive aggregates were hardly found in wild 
type-DAO expressing cells (Figure 5.5A). Further counting of cells containing 
ubiquitinated aggregates in wild type or mutant DAO expressing cells was carried out 
by our colleague Miles Payling. This quantification confirmed our observation of a 
significant increase in the number of cells containing ubiquitin-positive aggregates in 
cells expressing R199W-DAO than wt-DAO (Mitchell et al., 2010).
Taken together, in this study, we showed that the novel ALS-linked mutation R199W 
in DAO has a significant effect on DAO protein physiology which leads to the 
abolition of DAO enzyme activity. In addition, the expression of R199W-DAO, but not 
wt-DAO, induces the formation of ubiquitinated aggregates in NSC-34 cells. 
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Figure 5.5 Ubiquitinated aggregates in mutant DAO expressing NSC-34 cells. NSC-34 cells were 
fixed and stained for endogenous ubiquitin three days after transfected with wt- (A) and R199W- (B). 
Examples of intracellular ubiquitinated aggregates in transfected cells are indicated by arrows (B-i, B-ii 
and B-iii). Nuclei are shown with DAPI staining in the merge panel (blue). Scale bar: 20 µm
5.5 Discussion
5.5.1 A novel ALS-causative mutation, R199W-DAO
This study, together with previous work of our group, revealed a novel ALS-linked 
locus on chromosome 12, flanked by microsatellite markers D12S338 and D12S79. 
Although there are 146 RefSeq genes within this region, we selected our sequencing 
candidate genes based on their functions and expression sites. As ALS is 
characterised by the loss of motor neurones in both motor cortex and spinal cord, the 
disease causing protein is likely to be present in these regions thereby causing ALS 
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pathology. Therefore, a total of ten genes that are expressed in high abundance in 
spinal cord were sequenced, yielding a point mutation R199W in DAO which co-
segregated with disease in this family. The fact that R199 is a highly conserved 
residue between species (Figure 5.1B) suggests that it plays an important role in the 
physiological property of DAO protein, whereas the disruption of this property could 
lead to the development of ALS.   
5.5.2 DAO in CNS
As the most characterised function of DAO is to the oxidation of D-amino acids, it is 
necessary to take into account D-amino acid metabolism while evaluating the role of 
DAO in CNS. However, since D-amino acids were traditionally assumed to be utilised 
by bacteria and in low abundance in eukaryotes, the physiological role of DAO had 
been enigmatic. With the recent findings of high concentration of D-serine in 
mammalian brain (Hashimoto et al., 1995; Yasuda et al., 2001; Williams et al., 2006), 
the importance of DAO in the regulation of neuronal activation in higher organisms 
has been revalued.
Indeed, being produced from its isoform, L-serine, by serine racemase (SR), D-serine 
is an endogenous ligand for the glycine-binding site of NMDA receptors and thereby 
functions as a co-activator with glutamate at NMDA receptors (Hashimoto et al., 
1993a; Schell et al., 1997; Shleper et al., 2005). Current understanding suggests that 
the production of D-serine by SR takes place mostly in astrocytes with some reports 
showing its presence in neurones of various regions of the CNS (Yasuda et al., 2001; 
Williams et al., 2006). It is released into the synaptic cleft due to the activation of 
metabotropic and non-NMDA ionotropic glutamate receptors (Ribeiro et al., 2002; 
Mothet et al., 2005; Martineau et al., 2008) to facilitate neurotransmission mediated 
by NMDA receptors. The termination of this reaction relies on the uptake of 
extracellular D-serine by transporters such as ASCT2 and Asc-1 on astrocytes and 
neurones, where it is degraded by DAO (Urai et al., 2002; Dun et al., 2007; Rutter et 
al., 2007; Shao et al., 2009).
As the only known enzyme capable of destroying D-serine, the presence of DAO in 
the brainstem, medulla and spinal cord plays an important role in controlling the 
levels of D-serine (Kappor and Kapoor, 1997; Verrall et al., 2007). Similarly to SR, the 
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activity  of DAO is detected mainly in astrocytes (Arnold et al., 1979; Horiike et al., 
1987; Urai et al., 2002) but is also found in neurones at various concentrations 
(Moreno et al., 1999). Abnormal stimulation of NMDA receptors could lead to dys-
regulation of neuronal development and survival, therefore, it is not surprising to find 
that abnormal levels of D-serine, SR and/or DAO have been linked to Alzheimerʼs 
disease (Wu et al., 2004; Wu et al., 2007), schizophrenia (Hashimoto et al., 2003; 
Bendikov et al., 2007; Verrall et al., 2007; Burnet et al., 2008a; Madeira et al., 2008; 
Habl et al., 2009) and ALS (Sasabe et al., 2007).
5.5.3 Another model of ALS --- R199W-DAO-mediated pathogenesis
It was recently found that levels of D-serine and SR are elevated in mutant SOD1 
transgenic mouse models (Sasabe et al., 2007), which implies that a disruption in D-
serine metabolism takes place in ALS, albeit whether it is the consequence or cause 
of the disease is unknown. While the increased levels of D-serine may lead to hyper-
activation of NMDA receptors, which in turn triggers elevated influx of calcium, the 
impaired elimination of excessive D-serine could directly contribute to excitotoxicity. 
In support of this speculation, we reported a novel ALS-linked mutation in DAO which 
totally abolishes the activity  of DAO, and the expression of mutant DAO promotes the 
formation of ubiquitinated aggregates. Other parallel studies from our group have 
shown that the mutant protein is able to interact with wild type DAO, which leads to 
an interference of the wild type protein enzyme activity. In addition, increased levels 
of cell death were found in primary motor neurone cultures expressing or co-cultured 
with astrocytes expressing mutant DAO. Taken together, we showed that this 
mutation causes loss-of-function in DAO enzyme activity, dominant-negative effects 
by binding and interfering wild type protein, and gain-of-function in triggering the 
formation of ubiquitin-positive aggregates. All of these consequently lead to cell 
death. 
Interestingly, animals carrying a spontaneous mutant G181R-DAO have long been 
found (Sasaki et al., 1992). This point mutation leads to a complete abolition of DAO 
enzyme activity and, as a result, elevated levels of D-serine are found in these 
animals (Hashimoto et al., 1993b). In additional to enhanced NMDA receptor-
mediated excitation in spinal cord neurones (Wake et al., 2001), deficits in locomotor 
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activity  and spatial performance have also been reported with these animals 
(Maekawa et al., 2005; Almond et al., 2006). However, we have not been able to 
determine whether the loss of DAO enzyme activity  solely can cause ALS, or other 
neuronal toxicity triggered by the expression of R199W-DAO also contributes to 
disease pathogenesis. Comparing the G181R-DAO mice and our current 
understanding of R199W-DAO-linked ALS, it is likely that the loss of DAO activity 
which leads to hyper-activation of NMDA receptor results in a certain degree of motor 
deficits, nevertheless, other toxic effect brought about by the R199W  mutation may 
be required to aggravate the cellular disturbances occurring in ALS pathogenesis. To 
further verify this hypothesis, transgenic mice expressing R199W-DAO have 
currently been generated and are being characterised by our group. 
In summary, although we can not exclude the possibility that another disease-linked 
mutation is present in one of the unsequenced genes within the linkage chromosome 
region, we propose that R199W-DAO is responsible for ALS pathogenesis in this 
family based on the following facts: (1) the residue R199 is highly conserved 
throughout species; (2) this mutation co-segregates with disease within this family, 
and (3) the cell culture-based functional study showed that R199W disrupts the 
enzyme activity of DAO protein and the expression of R199W-DAO promotes the 
formation of cytoplasmic ubiquitinated aggregates and cell death. 
The results reported here, together with other functional studies concerning the 
properties of R199W-DAO, was published in PNAS, 2010 (Mitchell et al., 2010). 
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Chapter VI CHARACTERISATION 
OF ALS-LINKED T46I-VAPB
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6.1 Introduction
VAPB was recently identified as a gene linked to FALS (Nishimura et al., 2004). A 
point mutation in this gene, P56S, was reported in a large Brazilian pedigree which 
leads to a wide spectrum of motor neurone degenerative phenotypes including 
atypical ALS, typical ALS and spinal muscular atrophies (SMA) (Nishimura et al., 
2004; Marques et al., 2006). However, it is unclear how mutations in VAPB contribute 
to ALS pathogenesis. Further VAPB mutations have not emerged from screening 
FALS and SALS in Italian and UK populations (Conforti et al., 2006; Kirby et al., 
2007; Landers et al., 2008). Recently, our group identified a novel VAPB mutation in 
a FALS case, which is the first mutation found in a non-Brazilian case. In this study, 
the property of the VAPB protein carrying this mutation was evaluated in order to gain 
a better understanding of ALS disease causing mechanism. 
6.1.1 Current understanding of VAPB
The gene VAPB was first cloned as Scs2 in yeast (Nikawa et al., 1995), where it was 
shown to override inositol auxotrophy caused by  the deficiency of IRE1/Hac1 
(Nikawa et al., 1995; Kagiwada et al., 1998). Besides regulating the production of 
inositol via enhancing the expression of inositol 1-phosphate synthase (INO1) 
(Nikawa, 1994), IRE1 is also the sole signal transducer of the UPR in yeast. Due to 
this functional compensation with yeast IRE1, SCS2 was predicted to participate not 
only in lipid metabolism and trafficking, but also in ER stress. In mammals, there are 
two members of the VAP family: VAPA and VAPB, both of which are ER and pre-
Golgi resident proteins and involved in vesicle trafficking (Soussan et al., 1999; 
Prosser et al., 2008). An alternatively spliced form of VAPB, VAPC, was identified at 
the time that human VAPB was cloned (Nishimura et al., 1999). VAPC shares only 
the first half of MSP domain with VAPB which is followed by 29 VAPC-specific amino 
acids. Therefore, VAPC lacks CC  and TM domains (see below), does not interact 
with either VAPA or VAPB, and is not localised to the ER membrane (Kukihara et al., 
2009). It is believed to perform distinct roles from both VAPA and VAPB, and was 
recently reported to act as a regulator of hepatitis C virus propagation (Kukihara et 
al., 2009). 
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Except for the alternative spliced VAPC, VAP proteins consist of three functional 
domains, major sperm protein (MSP), coil-coil (CC) and transmembrane (TM) 
domain (Figure 6.1B). MSP is the most conserved domain throughout species and 
between VAPA and VAPB, which is believed to be crucial to the functions of the 
protein by mediating protein-protein interactions. It is currently  thought that the VAP 
protein uses the C-terminal TM domain as an anchor to the ER membrane with its 
MSP domain facing the cytosol, which functions as a docking site for VAP-interacting 
proteins (Kawano et al., 2006). One of the interacting targets of the MSP domain is 
the FFAT (two phenylalanines in an acidic tract) motif, which has been identified in a 
wide range of lipid-associated proteins (Loewen et al., 2003). Thus, VAPs regulate 
lipid metabolism and transfer between the ER and other organelles by interacting 
with proteins such as oxysterol binding proteins (OSBP), Nir proteins and ceramide 
transfer protein (CERT) (Wyles et al., 2002; Amarilio et al., 2005; Kawano et al., 
2006). In addition to regulating lipid transfer, VAPB is involved in the ER stress 
response by directly activating IRE1/XBP1 (Kanekura et al., 2005; Suzuki et al., 
2009). In Drosophila, VAP controls the number and size of boutons at the 
neuromuscular junction. Furthermore, loss of DVAP disrupts the synaptic microtubule 
cytoskeleton (Pennetta et al., 2002) causing an increase in miniature junctional 
potential amplitudes and postsynaptic glutamate receptor clustering (Chai et al., 
2008).
Despite the identification of the interaction with FFAT motif-containing proteins, very 
little is known about other cellular actions of VAPB. Immunochemistry studies have 
shown that both VAPA and VAPB can form homodimers and heterodimers with each 
other via CC and TM domains (Nishimura et al., 1999; Teuling et al., 2007) and the 
N-terminal MSP domain of Drosophila VAP can be released from cells and act as a 
ligand of the Eph receptor (Tsuda et al., 2008). However, this has not yet been 
verified in other species.
6.1.2 The identification of P56S-VAPB
The P56S mutation in VAPB was first identified in 2004 in a large Brazilian pedigree 
consisting of four generations, including 28 individuals affected by motor neurone 
degenerative diseases, where DNA was available from 12 affected and 5 healthy 
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individuals. This mutation was only  found in the affected cases of this pedigree, and 
later identified in an additional 22 patients of six kindreds also of Brazilian origin 
(Nishimura et al., 2004). However, the phenotypes associated with this mutation are 
variable from typical ALS to SMA (Nishimura et al., 2004; Marques et al., 2006).
Recent cell biology studies revealed that this mutation largely disrupts the properties 
of wild type VAPB, which results in abnormal localisation, increased affinity between 
wild type and mutant VAPB proteins, disruption of certain protein interactions and a 
cytotoxic gain-of-function effect (Kanekura et al., 2006; Mitne-Neto et al., 2007; 
Teuling et al., 2007; Gkogkas et al., 2008; Fasana et al., 2009; Suzuki et al., 2009). 
6.1.3 The identification of the novel ALS-linked VAPB mutation, T46I
In our previous study, a point mutation causing an amino acid change from threonine 
to isoleucine at VAPB codon 46 (T46I) was identified in one out of 107 FALS cases 
(Figure 6.1A). The index case with the amino acid substitution in VAPB was 
diagnosed with classical ALS. Signs at onset revealed on first examination at the age 
of 73 years, included wasting of the small muscles of the right hand. There were 
fasciculations in the left vastus medialis and both gastrocnemii. Plantars were flexor. 
Sensation was normal whereas speech and swallowing difficulties developed at the 
age of 75 years. The diagnosis was confirmed by nerve conduction studies. The 
patient had a brother with ALS who died within 4 months of diagnosis from 
bronchopneumonia. There were no further DNA samples available from this family, 
as the patient had no children. DNA was not available from any other affected 
members of this family  and this mutation was not found in any of the other FALS 
cases screened or in 257 control subjects (Caucasian which matched the index 
case).
This is the second ALS-linked VAPB mutation found worldwide and the first mutation 
identified in a non-Brazilian family. Interestingly  this mutation together with the 
previously identified P56S mutation causing ALS8, are located in a stretch of 16 
amino acids in the MSP domain that appears to be highly conserved throughout 
species (Figure 6.1B). This finding indicates that this 16 amino acid-stretch plays an 
important role in VAPB physiological functions, which, once disrupted, leads to the 
dysfunction of VAPB protein and contributes to ALS pathogenesis.  
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Figure 6.1 Identification of the novel ALS-linked mutation, T46I, in VAPB. A, A missense mutation 
C>T at nucleotide 137 (translation state site as +1) was identified in one FALS case but not present in 
control. B, The T46 residue is localised at a 16-amino acid region within MSP domain which is highly 
conserved in all VAP homologs. 
6.2 Aims
The T46 residue is located in the 16-amino acid highly  conserved region (Figure 6.1 
B) that has been shown to be essential for the physiological functions of VAPs 
(Kagiwada et al., 1998). We have therefore carried out a range of functional studies 
in cell culture to elucidate the potential pathological effects of this mutation and to 
further elucidate novel aspects of mutant VAPB-induced mechanisms in ALS.
6.3 Materials and Methods
6.3.1 Construction of GFP- and RFP-tagged VAPB
To generate the full length VAPB fragment, PCR was performed using a 5ʼ VAPB 
p r i m e r ( G C C A A A G G T G C T C C G C C G C ) a n d 3 ʼ V A P B p r i m e r 
(TTGGGAAGATTGCCTTGT) with a VAPB cDNA template purchased from OriGene. 
The annealing temperature of the full-length VAPB amplification was 55℃ . The PCR 
product was cloned into pcDNA3.1/NT-GFP-TOPO (Invitrogen) via TA cloning, which 
produced a N-terminal GFP fusion protein. For generating the RFP fusion VAPB 
construct, additional restriction enzyme cutting sequences of EcoRI (GAATTC) and 
BamHI (GGATCC) were inserted at the 5ʼ end of the VAPB 5ʼ and 3ʼ primers 
respectively. The PCR product  was cloned into pCR2 (Invitrogen) via TA cloning and 
then sub-cloned into pDsRed2-C1 (Clontech) via Eco RI/Bam HI. 
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To introduce T46I and P56S mutations, a traditional two-step  mutagenesis PCR was 
performed (Figure 6.2). In the first step, an internal primer containing the targeted 
mutant base in the centre was used with the 5ʼ VAPB primer (Tm= 55 ℃), the PCR 
product of which was purified and used as a mega primer for the second round of 
PCR. In the second PCR, the mega primer was used with the VAPB 3ʼ primer to 
produce the full length VAPB containing the corresponding nucleotide change (Tm= 
50 ℃), which were then cloned into either GFP or RFP vector as mentioned above. 
Full length wild-type VAPB was used as template for both rounds of PCR. The 
sequences of internal primers used to generate T46I and P56S were 
A C G T G G T G C T G T A A T C T T C A C C T T A A A A C a n d 
GATTCCGCTGTTGGACCTCACACAGTACCT respectively. The sequences of all 
PCR products were verified with sequencing.
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Figure 6.2 Cloning of full-length wild type and mutant VAPB. A, A flow chart demonstrating the 
two-step mutagenesis PCR. B, The PCR product of the first round PCR via which the point mutation 
was introduced. The products of which were then purified and used as the mega primers for the 
second round PCR to generate the full-length VAPB (C).  
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6.3.2 Preparation the Triton X-100 soluble and insoluble fractions
The strategy of preparing the soluble and insoluble fractions is as described by 
Kanekura et al. (2006). Two days after transfection with GFP-VAPBs, NSC-34 cells 
were lysed with cell lysis buffer (10 mM Tris-HCl pH 7.4, 1% Triton X-100, 1mM 
EDTA, protease inhibitors from Roche) by pipetting and a freeze-thaw cycle. After 
centrifugation at 12,000 ×g for 5 min, the supernatants were collected as the soluble 
fraction. The pellets were resuspended in 500 μl of lysis buffer and sonicated for 10 
seconds, which were then centrifuged at 12,000 ×g for 5 min. After complete removal 
of the supernatant, the remaining pellets, defined as the insoluble fractions, were 
resuspended in SDS-containing loading buffer for subsequent immunoblotting 
analysis. 
6.3.3 Establishment of wild type and T46I-VAPB permanently expressing cell 
lines
To establish VAPB stably expressing cell lines, NSC-34 cells were transfected with 
GFP-VAPB. One day after transfection, cells were trypsinised and plated in 10 cm 
plates at very low density  where G418 selection (400 μg/ml, Invitrogen) was carried 
out until visible cell colonies were formed. The expression of GFP-VAPB in each 
clone was validated by fluorescence microscopy and western blot. A PCR which 
amplified the transfected GFP-VAPB was performed and the products of which were 
sequenced to confirm the genotypes. 
6.3.4 Monitoring IRE1/XBP1 activation via Venus reporter 
Equal amount of Venus-XBP1 reporter (a gift from Prof. Miura, University of Tokyo) 
and RFP-VAPB constructs were co-transfected in NSC-34 cells. Cells were 
harvested at 24 hours or 48 hours after transfection. After washed twice with PBS, 
the number of cells expressing RFP and Venus fluorescent proteins was quantified 
by BD FACS flow cytometer. Transfection efficiency indicated by  the expression of 
RFP construct is shown in Table 6.1. 
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Table 6.1 Transfection efficiency of RFP constructs in NSC-34 cells.
(%)
24 hr transfection 48 hr transfection
Transfection 
efficiency 
SEM Transfection 
efficiency
SEM
vec 6.37 1.06 25.63 5.52
wt-VAPB 5.22 0.84 20.89 6.16
T46I-VAPB 5.49 0.87 18.48 7.79
P56S-VAPB 1.02 0.18 8.92 5.64
6.3.5 Protein precipitation from the medium
NSC-34 cells were plated one day before transfection. Shortly  after transfecting with 
GFP-VAPBs, the culture medium was replaced with serum free DMEM medium. Two 
days after transfection, cells were harvested and lysed in RIPA buffer as previously 
described. In the meantime, the culture medium was collected for precipitation. Two 
methods for protein precipitation from the medium were used in this study: acetone 
precipitation and trichloroacetic acid (TCA) precipitation. 
For the acetone precipitation, medium collected from the cell culture was mixed with 
four times its volume of pre-cooled acetone (-20 ℃) and was incubated at -20 ℃ for 
60 minutes. After centrifuging for 10 minutes at 13000×g, the protein pellet was then 
air dried at room temperature for 30 minutes. The pellet was resuspended in SDS-
containing loading buffer for subsequent immunoblotting analysis.
For TCA precipitation, the medium was mixed with equal volume of 20% TCA. The 
mixture was incubate on ice for 45 minutes before centrifuging (30 minutes at 
13000×g at 4 ℃). After the supernatant was removed, the pellet was washed with 
90% and 100% acetone subsequently. After the final wash, the pellet was air dried 
and resuspended in SDS-containing loading buffer for subsequent immunoblotting 
analysis. 
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6.3.6 Apoptotic analysis
NSC-34 cells were trypsinised, washed twice with ice-cold PBS, and stained using 
the Annexin V: PE apoptotic detection kit (BD Bioscience) according to the 
manufacturerʼs protocol. The cells were then analysed with a FACS flow cytometer 
(BD Bioscience).
6.4 Results
6.4.1 Both T46I and P56S mutations alter VAPB protein distribution in 
mammalian cell lines
Since the ALS-causing mutation, P56S, has been found to cause insoluble cytosolic 
aggregation of mutant VAPB, which traps wild type VAPB and disrupts normal 
functions, we tested whether the T46I mutation affected the sub-cellular distribution 
of the mutant protein. The N-terminal GFP-tagged wild type VAPB (wt-VAPB), T46I-
VAPB and P56S-VAPB constructs were generated and expressed in COS-7 cells. 
While the GFP vector gave a diffuse distribution throughout the cells (Figure 6.3A), 
wt-VAPB showed the typical ER localisation pattern of a web-like distribution within 
the cytosol extending from the nuclear surface (Figure 6.3B). On the other hand, both 
T46I-VAPB and P56S-VAPB constructs produced VAPB protein aggregates within 
the cells (Figure 6.3C-D) as previously  reported for P56S VAPB (Nishimura et al., 
2004; Kanekura et al., 2006; Teuling et al., 2007). However, there was greater 
variance in the distribution of T46I-VAPB, which showed different degrees of 
aggregation ranging from small granules to large coalesced structures, which were 
accompanied by the web-like ER distribution. Similar distribution patterns were found 
following transfection with these constructs in two neuronal cell lines, the 
neuroblastoma cell line, N2a (Figure 6.3E-H) and the spinal cord motor neurone cell 
line, NSC-34 cells (Figure 6.3I-L). In additional to GFP-tagged constructs, the N-
terminal RFP fusion VAPBs which were generated for further applications also 
displayed the same distribution patterns as found with GFP-VAPB (Figure 6.3M-P). 
The fact that both T46I and P56S caused VAPB protein aggregation in various cell 
lines regardless of the protein tag used suggests that these two mutations lead to 
some marked alterations in protein conformation that result in aggregation.
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Figure 6.3 Distribution of VAPB in mammalian cell lines. Cells were fixed 48 hours after 
transfection. The expression of GFP-VAPBs in COS-7 (A-D), N2a (E-H), NSC-34 (I-L) cells and 
RFP-VAPBs in NSC-34 cells (M-P) were shown. Nuclei were indicated by DAPI staining (blue). 
Scale bar of 20 µm is displayed.
6.4.2 Both T46I and P56S mutations reduce VAPB protein solubility
The P56S mutation has been shown to, not only alter VAPB protein localisation, but 
also reduce its solubility (Kanekura et al., 2006). In this study, the solubility of the 
VAPB protein was also evaluated. In the NSC-34 transiently transfected cells, it was 
found that although T46I-VAPB showed a different impact on VAPB protein 
distribution, the mutation affected protein solubility to a similar extent to the P56S 
mutation (Figure 6.4). The finding that both T46I and P56S mutations caused a shift 
in distribution from the Triton X-100 soluble fraction to the insoluble fraction further 
supported the observation that both mutations triggered VAPB protein aggregation. 
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Figure 6.4 Reduced protein solubility of T46I-VAPB and P56S-VAPB. A, NSC-34 cells were 
harvested 48 hours after transfection with the GFP-plasmids. The fractionation of soluble and 
insoluble fractions was as described in the methods. A tenth of the soluble fraction of cell lysate and 
half of the insoluble fraction were taken for SDS-PAGE. The GFP antibody was used to probe for the 
GFP-VAPB fusion protein. The experiment was repeated three times with the densitometry 
measurement shown in B. Mean values of the densitometry measurement are shown in the 
histograms and SEMs are indicated by the error bars..
6.4.3 The role of VAPB in IRE1/XBP1 activation
Although VAPB is highly localised to the ER, its effects on ER function are less well 
characterised. However, a few recent studies have shown evidence that VAPB may 
be involved in the signal transduction of the unfolded protein response (UPR) 
(Kanekura et al., 2006; Gkogkas et al., 2008; Suzuki et al., 2009), which is mediated 
via activation of three ER-localised stress sensor proteins, IRE1, PERK and ATF6.
In order to characterise the role of VAPB in the IRE1/XBP1 pathway, a XBP1-Venus 
construct was used as a reporter of IRE1/XBP1 activation (Iwawaki et al., 2004). 
Under un-stressed conditions, the pre-mRNA of the transcription factor, XBP1, 
contains a premature stop codon and thus produces an immature non-functional 
protein. When cells are under ER stress, the activated IRE1 causes the splicing of 
XBP1 pre-mRNA into a mature mRNA, which in turn produces the functional 
transcription factor. Based on the nature of this alternative RNA splicing, Iwawaki et 
al. (2004) developed this ER stress reporter by fusing a fluorescent protein, Venus, to 
the C-terminus of XBP1, which can only be expressed when the IRE1-mediated 
splicing takes place. Therefore, the presence of the fluorescence indicates the 
activation of IRE1 (Iwawaki et al., 2004).
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To investigate the activation of IRE1 in the presence of wild type or mutant VAPB, 
RFP-tagged VAPB constructs were generated and co-transfected with the XBP1-
Venus reporter into NSC-34 cells. The expression of RFP and Venus was detected 
with FACS, using the FL1and FL2 channel respectively. The background gain 
compensation was carried out as described in the methods (see chapter 2). A typical 
signal obtained after compensation shows that in the untransfected cells, neither 
Venus nor RFP signal are present (Figure 6.5A). Likewise, no RFP signal is detected 
in the Venus transfection and no Venus signal in the RFP transfection (Figure 6.5A). 
Once the compensation was corrected, the RFP and Venus positive gatings were 
defined using the single transfections as positive controls (Figure 6.5B). In this study, 
we used a strict definition for Venus positive gating. Instead of quantifying all Venus 
expressing cells, we gated only the ER stress-induced Venus expression, which was 
defined by comparing Venus transfected cells with and without the treatment of the 
ER stress inducer, thapsigargin (TG). The RFP positive cells were defined by 
comparing RFP vector single transfection to the untransfected cells (Figure 6.5B). 
These gatings were then applied to the experimental co-transfection conditions 
where the percentage of the ER stress-induced Venus positive cells in RFP 
expressing cells is shown for a representative experiment in Figure 6.5C. 
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Figure 6.5 The detection of the expressions of Venus and RFP using FACS. A, A example 
showing the detection of Venus and RFP after compensation adjustment. Of note, whereas the 
untransfected cells stay in the all negative quarter, there are no cells in the RFP positive area in Venus 
(TG) single transfection and no cells in the Venus positive area in RFP vector single transfection.  B, 
The gatings of Venus positive (upper panel) and RFP positive (lower panel) cells are shown. A six hour 
treatment of TG (500 nM) in a single transfection with Venus was used to show the ER stress-induced 
Venus signal. C, These gatings of RFP and Venus were then applied to the experimental conditions. 
The RFP positive cells were firstly gated, amongst the percentage of Venus positive cells was 
subsequently quantified. 
whole 
population RFP+ population
As previously reported, wt-VAPB showed a clear induction of IRE1 activity compared 
to the vector control in both 24 and 48 hour transfections (Figure 6.6A-B). This 
property was significantly impaired in both T46I- and P56S-VAPB expressing cells 
after 24 hour transfection (Figure 6.6A). The inhibitory effect of the mutations, 
especially  46I, can still be seen after 48 hour transfection, although not statistically 
significant (Figure 6.6B). This result indicates that both mutations impaired the 
efficiency of VAPB protein to activate IRE1/XBP1, which was clearly demonstrated in 
the short time period of transfection. We then challenged the cells with two widely 
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used ER stress inducers, thapsigargin (TG) and tunicamycin (TN), the former triggers 
ER stress by increasing cytosolic calcium concentration through inhibiting 
intracellular calcium pumps and the latter by blocking protein glycosylation. After 6 
hour treatment with either TN or TG, wt-VAPB activated IRE1/XBP1 to a even higher 
level compared to RFP vector (Figure 6.6C-D). A non-significant inhibitory effect, 
which partially diminished the VAPB-induced IRE/XBP1 activation during ER stress, 
was found with the mutation T46I (Figure 6.6C-D).
In a second series of experiments, we used NSC-34 permanent cell lines stably 
expressing either wt-VAPB or T46I-VAPB protein transfected with RFP-T46I-VAPB or 
RFP-wt-VAPB respectively and XBP1-Venus to determine whether mutant VAPB 
interfered with the ability  of wt-VAPB to activate this pathway. Although the 
expression of wt-VAPB in this stable cell line substantially induced IRE1/XBP1 
activation, transfection with RFP-wt-VAPB significantly  increased the magnitude of 
Venus induction (Figure 6.6E). However, in T46I-VAPB stable cells, transfection with 
RFP-wt-VAPB was not able to induced IRE1/XBP1 activation (Figure 6.6E), which 
indicated that endogenous T46I-VAPB may interact with, and prevent exogenously 
expressed wt-VAPB from promoting IRE1/XBP1 activation. 
In summary, our results show that exogenously expressed wt-VAPB significantly 
induces IRE1/XBP1 activation with or without ER stress inducers. This property, 
however, is reduced in T46I-VAPB. In addition to the lack of ability  to activate IRE1 
pathway, T46I-VAPB also inhibits the action of the wild type protein. 
138
Figure 6.6 VAPB participates in IRE1/XBP1 activation. A-B, NSC-34 cells co-transfected with 
XPB1-Venus and RFP-VAPB for 24 (A) or 48 (B) hours. The p values from one-way ANOVA test are 
0.001 and 0.0269 respectively.  C-D, NSC-34 cells co-transfected with XBP1-Venus and RFP-VAPB 
for 24 hours. Cells were treated with TN (C) or TG (D) 6 hours before harvested for sorting. The p 
values from one-way ANOVA test are 0.0035 and 0.004 respectively. E, NSC-34 cells stably 
expressing wild type or T46I-VAPB were co-transfected with XBP1-Venus and RFP-VAPB for 24 
hours. Cells were then analysed as previously described. All experiments were repeated for at least 
three times. Values of means are shown in the histograms and SEMs are indicated by the error bars. 
Bonferroni’s multiple comparison test was used as a post-test after one-way ANOVE to compare 
between each individual condition, the significance of which are shown on the graphs. * p<0.05; ** 
p<0.01. 
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6.4.4 Expression of VAPB does not affect the phosphorylation of eIF2α
In addition to IRE1, the activation of another ER stress sensor present in the ER 
membrane, PERK, was also investigated. This pathway is involved in the regulation 
of translational suppression and the induction of certain ER chaperone proteins 
which are mediated in part through the phosphorylation of eukaryotic translation 
initiation factor 2A (eIF2α). Initially, the time course of eIF2α phosphorylation in 
response to TG and TN was monitored to establish the pattern of its activation upon 
ER stress. As shown in figure 6.7A, the phosphorylation of eIF2α was a fast 
response which could be detected 30 minutes after TG was added in NSC-34 cells 
and 60 minutes in N2a cells. However, this induction of eIF2α phosphorylation was 
substantially switched off after 6 hours of TG treatment and was never obviously 
induced in our TN treatments. This result suggested that this pathway serves as fast 
acting response to ER stress which is switched off upon the prolonged stress. To 
evaluate the impact of VAPB on eIF2α phosphorylation, we compared the response 
of VAPB expressing cells to untransfected and vector transfected cells. However, 
phosphorylation of eIF2α was not significantly modified in the presence of either wild 
type or mutant VAPBs using either transiently  transfected or permanent cell lines 
(Figure 6.7B, C). Although TG markedly increased the level of phosphorylated eIF2α, 
this induction was not affected by either wild type or mutant VAPB (Figure 6.7B, C). 
In summary, there is no evidence from these studies that either wild type or mutant 
VAPB affects the phosphorylation of eIF2α in the presence or absence of 
pharmacologically-induced ER stress. 
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Figure 6.7 Phosphorylation of eIF2α in NSC-34 cells. A, The activation time course of eIF2α 
phosphorylation in NSC-34 and N2a cells was monitored after the application of ER stress inducers, 
TN or TG, were added. Cells were harvested at the indicated time point and the level of endogenous 
phosphorylated eIF2α is shown. B-C, The level of phosphorylated eIF2α was analysed in transiently 
transfected cells (B) and in VAPB stable expression cell lines (C) with or without TG treatment (500 
nM for 30 minutes prior to harvest). After correcting for the loading control, actin, the level of 
phosphorylated eIF2α was quantified. Both experiments were repeated at least three times. Values of  
means are shown in the histograms and SEMs are indicated by the error bars.
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6.4.5 Mutant VAPB triggers ubiquitin aggregation and impairs ubiquitin-
proteasome degradation system (UPS)
The presence of ubiquitin-positive aggregates is a widely used marker of the 
progression of neurodegenerative diseases, which occurs in ALS and the G93A 
SOD1 mouse model of ALS. To investigate whether the expression of mutant VAPB 
triggered the formation of ubiquitin-positive aggregates, the anti-ubiquitin antibody 
was used to stain NSC-34 cells transiently transfected with GFP-VAPBs. The number 
of cells containing ubiquitinated aggregates was quantified for each genotype. Whilst 
GFP-transfected cells contained few ubiquitinated aggregates, aggregates were 
abundant in both T46I- and P56S-VAPB expressing cells compared to wt-VAPB 
expressing cells (Figure 6.8). Although it was previously reported that P56S-VAPB 
was highly  ubiquitinated when compared to wild type protein (Kanekura et al. 2006), 
we did not find any co-localisation of VAPB, either wild type or mutant, with ubiquitin 
aggregates (Figure 6.8). While the number of wt-VAPB expressing cells containing 
ubiquitinated aggregates was similar to that seen in the vector control (Figure 6.9A), 
a significant increase in the proportion of cells expressing either T46I- or P56S-VAPB 
was found compared to wt-VAPB (ANOVA p = 0.0047) (Figure 6.9A).
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Figure 6.8 Ubiquitinated aggregates in mutant VAPB expressing NSC-34 cells. NSC-34 cells 
were fixed and stained for endogenous ubiquitin three days after transfected with wt- (A), T46I- (B) 
and P56S-VAPB (C). Examples of intracellular ubiquitinated aggregates in transfected cells are 
indicated by arrows. Ubiquitinated aggregates found in non-transfected neighboring cells are indicated 
by open arrow heads (B-ii, B-iii and C-i). Nuclei are shown with DAPI staining in the merge panel 
(blue). Scale bar of 20 µm is displayed.
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Previous studies of mutant SOD1 have suggested that a non-cell autonomous effect 
occurs, which may be a consequence of secretion of the mutant protein. In order to 
determine whether this is relevant to VAPB, which is known to be secreted in a 
truncated form in Drosophila (Tsuda et al., 2008), we also analysed the effect of 
VAPB expressing cells on neighbouring GFP negative cells. Indeed, we found a 
significant effect due to T46I-VAPB (ANOVA p = 0.022) (Figure 6.8B and 6.9B), which 
suggests that mutant VAPB expressing cells secrete a factor that can influence these 
neighbouring cells. A similar non-significant effect was also seen for P56S-VAPB 
expressing cells (Figure 6.8C and 6.9B). To investigate whether there is any form of 
VAPB released into the medium, which contributes to the response in the 
untransfected neighbouring cells, the culture medium was collected and precipitated 
for VAPB proteins. Nevertheless, using either acetone protein precipitation or TCA 
precipitation, a faint band with the size corresponding to the full length GFP-VAPB 
was identified from the medium of wild type transfection but not of the mutants 
(Figure 6.9C). Although a presumably N-terminal 18kDa truncated form of VAPB was 
found in human serum (Tsuda et al., 2008), we did not recover any N-terminal 
truncated VAPB from the culture medium in any of the transfections (Figure 6.9C). In 
addition, we used the VAPB antibody provided by  Dr. Lev (Amarilio et al., 2005) to 
investigate whether the expression of exogenous GFP-VAPBs affects the distribution 
of endogenous VAPB in the untransfected neighbouring cells. As shown in Figure 
6.10, NSC-34 cells did express VAPB, although at a lower level compared to the 
overexpressed GFP-VAPBs. However, we could detect no evidence that mutant 
VAPB expressed in the neighbouring cells affected the distributions of endogenous 
VAPB in untransfected cells. 
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Figure 6.9 Mutant VAPB induces ubiquitin aggregate formation in both mutant protein 
expressing and neighboring cells. A-B, The number of GFP-positive cells (A) and GFP-negative 
cells (B) containing ubiquitinated aggregates in different GFP-VAPB transfections was counted. 
Total number of 200 cells were counted for each condition from three independent transfections. 
The p values from the one-way ANOVA test are 0.0047 (A) and 0.022 (B) respectively. Bonferroni’s 
multiple comparison tests were applied as a post-test and the significance is shown in the graphs. 
Values of  means are shown in the histograms and SEMs are indicated by the error bars. * p<0.05; 
** p<0.01. C, NSC-34 cells transfected with GFP-VAPBs were harvested two days after transfection. 
The two-day serum free culture medium was also collected for TCA precipitation. In this blot, the full 
length 54kDa GFP-VAPBs (27kDa of GFP plus 27kDa of VAPB, indicated by the arrow) were clearly 
shown in the cell lysates from transfection. A low level of full length GFP-VAPB  was also found in 
the medium of the wt-VAPB transfection (indicated with the star), but not in other conditions. No 
truncated form was found. Marker (M) lane was shown within which the size markers from the top 
are: 75, 50, 37 and 25 kDa respectively. 
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Figure 6.10 Distribution of endogenous VAPB was not affected by exogenous mutant VAPB. 
NSC-34 cells were fixed 72 hours after transfection with the GFP-plasmids. Exogenous GFP-VAPB is 
shown in green whereas endogenous and exogenous VAPB is shown in red. Nuclei are shown with 
DAPI staining in the merge panel (blue). Scale bar of 20 µm is displayed.
In addition to the accumulation of cellular ubiquitin-positive aggregates, evidence 
from ALS-linked mutant SOD1 studies has shown the involvement of ubiquitin-
proteasome degradation system (UPS) impairment in ALS pathogenesis (Urushitani 
et al., 2002; Kabashi et al., 2004; Urushitani et al., 2004; Cheroni et al., 2005; 
Kabashi et al., 2008a). Therefore, we investigated whether UPS was impaired in 
mutant VAPB expressing cells. To examine the activity  of UPS, a GFP-tagged 
reporter, GFP-CL1, developed by Bence et al., (2001) was used. This reporter 
contains a GFP protein tagged with a short degradation signal peptide, which, when 
expressed in cells with efficient UPS, is targeted to the proteasome and degraded 
rapidly. However, in the cells with impaired UPS, the fluorescent protein accumulates 
and can be detected by FACS (Bence et al., 2001). 
As shown in Figure 6.11A, when co-transfected into NSC-34 cells with and RFP-
VAPB constructs, GFP-CL1 was more likely to accumulate in cells expressing mutant 
than wild type VAPB. Similarly, an increased number of cells with GFP-CL1 
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accumulation were observed in T46I-VAPB permanent cell lines transfected by GFP-
CL1 compared to cells expressing wt-VAPB (Figure 6.11B). 
Figure 6.11 Accumulation of GFP-CL1 in mutant VAPB expressing cells. A, NSC-34 cells were 
co-transfected with RFP-VAPBs and GFP-CL1 for 72 hours. PSI treated cells were used as positive 
control for CL1 accumulation. The number of GFP-CL1 positive cells are shown. Values of means are 
shown in the histograms and SEMs are indicated by the error bars. B, One representative experiment 
of GFP-CL1 transfecteion in wt- or T46I-VAPB permanently expressing cell lines.
In summary, these data show that both T46I- and P56S-VAPB induce the formation 
of ubiquitin-positive aggregates without being recruited into these aggregates. The 
accumulation of cellular ubiquitin-positive aggregates could be a result of UPS 
impairment which occurs in both T46I- and P56S-VAPB expressing cells. 
Furthermore, T46I-VAPB induces ubiquitinated aggregates not only  in the mutant 
protein expressing cells, but also in the untransfected surrounding cells. This result 
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suggests a non-cell autonomous effect of the mutant protein expressing cells on 
surrounding cells. However, it is unlikely that the mutant VAPB protein directly 
contribute to this effect since no mutant VAPB was found in the cell culture medium. 
The factor that mediates this non-cell autonomous toxicity is yet to be identified. 
6.4.6 The expression of T46I-VAPB leads to cell death
Although the UPR initially plays a cytoprotective role, when the stress is prolonged, a 
switch from this pro-survival program to a pro-apoptotic program occurs, which leads 
to cell death. To investigate whether the presence of mutant VAPB proteins induces 
apoptosis, cells permanently expressing wt-VAPB or T46I-VAPB were stained for the 
apoptotic markers, annexin V and 7-AAD (Figure 6.12A). Annexin V is a widely used 
marker which features the early apoptosis by binding to phosphatidylserine (PS) that 
redistributes from the inner plasma membrane to the outer plasma membrane soon 
after apoptosis is induced. A  marked increase in the number of annexin V positive 
cells expressing T46I-VAPB compared to cells expressing the wild-type protein was 
found (Figure 6.12A, B). We also examined the appearance of 7-AAD, which has a 
strong affinity  for DNA and can only get access to DNA when the cell membrane is 
disrupted, that happens as the late cell death event. In this case as well, we 
observed that the expression of the mutant protein was accompanied by a significant 
increase in the number of 7-AAD-positive cells when compared to cells expressing 
wt-VAPB (Figure 6.12A, B). In order to assess the effect of the mutant protein on wt-
VAPB, a co-culture was set up, in which the permanent cell line expressing wt-VAPB 
was co-cultured with the same number of cells expressing T46I-VAPB.  The total 
number of cells in the co-culture was the same as that in the single cultures (total = 
3,000 cells in each condition). Although only  half the cells in the co-culture expressed 
T46I-VAPB, a significantly increased number of annexin V-positive cells were 
detected (ANOVA p = 0.0004, Figure 6.12C). 
In summary, these results show that the expression of T46I-VAPB induces cell death. 
In addition, in agreement with the non-cell autonomous effect observed in the 
induction of ubiquitinated aggregates, it is also found that the co-culture of mutant 
VAPB expressing cells with wt-VAPB expressing cells leads to even higher 
percentage of cell death than T46I-VAPB pure cultured cells, which indicates there is 
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an unidentified interaction between cells expressing different genotypes of VAPB, 
and this interaction affects cell physiology and survival.
Figure 6.12 The expression of T46I-VAPB leads to greater level of cell death. A, A demonstration 
of using FACS to quantify annexin V and 7-AAD positive cells. NSC-34 cells stably express wt-VAPB 
or T46I-VAPB were stained with the two apoptotic markers. The staining positive gating was made by 
comparing with the unstained cells (shown as dash line in the graph).  B, The number of annexin V 
and 7-AAD positive cells from four experiments were quantified. The p values from unpaired t-test are 
0.0038 and 0.0315 for annexinV and 7-AAD respectively. C, A total of 3000 cells were plated in each 
condition, whereas equal amounts of wild type and T46I-VAPB expressing cells were seeded in the 
co-culture. Cells were harvested and stained for annexin V three days after plating. Values of  means 
are shown in the histograms and SEMs are indicated by the error bars. The p value from one-way 
ANOVA test is 0.0004 and Bonferroni’s multiple comparison test was applied as a post-test. * p<0.05; 
** p<0.01; *** p<0.001
6.5 Discussion
In this chapter we have reported the identification of a novel mutation in VAPB which 
is not only the second mutation in VAPB to be found associated with FALS but also is 
the first one to be found in a non-Brazilian kindred. Using a motor neurone cell line, 
we showed that this mutation causes insoluble VAPB protein aggregation, impairs 
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the ability of VAPB to induce IRE1/XBP1 activation and induces the formation of 
intracellular ubiquitinated protein aggregates and cell death. In addition to these 
direct effects occurring in the mutant protein expressing cells, substantial evidence 
also supports the effect of the non-cell autonomous pathogenesis whereby cells that 
do not express mutant VAPB are affected by their mutant protein expressing 
neighbouring cells leading to intracellular ubiquitinated aggregation and cell death.
6.5.1 The redistribution of VAPB proteins caused by T46I and P56S
A sub-cellular redistribution of disease-causing mutant proteins has been reported to 
occur in several neurodegenerative diseases. In ALS, the abnormal cytoplasmic 
aggregates of disease-associated mutant proteins are observed in SOD1, TDP-43 
and FUS mutant protein expressing cells and in tissue sections from ALS spinal cord 
(Bruijn et al., 1998; Sreedharan et al., 2008; Kwiatkowski et al., 2009; Vance et al., 
2009), which is believed to be the result of protein conformational change caused by 
the disease-causing mutations. Recent studies have suggested that these mis-
localised mutant protein aggregates cause gain-of-function toxicity which 
subsequently contributes to the disease development. 
VAP is known to be localised on membranes of the ER and pre-Golgi, where it 
displays a typical web-like ER distribution. However, both T46I and P56S mutations 
lead to VAPB protein aggregation causing a shift to the detergent insoluble 
cytoplasmic compartment. The study of P56S showed that this mutation induces a 
conformational change of VAPB protein which results in a greater tendancy to form 
oligomers with both wild type and mutant VAPB (Kanekura et al., 2006; Kim et al., 
2010). It is now believed that the mutant VAPB aggregates are still localised on 
certain parts of the ER membrane since they are colocalised with some of the ER 
resident markers, such as PDI and bap31, but not with Sec 61ß, Trip and calnexin 
(Teuling et al., 2007; Fasana et al., 2009), and that the formation of the insoluble 
inclusions may distort the morphology of ER (Fasana et al., 2009). Unlike P56S, 
which causes a total exclusion of mutant VAPB from the web-like ER localisation, 
T46I retains the potential for VAPB protein to stay in their normal physiological 
residence or to form the aggregates. Whereas P56S-VAPB can only be found in 
cytoplasmic inclusions, there is a large variance in T46I-VAPB distribution. In all the 
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cell lines that we tested, T46I-VAPB was sometimes found to display the similar 
distribution pattern in some cells as the wild type proteins, and in other cells, it 
showed a peri-nuclear web-like distribution together with cytoplasmic aggregates of 
greater size than that was found with P56S-VAPB. However, although the pattern of 
T46I-VAPB distribution is variable, the presence of T46I-VAPB aggregates that was 
observed is independent of the period (24-72 hours of transfection) and level of 
protein expression. 
VAPB is known to form homodimers via the CC domain and a dimerisation motif in 
the TM domain. The protein conformational change induced by the P56S mutation 
increases the oligomerisation affinity  which is crucial for the formation of the 
cytoplasmic inclusions (Kim et al., 2010). It is still unknown what impact T46I has on 
VAPB protein conformation and how it affects VAPB protein dimerisation. 
Nevertheless, in our protein solubility  studies, we showed that although T46I has a 
different influence on protein behaviour in localisation, it decreases VAPB protein 
solubility to the similar level as P56S. This result indicates that, as with P56S-VAPB, 
T46I-VAPB has a propensity to form oligomer aggregates which is less mobile 
compared to the wild type protein and this mobility impairment may lead to a 
compromise of VAPB on its role in mediating the crosstalk of ER and Golgi. 
6.5.2 The role of mutant VAPB in ER stress
The functions of VAPB have long been associated with ER-based mechanisms due 
to its sub-cellular localisation. Furthermore, the early  yeast studies showed that the 
expression of the yeast homolog VAP, Scs2, restores inositol auxotrophy in IRE1/
Hac1 mutant cells (Nikawa et al., 1995; Kagiwada et al., 1998), which not only 
implies a role of VAP in lipid transfer and/or synthesis pathway, but also sheds light 
on the crosstalk between VAP and IRE1/XBP1. This crosstalk has been verified in 
mammalian systems where the expression of VAPB triggers the cleavage of XBP1, 
an initial signal for IRE1 activation (Kanekura et al. 2006; Suzuki et al. 2009). 
However, whereas mutations in SOD1 cause the protein to activate all three ER 
stress responsive pathways, both T46I and P56S impair the ability  of VAPB to 
activate IRE1/XBP1. 
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Among the three ER stress responsive pathways, IRE1/XBP1 is the most ancient 
pathway which mediates the induction of ER chaperones and components of ERAD 
in response to ER stress in yeast, C. elegans, and Drosophila (Mori, 2003; Shen et 
al., 2005; Hollien and Weissman, 2006). This ER stress responding mechanism has 
been refined in eukaryotic cells where three branches of signal transduction 
pathways are activated in ER stress, each of which has a distinct role and also 
shares some common targets with each other. IRE1/XBP1 is the last of the three to 
be activated upon ER stress, which is activated several hours after PERK and ATF6. 
One of the effects of IRE1/XBP1 is to induce the expression of ER chaperones, such 
as Grp78 and PDI, which are also the targets of ATF6 (Lee et al., 2003). The unique 
role of IRE1/XBP1 is in the induction of ERAD components (Travers et al., 2000; Lee 
et al., 2003; Yoshida et al., 2003; Oda et al., 2006) and activation of the JNK pathway 
(Urano et al., 2000) that leads to cell death, both of which take place at a later time 
point during ER stress (Travers et al., 2000; Yoshida et al., 2003). In addition, IRE1/
XBP1 has been indicated to play a role in regulating phospholipid biosynthesis in 
certain cell types (Shaffer et al., 2004; Sriburi et al., 2004; Bernales et al., 2006), 
although the relationship between ER expansion and UPR is still unclear. However, 
while ER stress is prolonged and all these efforts to compromise the condition are 
not able to relieve the cells from stress, IRE1 plays a critical role in switching from the 
pro-survival program to the pro-apoptotic program, in which JNK pathway is activated 
and in turn modulates Bcl-2 family  proteins that leads to cell death (Urano et al., 
2000; Hetz et al., 2006). Nevertheless, this pathway is essential for mammals since 
neither IRE1 nor XBP1 knockout mice is viable (Reimold et al., 2000; Zhang et al., 
2005; Iwawaki et al., 2009). In this study, we showed that cells expressing either 
T46I- or P56S-VAPB are less able to activate IRE1/XBP1 pathway and furthermore 
T46I-VAPB was able to markedly  interfere with the wild type protein. This 
compromised IRE1/XBP1 activation may lead to an incomplete or delayed induction 
of ERAD and thus make the cells more vulnerable to ER stress. 
The detailed mechanism whereby VAPB participates in UPR is still unclear. Although 
there is no evidence indicating a direct interaction between VAPB and IRE1 or XBP1 
(Gavin et al., 2002), VAPB does participate in IRE1/XBP1 activation since the 
knockdown of endogenous VAPB impairs the activation of IRE1/XBP1 (Kanekura et 
al., 2006). However, it is still unclear how T46I and P56S mutations disrupt this 
function of VAPB protein. One possibility is that both mutations directly interfere with 
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the interactions of VAPB with the unidentified proteins, which is required for VAPB to 
perform its biological activity. The other possibility is that this is a consequence of 
VAPB oligomerisation. It has been shown that both mutations displace VAPB protein 
that also sequesters the wild type protein from its natural evenly ER localisation to 
form the insoluble aggregates. The formation of these oligomers may make it difficult 
for any substrate to get access to VAPB protein which then results in a lower 
efficiency in activating IRE1/XBP1.   
In this study, we also monitored the second ER stress-responsive pathway, PERK, 
which is the earliest responsive pathway that is activated shortly after ER stress. 
Once activated, PERK inhibits general protein translation via the phosphorylation of 
eIF2α and induces the expression of a group of stress-coping genes via ATF4 (Ron 
and Walter, 2007). Although we could not find any impact of either wild type or mutant 
VAPB on the level of eIF2α phosphorylation, we cannot exclude the possibility  that 
VAPB protein may have rapid and transient effects on the PERK pathway. 
The participation of VAPB in the ATF6 pathway is ambiguous. A study in 2008 
claimed to find a direct interaction between ATF6 and VAPA, wt-VAPB and P56S-
VAPB in yeast two-hybrid, and a non-perfect colocalisation of either wt- or P56S-
VAPB with ATF6 was shown in HEK 293 cells (Gkogkas et al., 2008). Using a 
reporter responsive to both XBP1 and AFT6, the authors found that both wt- and 
P56S-VAPB reduced the activity  of this reporter (Gkogkas et al., 2008). However, a 
contradictory result was reported later using the same reporter, which showed that 
wt-VAPB induced the activity of this reporter whereas P56S-VAPB did not (Suzuki et 
al., 2009). Furthermore, ATF6 was ruled out as a contributor to the activation of this 
reporter, since the activity of this reporter was not affected by the presence of 
dominant negative ATF6 but was abolished by dominant negative IRE1 (Suzuki et al., 
2009). The reason for these conflicting results is unclear. The ATF6 pathway 
emerged later in evolution and is a metazoan-specific ER stress transducer. Unlike 
IRE1 and PERK, both of which dimerise upon ER stress allowing for trans-
autophosphorylation, which in turn activate their respective substrates, the active 
ATF6 translocates from the ER membrane to Golgi where it is subject to cleavage 
(Ye et al., 2000; Shen et al., 2002). The cytosolic effector portion of ATF6 is then 
imported into nucleus where it functions as a transcription factor enhancing the 
expressing of ER chaperones, XBP1 and CHOP (Haze et al., 1999; Wang et al., 
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2000; Szegezdi et al., 2006). In our study, we have tried to monitor the cleavage and 
translocation of ATF6 in NSC-34 cells. However, this was not possible as we could 
not find an antibody that detected the endogenous ATF6 in NSC-34 cells. An 
alternative approach will be to generate a fluorescence-tagged ATF6 construct and 
monitor its behaviour in the presence of either wild type or mutant VAPB.
6.5.3 The reduction of cell viability caused by T46I-VAPB
In this study, we have shown that the expression of T46I- and P56S-VAPB promote 
the formation of cytoplasmic ubiquitinated aggregates in NSC-34 cells. The presence 
of cytoplasmic ubiquitin-positive aggregates is a common feature of ALS, which is 
found in both FALS and SALS, and also in ALS animal models (Leigh et al., 1988; 
Hirano, 1996; Bruijn et al., 1997; Bendotti and Carri, 2004). Although P56S-VAPB 
was shown to be highly ubiquitinated compared to the wild type protein in an 
immunochemistry study (Kanekura et al., 2006), we did not find that either of the 
mutant VAPBs colocalised with the ubiquitinated aggregates. Consistent with our 
result, a recent study also found TDP-43/ubiquitin-positive aggregates in motor 
neurones of P56S-VAPB transgenic mice, which did not contain P56S-VAPB 
aggregates (Tudor et al., 2010). Taking these results together, we propose both T46I- 
and P56S-VAPB induce ubiquitin-positive aggregation in the mutant protein 
expressing cells, however, the insoluble VAPB inclusion whilst being retained on 
certain region of ER membrane, is not recruited into the ubiquitinated aggregates. As 
T46I and P56S mutations have been identified in families with relatively  late disease 
onset age (this study and Nishimura et al., 2004) and there is no ALS phenotype or 
neuronal loss in the nervous system targeted P56S-VAPB transgenic mice (Tudor et 
al., 2010), it is possible that mutations in VAPB cause a slow-acting toxicity or 
increase cell vulnerability to certain stress. In agreement with this idea, we found that 
T46I-VAPB induced cell apoptosis in the cell line permanently  expressing mutant 
protein, where the mutant protein consistently  increases annexin V  positive cells by 
10% compared to the wild type protein expressing cells. Moreover, since both 
mutations impair the degree of IRE1/XBP1 activation, being unable to deal with the 
ER stress efficiently, cells may undergo apoptosis upon ER stress challenge (Suzuki 
et al., 2009). 
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6.5.4 The non-cell autonomous effect
In this study two lines of evidence supported a non-cell autonomous effect in the non-
mutant protein expressing cells, the appearance of sub-cellular ubiquitinated 
aggregates and increased cell death. In the first instance, we found that the 
untrasnsfected NSC-34 cells cultured with T46I-expressing cells contained similar 
level of ubiquitinated aggregates to the mutant protein expressing cells. This effect, 
however, did not occur in the cells transfected with wt-VAPB, where the surrounded 
untransfected cells were less likely  to contain ubiquitinated aggregates compared to 
the wt-VAPB expressing cells. In the later experiment where equal numbers of wt-
VAPB expressing cells were cultured with T46I-VAPB expressing cells, surprisingly, 
the level of apoptotic cells was markedly greater than T46I-VAPB expressing pure 
culture. It is unclear whether it is the wt- or T46I-VAPB expressing cells that had 
contributed to the additional apoptotic cells in the co-culture. In summary, this result 
suggests that mutant VAPB expressing cells are able to affect neighbouring cells 
that, whilst not producing the mutant protein themselves, become stressed and 
eventually undergo cell death.
This non-cell autonomous toxicity could be a direct effect from the disease-causing 
protein or a secondary effect which is triggered by an unidentified factor regulated by 
VAPB. There is no evidence showing that mutant VAPB is secreted and causing 
cytotoxicity  on neighbouring cells. On the contrary, the P56S mutation is suggested 
to prevent the cleavage and secretion of VAPB protein which conducts biological 
signalling via binding to Eph receptor (Tsuda et al., 2008). The Eph receptors and 
ligands, both of which are cell surface-bound, mediate the short-distant cell-to-cell 
communication which regulates a wide range of physiological processes including 
oocyte maturation, blood vessel formation and the establishment of neurone-neurone 
connection (Palmer and Klein, 2003). In addition, a sub-type of Eph receptor-ligand 
binding is known to regulate NMDA receptor clustering (Calo et al., 2006) and 
neuronal survival in cultured cells and in mammalian CNS (Magal et al., 1996; Ricard 
et al., 2006). The biological activity resulting from this Eph signalling depends on 
which sub-type of receptor and ligand participate in the interaction, it also depends 
on the cell type and the tissue environment where the interaction takes place. 
However, unlike the Eph ligand, ephrin, the secreted MSP domain of VAPB is not 
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plasma membrane-bound and it may act as an antagonist to ephrin signalling (Tsuda 
et al., 2008). Whether this VAPB-Eph interaction leads to positive or negative 
regulation of the downstream signalling cascades is still unclear. 
Surprisingly, we were not able to recover any N-terminal truncated form of VAPB from 
the culture medium. Instead, a full length protein was detected from the medium of 
wt-VAPB transfection, which was not present in Tsudaʼs study (2008). This difference 
may reflect the nature of the cell type that is used. In this study, we used the motor 
neurone cell line, NSC-34, whereas the epithelium cell line, HEK 293, and wing disc 
of Drosophila were used in Tsudaʼs study (2008). In addition, instead of a self-
generated VAPB antibody, which was used in Tsudaʼs study, we used a GFP antibody 
which can only recognise the N-terminal truncated and full length VAPB. It is still 
unclear whether the full length VAPB we detected from the wt-VAPB transfecting cell 
culture medium contains any biological activity that it may act as a cytoprotective 
signal to the neighbouring cells. Also, it is uncharacterised how mutant VAPB 
expressing cells convey toxicity  since no fragment of mutant protein was found 
released into the medium. One candidate mechanism is that through the dys-
regulation of ER function and ER-Golgi trafficking caused by mutant VAPB (Teuling et 
al., 2007; Prosser et al., 2008), some unidentified cytotoxic substances are released 
from the cells and trigger these non-cell autonomous effects. This hypothesis, 
however, warrants more investigation.
6.5.5 FFAT binding and lipid metabolism
One of the well documented functions of VAP proteins is the regulation of lipid 
trafficking and metabolism via interacting with FFAT motif-containing proteins. The 
FFAT motif, two phenylalanines in an acidic tract (EFFDAxE), is found in a wide 
range of lipid associated proteins, such as CERT, OSBP and Nirs (Loewen et al., 
2003; Kawano et al., 2006). CERT is required for the transport of ceramide from the 
ER to the Golgi complex, a process critical for the synthesis and maintenance of 
normal sphingolipid levels (Acharya and Acharya, 2005). Flies lacking CERT activity 
exhibit increased sensitivity to oxidative damage, motor disabilities and reduced life 
span (Rao et al., 2007). Similarly, inactivation of CERT in mice, causes increased 
levels of ceramides in the ER, dilatation of the ER, induction of UPR and loss of 
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functional and structural integrity of mitochondria (Wang et al., 2009). OSBPs affect 
membrane dynamics and act as sterol sensors controlling local lipid composition 
(Yan and Olkkonen, 2008). The ER membrane protein, VAP, thus functions as a dock 
to recruit these FFAT containing proteins and mediates their trafficking between ER 
and Golgi (Amarilio et al., 2005; Loewen and Levine, 2005; Kawano et al., 2006; 
Peretti et al., 2008). 
The degree of damage imparted by the P56S mutation in FFAT binding is still under 
debate. Despite the early  yeast screening suggested that mutation at P56 residue did 
not affect the binding of VAP to FFAT motif (Loewen and Levine, 2005), this binding 
was later showed being blocked by P56S in mammalian cells (Teuling et al., 2007; 
Suzuki et al., 2009). However, the idea that the P56S mutation could interfere with 
the interaction between VAPB and FFAT motif has been challenged, as the addition 
of FFAT peptide dissolves VAPB aggregates caused by the P56S mutation (Prosser 
et al., 2008). P56S is known to induce a conformational change of the VAPB protein, 
which markedly  enhances VAPB oligomerisation and may thus structurally prevent 
FFAT-containing proteins gaining access to VAPB protein. This hypothesis is 
supported by  a recent study showing that although FFAT-containing proteins do not 
colocalise with P56S-VAPB aggregates, they interact with P56S-MSP which lacks the 
dimerisation domains and exists as a monomer in cells (Kim et al., 2010). 
The T46 residue is located in a conserved core of VAP responsible for binding the 
FFAT motif (Kaiser et al., 2005; Loewen and Levine, 2005). Therefore it is very likely 
that the T46I mutation affects the ability of VAPB to interact with these proteins and 
as a consequence causes dysfunction in lipid metabolism, which may play a crucial 
role in ALS pathogenesis. Further support for this concept comes from a study  of ALS 
patients carrying the P56S-VAPB mutation who showed hyperlipidemia with a 
significant increase in cholesterol and triglyceride levels (Marques et al., 2006) and 
more recent studies have revealed that ALS patients were more likely to show 
evidence of hyperlipidemia compared to controls (Dupuis et al., 2008). To conclude, 
T46I mutation is very likely to perturb  the interaction between VAPB and FFAT motif, 
or it could prevent the interaction by enhancing the formation of VAPB aggregates as 
P56S does. The correlation between the resulting lipid metabolism dysfunction and 
ALS pathogenesis warrants further investigation. 
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6.5.6 Drosophila model of T48I-VAPB
The nervous system targeted transgenic fly  expressing Drosophila VAP bearing the 
T48I mutation (T48I-DVAP), equivalent to human T46I in VAPB, has been generated 
and studied by our collaborator in the University of Edinburgh, Dr. Pennetta. In 
Drosophila, DVAP controls the number and size of boutons at the neuromuscular 
junction. Furthermore, loss of DVAP disrupts the synaptic microtubule cytoskeleton 
(Pennetta et al., 2002) causing an increase in miniature junctional potential 
amplitudes and postsynaptic glutamate receptor clustering (Chai et al., 2008). The 
expression of T48I-DVAP leads to premature death which is a result of the severe 
loss of integrity of nervous system. Consistent with our observation in cell culture, the 
expression of T48I-DVAP leads to formation of intracellular aggregates and ER 
fragmentation. As with P56S (Chai et al., 2008), when co-expressed with wt-DVAP, 
T48I-DVAP alters the distribution of wild type protein causing it to be relocated to 
DVAP aggregates. Targeted expression of T48I-DVAP into the eye of the fly causes 
cell degeneration. These neuropathological features, together with the up-regulation 
and accumulation of the ER chaperone protein HSP70 in clusters, indicate a gradual 
overwhelming of the neuronal capacity to properly handle the pathogenic DVAPs.
In summary, our results together with Drosophila transgenic study  have shown that 
the T46I mutation causes VAPB protein aggregation, increases ER stress loading 
through disruption of ER structure, impairs UPR activation, and leads to cell 
degeneration. 
6.5.7 Proposed mechanism underlying T46I-VAPB pathogenesis
The up-regulation of ER stress-responsive proteins has been found in mutant SOD1 
expressing cells (Nishitoh et al., 2008; Oh et al., 2008), transgenic mice (Wootz et al., 
2004; Atkin et al., 2006; Kikuchi et al., 2006; Ito et al., 2009) and SALS spinal cords 
(Ilieva et al., 2007; Atkin et al., 2008). Detailed investigation of mutant SOD1 mice 
found that the up-regulation of ER stress occurs exclusively in motor neurones 20-30 
days before denervation and 100-140 days before cell death in ALS models (Saxena 
et al., 2009). It is unclear why ER stress is induced in certain motor neurones that are 
more vulnerable in ALS whereas the disease-resistant cells show no sign of facing 
ER stress challenge. However, enforced activation of ER stress-responsive pathway 
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by salubrinal treatment abolishes the sensitivity to ER stress and prolongs the life 
span of these transgenic mice (Saxena et al., 2009). This result suggests that 
disease-affected motor neurones are prone to ER stress, and the responsive 
mechanisms following a stress challenge is not sufficient to restore cell homeostasis. 
This failure to cope with stress eventually leads to cell death. 
In supporting this hypothesis, our study together with previous reports on P56S have 
shown that mutations in VAPB impair the ability to activate the ER stress-responsive 
pathway, IRE1/XBP1 (Kanekura et al., 2006). There is no evidence showing that the 
activation of the two other ER stress-responsive pathways takes place to 
compensate for the loss of IRE1/XBP1 activity. Moreover, IRE1 does play a unique 
role in up-regulating ERAD components, such as EDEM and Derlin-2 (Lee et al., 
2003; Yoshida et al., 2003; Oda et al., 2006), which in turn facilitate the clearance of 
mis-folded proteins in ER. The capacity of ERAD is easily saturated in cells under ER 
stress (Travers et al., 2000) and thus the stress-induced up-regulation of ERAD 
components is essential to efficiently remove mis-folded proteins. Therefore, the loss 
of IRE1/XBP1 activation in mutant VAPB expressing cells could lead to a 
compromise of ERAD machinery and the chronic accumulation of undegraded 
proteins results in ubiquitinated aggregates which eventually causes cell death. 
The data presented in this chapter, together with the results from the fly model, were 
submitted to Journal of Biological Chemistry and are currently under revision.
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Chapter VII DISCUSSION
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7.1 Overview
Since the early descriptions of ALS in the 1880s, our understanding of the disease 
has increased profoundly  with the identification of disease-causing mutations and the 
characterisation of pathological features in ALS. In addition, the usage of cell culture-
based functional studies and animal models of disease allow us to characterise the 
cellular disturbances occurring in disease-affecting cells, which then lead to motor 
neurone death. However, although evidence has been gathered to show that 
disease-causing perturbations occur in protein degradation system, cytoskeleton 
organisation, RNA processing and functions of organelles, such as ER and 
mitochondria, it is still unclear how these events are initiated in specific cell types, i.e. 
motor neurones and glia, and effective treatment for the disease is still unavailable. 
To gain a better understanding of ALS pathogenesis, studies have been conducted 
which focus on revealing the disease causing mechanisms of FALS-linked mutant 
proteins and exploring the involvement of FALS-linked genes in sporadic cases. 
Interestingly, the recently identified ALS-linked gene, TDP-43, not only accounts for 
~3% of FALS cases, but also ~1.5% of SALS cases. Furthermore, the “TDP-43 
pathology”, i.e. redistribution from nucleus to cytoplasm inclusions, is found in most 
SALS and non-SOD1 FALS cases (Neumann et al., 2006; Mackenzie et al., 2007; 
Tan et al., 2007). Besides TDP-43, another FALS-linked gene, VAPB, was shown to 
be down-regulated in SALS spinal cord and mutant SOD1 transgenic mice (Teuling et 
al., 2007; Anagnostou et al., 2010). These findings of the involvement of two FALS-
linked genes in SALS suggest that the familial and sporadic forms of disease share 
some common mechanisms in disease pathogenesis, which lead to universal 
pathological features, such as the presence of ubiquitin-positive aggregates and the 
occurrence of other cellular disturbances that later cause cell death. 
In this study, we aimed to investigate the involvement of TDP-43 in our FALS cohort, 
explore the potential cause for down-regulated VAPB in SALS and gain a better 
understanding of disease-causing mechanism by studying the novel ALS-linked 
mutations in DAO and VAPB. We showed the prevalence of TDP-43 mutations in our 
FALS cohort of 4.6%, which is similar to the occurrence revealed by other studies. In 
addition, characterisations of novel ALS-linked mutations, R199W-DAO and T46I-
VAPB, were carried out to reveal the potential disease-causing mechanisms. Both 
mutations were shown to disrupt the biological functions of wild type proteins and to 
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trigger the formation of cellular ubiquitin-positive aggregates in a motor neurone cell 
line. Finally, we showed using an association study that a SNP, rs6100067, is linked 
to reduced VAPB expression levels in SALS, which demonstrates a common VAPB 
pathology occurring in SALS and VAPB-FALS. 
 
7.2 Role of TDP-43 in ALS pathogenesis 
Although TDP-43 has only recently  been identified as an ALS-causing gene in ~3% 
FALS and 1.5% SALS (Dion et al., 2009), its role in ALS pathogenesis has been the 
centre of many  investigations because of the wide spread “TDP-43 pathology” found 
in neurodegenerative diseases (Geser et al., 2010). In addition to the protein 
redistribution from nucleus to cytoplasmic inclusions, other features of pathological 
TDP-43 are that they are highly ubiquitinated, phosphorylated and cleaved by 
caspase (Neumann et al., 2006; Zhang et al., 2007; Rutherford et al., 2008; Van 
Deerlin et al., 2008). Although it is not yet clear what triggers TDP-43 cytosolic 
redistribution, cell culture expression studies have shown that the redistribution of 
TDP-43 is sufficient to convey its neuronal toxicity (Winton et al., 2008; Barmada et 
al., 2010). This TDP-43 pathology is found in a wide spectrum of neurodegenerative 
diseases, including ALS (Neumann et al., 2006), FTD with/without MND (Arai et al., 
2006; Neumann et al., 2006; Cairns et al., 2007) and Alzheimer's disease (Arai et al., 
2009; Davidson et al., 2009), and therefore is believed to play an important role in 
mediating neurodegeneration.  
Interesting, TDP-43 pathology  is found in most ALS cases regardless of whether they 
carry  a mutation in this gene (Pamphlett et al., 2009), the only exception is SOD1-
ALS (Mackenzie et al., 2007; Tan et al., 2007). Being the first identified ALS-linked 
gene (Deng et al., 1993), SOD1 has been found to contain mutations accounting for 
~20% of FALS cases and transgenic animals expressing ALS-linked mutant SOD1 
are widely used as ALS animal models. Importantly, mutant SOD1 transgenic 
animals recapitulate the pathological features and protein toxicity seen in patients 
carrying SOD1 mutations, which makes it as a useful model to study ALS-causing 
mechanisms. As many mutant SOD1-mediated perturbations, such as oxidative 
stress (Andrus et al., 1998; Hall et al., 1998) and mitochondrial dysfunction (Kong 
and Xu, 1998; Bendotti et al., 2001; Higgins et al., 2003), are also observed in non-
162
SOD1-ALS (Atsumi, 1981; Shaw et al., 1995; Ferrante et al., 1997), it is widely 
accepted that SOD1-ALS and non-SOD1-ALS share a common disease pathogenic 
mechanism. However, this idea is now challenged with the finding that TDP-43 
pathology is exclusively absent in SOD1-ALS (Mackenzie et al., 2007; Robertson et 
al., 2007; Tan et al., 2007; Turner et al., 2008). Moreover, we have just recently 
shown that TDP pathology is absent too in our FALS case carrying the R199W-DAO 
mutation (Mitchell et al., 2010). On the other hand, TDP-43 pathology is observed in 
transgenic mice expressing P56S-VAPB (Tudor et al., 2010), which suggests TDP-43 
is involved in mutant VAPB-induced ALS pathogenesis whereas it is not so with 
mutant SOD1 or DAO. 
Taken together, these results show that ALS pathogenesis can be divided into two 
categories: one includes TDP-43 pathology and one does not. The former includes 
SOD1- and DAO-ALS whereas the later contains the majority  of ALS cases, including 
VAPB-ALS. Since TDP-43 redistribution can be induced simply by overexpressing 
the protein (Barmada et al., 2010), one possible cause of this TDP-43 pathology 
observed in the second disease category could be the dysregulation of gene 
expression. However, to reveal the exact cause of TDP-43 redistribution, detailed 
comparison of cell signalling between SOD1- and non-SOD1-mediated ALS is 
required. In addition, it would be interesting to see whether the inhibition of TDP-43 
redistribution benefits disease-affecting cells and thus serves as a a therapeutic 
target for disease development.
7.3 Emerging ALS mechanism caused by mutant VAPB
Since the identification of the first ALS-linked VAPB mutation, P56S, in 2004 
(Nishimura et al., 2004), studies have been carried out to characterise the disease-
causing mechanism initiated by mutant VAPB and to investigate the prevalence of 
VAPB in other ALS populations. However, until this study, no other VAPB mutation 
had been found in either sporadic or familial cases (Conforti et al., 2006; Kirby et al., 
2007; Landers et al., 2008; Millecamps et al., 2010). The T46I VAPB mutation was 
identified in one FALS patient with classic ALS and absent in 257 healthy controls or 
other ALS/control populations screened before (Conforti et al., 2006; Kirby  et al., 
2007; Landers et al., 2008; Millecamps et al., 2010). This mutation occurs at a 
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conserved amino acid and is suggested as to be irreplaceable for VAPB biological 
functions, such as FFAT binding (Loewen and Levine, 2005). 
Taken together, both our study and previous reports concerning P56S-VAPB show 
that both ALS-linked VAPB mutations impair protein properties, which results in the 
change of VAPB protein solubility and promotes the formation of VAPB aggregates 
(this study; Nishimura et al., 2004; Kanekura et al., 2006). The alterations in these 
protein properties not only  affect the mutant protein, but also result in the dysfunction 
of wild type protein by sequestering it into these insoluble aggregates (this study; 
Kanekura et al., 2006; Suzuki et al., 2009). The impacts of this VAPB protein 
deprivation from its biological localisation include the functional impairment of VAPB 
protein and the distortion of ER membrane (our fly  work and Fasana et al., 2010). 
VAPB is an ER membrane protein that is involved in docking FFAT-motif containing 
lipid-binding proteins (Loewen et al., 2003; Loewen and Levine, 2005; Kawano et al., 
2006) and also takes part in ER-Golgi trafficking as well as vesicle export (Amarilio et 
al., 2005; Prosser et al., 2008). The ALS-linked VAPB mutations substantially 
interfere with the interactions between VAPB and FFAT-motif containing proteins 
(Teuling et al., 2007; Suzuki et al., 2009; Kim et al., 2010), and impairment in vesicle 
trafficking is observed in P56S-VAPB expressing cells (Prosser et al., 2008). 
However, the most profound influence of mutant VAPB is found in UPR. Although the 
precise signalling pathway of VAPB in IRE1/XBP1 activation is not yet characterised, 
VAPB protein is required for the activation of this branch of UPR (Kanekura et al., 
2006), whereas both T46I and P56S mutations disrupt the ability  of VAPB protein to 
activate IRE1/XBP1 (this study; Kanekura et al., 2006; Suzuki et al., 2009). As ER 
stress is evident in ALS patents (Ilieva et al., 2007; Atkin et al., 2008) and animal 
models (Tobisawa et al., 2003; Kikuchi et al., 2006) with the up-regulation of UPR 
markers, it is speculated that the occurrence of ER stress is a pathological feature of 
ALS, which directly contributes to ALS-caused motor neurone loss (Saxena et al., 
2009). On the other hand, the cause of ER stress in ALS is not clear. 
Here we propose a mechanism where VAPB contributes to the dysregulation of the 
UPR that occurs in ALS pathogenesis (Figure 7.1). With increased propensity to form 
aggregates, mutant VAPB not only distorts ER structure but also becomes less 
accessible to its interacting proteins, both of which contribute to the build-up  of ER 
stress. Still worse, the expression of mutant VAPB impairs the activation of IRE1/
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XPB1, and thus prevents the cells from resolving ER stress in a timely and efficient 
way. Intensified levels of ER stress lead to the accumulation of ubiquitin-positive 
aggregates and eventually  cell death. This mechanism not only explains the way 
mutant VAPB causes ALS, but may also apply to ALS in general since a marked 
reduction of VAPB expression is found in ALS patients (Anagnostou et al., 2010) as 
well as animal models (Teuling et al., 2007). As VAPB is required for IRE1/XBP1, the 
deprivation of VAPB in ALS results in an inefficient UPR activation and further 
signalling cascades. 
Figure 7.1 VAPB-initiated ALS pathogenesis. Mutations in VAPB result in a reduced UPR activation 
through IRE1 as well as mis-regulation of vesicle trafficking and lipid  trafficking and metabolism. In 
addition, mutant proteins sequester wild type VAPB and VAPA into aggregates, which in turn impair 
the function of the wild type protein. All these effects on cellular events eventually leads to motor 
neurone cell death and contribute to ALS development. 
7.4 Future work
In this study, we demonstrated that T46I-VAPB triggers cell death by impairing IRE1/
XBP1 activation, UPS and promoting the formation of ubiquitin-positive aggregation. 
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In addition to induce cellular disturbances in mutant VAPB expressing cells, T46I-
VAPB also plays a role in mediating non-cell autonomous toxicity and triggers 
ubiquitinated aggregate formation in the neighbouring untransfected cells. However, 
the mechanism through which mutant VAPB exerts its non-cell autonomous toxicity is 
not yet characterised. One possibility  is that mutant VAPB itself is secreted and 
mediates the toxicity, though we did not find evidence supporting this hypothesis. 
Another possibility is that mutant VAPB causes this toxicity  indirectly by  affecting the 
release of other neurotrophic or toxic substances. This idea is supported with the 
observation that the expression of mutant VAPB impairs intracellular vesicle 
trafficking (Prosser et al., 2008). However, the substance that is regulated by VAPB is 
yet to be identified. 
Other aspects of cellular mechanism concerning VAPB biological functions include 
lipid metabolism, as suggested by the yeast studies (Nikawa et al., 1995; Kagiwada 
et al., 1998), neurotransmitter release (Skehel et al., 1995) and the development of 
boutons at neuromuscular junctions (Pennetta et al., 2002). The characterisation of 
the mechanism whereby ALS-linked VAPB mutations act and how they contribute to 
ALS phenotype require further studies. 
Furthermore, we showed that a SNP, rs6100067, is associated with VAPB expression 
levels in SALS. As a significant down-regulation of VAPB is found in two thirds of 
SALS cases (Anagnostou et al., 2010) and this functional deprivation of VAPB could 
lead to UPR impairment as discussed above, rs6100067 may present as a risk factor 
for ALS development. To clarify this, an association study with larger ALS and control 
cohorts is required. As this SNP is intronic, being localised at no known regulation 
elements, the way in which rs6100067 influences VAPB expression is still unclear. It 
may be linked to a yet-to-identified functional variant, which affects VAPB expression, 
or it may influence VAPB expression in an unidentified fashion. To address this 
question, a detailed SNP linkage study and a cell culture-based functional analysis 
are required.
In addition to VAPB, we reported a novel ALS-linked gene, DAO. We have shown 
that the ALS-linked DAO mutation, R199W, causes the loss of DAO enzyme activity 
in a dominant-negative fashion (Mitchell et al., 2010), which subsequently potentiates 
NMDA receptor-mediated glutamate excitotoxicity. However, mutant DAO may obtain 
another gain-of-function toxicity and its impacts on other cellular mechanisms are not 
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fully characterised. To gain better understanding of mutant DAO-induced ALS, we 
have generated transgenic mice expression human DAO containing R199W 
mutation. The future work will focus on the characterisation of this transgenic animal 
model.   
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